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Stellingen behorende bij het proefschrift: 
Improving drug delivery to the lungs 
Towards better inhalation therapy 
lnhaleren van geneesmiddelen via een inhalator met een hoge interne weerstand kan 
leiden tot een betere longdepositie dan met dezelfde inademingsnelheid inhaleren via 
een inhalator met een lage interne weerstand. (dit proefschrift) 
2 Ook bij optima le omstandigheden die gericht zijn op het bereiken van de perifere lucht­
wegen, is een concentratieverschil van minimaal een factor 25 met de hogere luchtwe­
gen ten nadele van de perifere luchtwegen onvermijdelijk. (dit proefschrift) 
3 In vitro onderzoek van de combinaties van geneesmiddel en toedieningsvorm is belang­
rijk voor het beoordelen van de in vivo resultaten. (dit proefschrift) 
4 Een mindmap is een goede manier om de samenhang van studies in een proefschrift 
duidelijk te maken. (dit proefschrift) 
5 Het is het beste om dosisaerosol-voorzetkamer combinaties te gebruiken in een ruimte 
met een hoge relatieve luchtvochtigheid. (dit proefschrift) 
6 Communicatie is volgens het CanMEDS model een van de zeven essentiele competenties 
·n' de opleiding tot medisch specialist en deze competentie is ook onmisbaar in weten­
schappelijke communicatie. (dit proefschrift) 
7 Onder de grootste druk komen de mooiste diamanten tot stand. 
(Maarten van der Weijden op Twitter) 
8 Het fe"t 1dat een dure placebo pi-�stiller krachtiger werkt dan een goedkope wijst op het 
grate belang van positieve suggestie als vorm van geneeskunst in de geneeskunde. 
(Waber RL et al. Commercial features of placebo and therapeutic efficacy. JAMA 2008; 
299(9):1016-7) 
9 Het betalen van een faire prijs (Fair Trade, Fair Wear) voor producten kan tot een 
eerlijkere verdeling van welvaart leiden en ontwikkelingshulp deels overbodig maken. 
10 Het enorme aanta �etingen met laserdiffractie maakt dat het essay " Why most published 
research findings are false" (Ioannidis J, PLoS Med 2005; 2(8): el 24) op deze studies niet 
van toepass·n'g is. 
11 Look for the bare necessities, the simple bare necessities, forget about your worries and 
your strife. (Baloo in the Junglebook mov·e� 
Bart L. Rottier, november 2012 
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1.1 General principles of inhalation therapy 
Drug inhalation is the cornerstone in the treatment of pulmonary diseases like asthma and chronic 
obstructive pulmonary disease (COPD). Treating these diseases by specific targeting of the airways with 
bronchodilating and anti-inflammatory drugs has resulted in major improvements to control these 
diseases. Asthma and COPD are highly prevalent diseases and cause considerable morbidity and mortality. 
Therefore, many patients would potentially benefit from improved inhalation devices or a better use of 
existing devices. Besides asthma and COPD, other less prevalent diseases may (partially) be treated with 
aerosol therapy such as cystic fibrosis (CF), chronic lung disease (CLO or bronchopulmonary dysplasia BPD), 
primary ciliary dyskinesia (PCD) and incidentally bronchiolitis in infancy, laryngotracheobronchitis, non-CF 
bronch iectasis, a I pha-1-a ntitrypsi ne deficiency ( www.cl in ica Itri a ls.gov) and pu I mona ry hypertension.1-5 
Tuberculosis and lungcancer may be indications for inhaled therapy in the near future. Tuberculosis is 
a clear and present danger with an estimated 1.7 million deaths each year and more than 9 million 
new cases.2-3 In this contagious disease, inhaled drug treatment could target alveolar macrophages that 
harbour TB bacilli, and lead to high drug concentrations in lung tissue as well as systemic delivery.4•5 Lung 
cancer is a prevalent disease, for which the combination of high local doses and few systemic effects of 
inhaled chemotherapy would be a great advantage as would be the inhalation of immunosuppressants 
after lung transplantation.6-0 
Next to inhaled treatment of pulmonary diseases, inhaled therapy to provide systemic drug delivery via 
the lung may open the way for treatment of systemic disorders like diabetes mellitus with insulin, or 
delivering vaccines (e.g. influenza, measles). 
Many drugs have been registered for inhalation or are under development (Table 1.1). 
However, inhaled therapy is not that simple. Drug deposition in the lung after inhalation therapy is 
highly variable and ranges from 1-500/o of the label claim depending on a variety of factors such as 
the inhalation device, delivered drug mass, inhalation manoevre (technique, inspiratory flow rate and 
breath hold), adherence to treatment , disease related and environmental factors.9-12 Improvements in 
lung deposition may therefore, potentially increase treatment efficacy, reduce costs and save time spent 
on treatment, thereby possibly increasing adherence to treatment. 
Although inhalation therapy has many potential advantages, there is considerable room for improvement 
of drug delivery to the lungs. The general aim of this thesis is to investigate possible improvements in 
inhalation treatments for pulmonary and non-pulmonary diseases. 
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Examples 
aztreonam, ciprofloxacin, colistin, gentamicin, tobramycin 
ipratropriumbromide, tiotropriumbromide, aclidiniumbromide 
amfotericin B, ambisome, pentamidine 
ribaverin, zanamavir 
isoniazid, streptomycine 
salbutamol, terbutalin, salmeterol, formoterol 
gemcitabine, doxorubicin, cisplatin 
Cystic Fibrosis Transmembrane Regulator (CFTR) 
beclomethasone/beclomethasone extra fine, budesonide, 
ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone 
cyclosporine 
alfa-1-antitrypsine, surfactant protein 
acetylcysteine, DNAse, hypertonic saline, mannitol 
Magnesi umsu I phate 
hypertonic saline, mannitol 
iloprost 
insulin, L-DOPA, vaccines, morphine, fentanyl, dihydroergotamine, 
interferon beta 
Table 1.1: examples of inhaled drug treatment 
Advantages of inhaled drugs 
A key advantage of drug delivery by inhalation for pulmonary diseases is that it enables delivery of a 
high dose of aerolized drugs to the target area with considerably less systemic side effects. Therefore the 
dose used by inhalation can be up to a factor 10 lower than an intravenous or oral dose. This favorable 
benefit-harm ratio can be illustrated by the side effects of 8
2
-agonists, which have no or only mild 
side effects when inhaled, but important side effects as tachycardia and agitation when administered 
orally or intravenously.13 In the same way, inhaled corticosteroids and antibiotics also have less side 
effects compared with systemically distributed drugs. Further, some drugs such as DNAse or hypertonic 
saline can only be administered by inhalation. Advantages of treating systemic diseases with aerolized 
medicine are that this route is feasible for drugs that are poorly absorbed orally or degrade by first-pass 
losses in the liver.14 Another advantage of inhalation therapy is the potential reduction in the use of 
injections (vaccines, insulin) and, depending on the formulation, the absence of a need for keeping drugs 
refrigerated, which would be a huge advantage in many developing countries with lower costs and easier 
logistics. 
Finally, aerosol drug delivery has a rapid onset of action for both local and systemic effects compared to 
orally taken drugs. Particular for drugs like 82 -agonists this advantage is of great importance. 
Disadvantages of inhalation therapy 
Despite the advantages of high local concentrations with low systemic effects, inhalation therapy in 
daily practice is challenging due to a flawed inhalation technique by many individuals using this form of 
treatment. Inhalation manoeuvres may be time consuming (especially when drugs are to be nebuliszed 
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or when multiple doses are required). which may reduce treatment adherence. Many different inhalation 
devices are available and most of them require different inhalation manoeuvres to obtain an optimal 
result. Repeated instruction is required,15 but in spite of that, many devices are still widely used incorrectly 
because their precise principle of operation is unknown to the patient and healthcare workers. In clinical 
trials, adherence to medication, is estimated to be around 700/o, but mean adherence rates clearly decline 
with increased dosing frequency. 16 Inhalation devices that are more easy to use might therefore probably 
improve adherence. 
The bronchial tree 
The bronchial tree is a branching system starting with the trachea (generation 0) which divides into 
a main stem bronchus for each lung (generation 1) and then continues to branch by dichotomy like 
a tree, thereby progressively reducing the airway diameters (Figure 1.1).17 Bronchi and bronchioles are 
conducting structures whose main function is to distribute the air into the peripheral units and are 
therefore called the "conducting airways''. Non-respiratory bronchioles are transitional elements and form 
the "transitional zone" taking the air into the respiratory bronchioles, alveolar ducts and alveoli which 
comprise the "respiratory zone" where gas exchange takes place. This model of branching results in an 
exponentially increasing cross sectional area for airflow and therefore, resistance and air velocity decrease 
towards the alveoli. The relatively large conducting airways (generations 1-11) contribute to less than 10/o 
of the total surface area of the lung, the transitional airways (generations 12-16) add only 40/o and the 




Figure 1.1 The branching airways with exponentially increasing 
surface area towards the smaller airways. 
Upper airways 
Airway generations O -11: conducting airways 
1 °10 surface area 
Airway generations 12-16: transitional airways 
40/o surface area 
Airway generations 17-23: respiratory airways 
or peripheral airways 
950/o surface area 
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Deposition mechanisms in the airways 
Particles travelling with the air flow through the respiratory tract are subjected to different forces. When 
a particle has the same velocity and flow direction as the surrounding streamlines of the air, only the force 
of gravity (F6) is relevant. This force (F6 = m.g, in which m is the particle mass and g the acceleration of 
gravity) causes the particle to fall (settle). When the particle enters a bifurcation where the streamlines 
of the airstream change direction, particles trajectories may deviate from these air streamlines. Particles 
with higher inertia (mass) than air molecules tend to continue travelling in the original direction. This 
creates a friction force (resistance) with the air molecules flowing around the particles, expressed as 
(Stokes') drag (or resistance) force: FD = 3.TI.TJ.U PA.D, in which TJ is the viscosity of the air, UPA is the air 
velocity relative to the particle and D is the particle diameter. This drag force changes the flow direction 
of the particle towards that of the surrounding air and reduces the velocity in the original flow direction. 
The distance over which the particle velocity in the original direction is reduced to zero by the resistance 
force is called the stopping distance (S). This stopping distance is a function of particle momentum, which 
is the product of initial particle velocity (U0) and particle mass (m). The higher the initial particle velocity 
and/or particle mass are, the longer the stopping distance. Whether a particle travels into the next airway 
generation thus depends on the velocity and mass of the particle and the airway diameter. The two 
mechanisms of deposition that are related to these forces and the particle stopping distance are inertial 
impaction and sedimentation. A third mechanism of deposition is diffusion (Figure 1.2). 
Inertial impaction is the deposition of aerosol particles on the walls of an airway conduit by a high 
momentum. This is either due to high velocity, high particle mass or both. Inertial impaction is the 
predominant way of deposition in the upper respiratory tract (conducting airways), where the air (particle) 
velocity is still relatively high and particles of all sizes (including the largest ones) enter. 
Sedimentation is particle settling by the force of gravity. Sedimentation mainly occurs in the central and 
peripheral airways, where the air velocity is much lower and distances to the airway wall are shorter. As 
soon as the drag (resistance) force (FD) and gravity (F6) are in equilibrium, a stationary settling velocity for 
the particle is achieved. Sedimentation is a time dependent mechanism of deposition and the efficacy 
of particle settling by sedimentation may thus be increased by a longer residence time of particles in the 
airways by a breathhold. 
Diffusion is movement of particles by collision with air molecules. Significant travelling distances by 
diffusion are only achieved for particles smaller than 0.1 micron. Since particles of this small size hardly 
carry any drug mass, diffusion does not contribute relevantly to lung deposition. 
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How to define aerosol particles 
Figure 1.2 Deposition mechanisms in the airways: 
inertial impaction, sedimentation and diffusion 
Fe= centrifugal force, Fg =gravitational force 
Size is one of the key determinants of the behaviour of each particle and the amount of drug it carries. 
It is therefore essential to know the particle size distribution of an aerosol in order to make a prediction 
of the amount of drug that can be deposited in large, intermediate or small airways. When particles 
are not round (spherical) but are irregular of shape, e.g. most solid particles from a dry powder device, 
a prediction of the behaviour in the airway is possible by determining the aerodynamic diameter. The 
aerodynamic diameter takes both size, shape and density into account. Some large particles, such as large 
porous particles as used for the Exubera insulin formulation and the Tobramycin Inhalation Powder (TIP) 
may be very light despite their size and are therefore more likely to follow the airstream into the smaller 
airways than to impact in the larger airways. Thus, large size but low density particles may have the 
same aerodynamic behaviour as smaller particles with higher density, i.e. these particles have the same 
aerodynamic diameter. 
The definition of aerodynamic diameter DA is the diameter of a round droplet with the density of water 
(unit density, 1 g/cm3) having the same terminal settling velocity in still air as the particle considered. 
Particles with the same aerodynamic diameter all have the same stopping distance, the same settling 
velocity and experience the same drag force. The volume of an irregularly shaped particle can also be 
expressed as an equivalent volume diameter DE of a round (sphere) particle. The aerodynamic diameter 
DA results from the equivalent volume diameter DE when additionally taking the dynamic shape factor (x) 
and particle density (p) into account. 
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The dynamic shape factor (x) is the ratio of the actual resistance force on the irregularly shaped particle 
to the resistance force on a round particle having the same volume (DE) and the same velocity relative to 
the air. Both particle density p and the dynamic shape factor x vary from 1 to 1.5 for solid (non-porous) 
particles, which results in aerodynamic diameter DA varying in a range from 0.82 to 1.22 times DE. 
As an example, the volume of an irregularly shaped particle with a dynamic shape factor ( x )  = 1. 17 and 
particle density (p) = 1.50 g/cm3 leads to an aerodynamic diameter DA = 1. 14DE ( Figure 1.3}. 
p = 1 . 5 g/cm3 
X = 1 . 0 
Equ iva lent vo lume 
d iameter 
p = 1 . 5 g/cm3 
x = 1 . 1 7 
I rregu la r  part ic le 
p = 1 . 0 g/cm3 
x =  1 . 0 
Aerodynamic 
d iameter 
Figure 1 .3 Methods to characterise irregularly shaped particles in the aerosol technology. DE is the equivalent volume 
diameter: the diameter of a sphere (round particle} having the same volume as the irregular particle in consideration. 
DA is the aerodynamic diameter, defined as the diameter of a sphere (c = 1) with the density of water (r = 1 g/cm3) having the 
same settling velocity in still air. Particles with the same DA have the same aerodynamic behaviour. 
A mathematical model, used by the International Commission on Radiological Protection predicts that 
particles < 5 µm (aerodynamic diameter) are most appropriate for deposition in the lung.1 9  In patients, it 
has been shown that inhalation of particles within the aerodynamic diameter range 1-3 µm and inhaled 
with a flow rate of 30 L/min to total lung capacity followed by a 3-5 second breath hold, results in the 
best distribution over the whole lung.20 Particles smaller than 1 µm (aerodynamically) are largely exhaled 
after inhalation; particles larger than 3-5 µm impact predominantly in the upper airways. A combination 
of a specific aerodynamic diameter and inhalation manoeuvre therefore determines whether particles 
deposit mainly in the conducting, transitional of peripheral airways. The effect of particle size may be 
different in patients with obstructive airways compared to healthy controls. Total lung deposition of 
monodisperse 1 µm particles increased in subjects with airway obstruction (smokers, patients with asthma 
and COPD) in proportion to the severity of obstruction as measured with FEV, .21 This may also be true 
in children as their airway diameters are smaller than adults, especially when compromised by disease. 
Inflammation, mucus hypersecretion and bronchoconstriction cause a reduction of airway diameter and 
result in enhanced flow velocity and turbulence, which in turn increases deposition in the airways. 
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Aerosol generation devices 
Aerosol generation devices can be divided into four different groups depending on their principle of 
operation: pressurized metered dose inhalers (pMDls), dry powder inhalers (DPls) nebulizers and soft mist 
inhalers.22-25 Auxiliary equipment to these devices is available to increase ease of operation or to improve 
lung deposition such as spacers or valved holding chambers, breath triggered dose release mechanisms 
for pMDl's, computer controlled breathing and breathing pattern adapted aerosol delivery for nebulizers 
and soft mist inhalers. 
Pressurized metered dose inhalers (pMDls) 
pMDls have a pressurized reservoir chamber holding the drug in solution or suspension. The drug is 
released from a metering chamber with a fixed volume. The dose release is actuated manually and a good 
press and breathe (hand-lung) coordination is needed to inhale the drug into the peripheral airways. 
With the phasing out of chlorofluorocarbon (CFC) propellants, completed in 2013, and the switch to 
hydrofluoroalkane (HFA) propellants, certain aerosol characteristics changed. Particularly the plume 
released by an H FA-pMDI may have a lower velocity and a higher temperature because of less propellant 
evaporation, especially if ethanol is added as co-solvent for the drug. For adults who might still directly 
inhale from the pMDI, the lower plume velocity reduces mouth and throat deposition whereas the higher 
plume temperature reduces the so called ·cold freon effect ' that makes patients sometimes stop inhaling. 
Moreover, beclomethasone in HFA (with ethanol co-solvent) changed to a smaller median particle size, 
whereas fluticasone (without co-solvent) did not, which may have implications for area of deposition. 
Children need to use pMDls with a valved holding chamber (VHC, also referred to as spacers), as press -
breath coordination cannot be expected to be adequate. The use of a VHC can reduce mouth and throat 
deposition as the aerosol is not released with a high plume velocity from the spacer. Furthermore, the 
cold freon effect is eliminated as the aerosol temperature rapidly increases within the VHC and there is no 
need to coordinate actuation with inhalation. A VHC has a one way valve that allows inspiration through 
the chamber only; the exhaled breath is diverted and does not enter the VHC . 
Valved holding chambers either have a face mask, which should have a close fit, or a mouthpiece. As the 
nose is built as an efficient filter to protect the lungs, as soon as children can control breathing through 
their mouth, a mouthpiece should be used. The lower aerosol plume velocity and higher temperature from 
HFA inhalers compared to CFC inhalers may respectively lead to less impaction in the spacer and less 
condensation of water on aerosol particles. 
Breath actuated pMDls are a special type of pMDls which release a drug dose triggered by an inspiratory 
flow rate of 30 L/min (Autohaler ®) or 20 L/min (Easibreathe® also called Redihaler®). The air flow switches 
a valve when the trigger flow rate is achieved and this enables a preloaded spring to open the metering 
chamber and to release the dose. 
Dry Powder Inhalers (DPls) 
DPls are devices that deliver medication to the lungs as a dry powder aerosol.26 Most DPls with B2 
-agonists and corticosteroids contain micronized drug blended with larger (lactose) carrier particles which 
dilutes the drug and improves the flow properties of the powder. Dilution and improvement of the flow 
characteristics are needed for reproducible drug dosing. Because the micronised drug particles adhere to 
the surface of the carrier crystals, the stability of the powder is high (no segregation) but the carrier-drug 
agglomerates are too large to be inhaled. Release of the drug particles from the carrier crystals during 
inhalation is needed. This process is called dispersion or de-agglomeration. The energy for dispersion is 
IMPROVING DRUG DELIVERY TO THE LUNGS 1 6  Towards better inhalation therapy 
Chapterl Introduction and aim 
derived from the inhaled air stream; this energy generates forces to break-up the adhesive forces between 
drug and carrier particles. As the kinetic energy increases with increasing air flow rate through the DPI, 
the fraction of released drug particles may increase with the flow rate as well. The drug particles are 
carried deep into the lungs, while the larger carrier particles deposit mainly in the oropharynx. 
Nebulizers 
Current nebulizers convert drug solutions or suspensions into an aerosol by either a jet stream generated 
by a compressor (a nebulizer-compressor system) or by means of high frequency (ultra sonic) vibration 
applied to the surface of the drug solution. In the Netherlands ultra sonic nebulizers are scarcely used and 
therefore, this type of nebulizer is not being discussed. 
A jet nebulizer basically consists of a nebulizer cup with the drug solution or drug suspension) connected 
to a so-called two-fluid nozzle. The two-fluid nozzle consists mostly of two tubes (capillaries). One 
tube starts in the nebulizer cup (to transport the drug solution), the second tube is connected to a 
pressure system. The pressurised air Uet flow) causes a negative pressure and this creates suction and 
as a consequence the liquid starts to rise in the capillary. As soon as the liquid has reached the end of 
the tube, the liquid surface of the drug solution is disrupted by turbulence from the jet stream and small 
droplets are formed. An impact body (baffle) is placed over the two-fluid nozzle and larger droplets impact 
against the baffle and fall back in the nebulizer cup. Only the smallest particles within the aerodynamic 
size range appropriate for inhalation can pass the baffle (Figure 1.4}. This mechanism results in relatively 
long nebulization times. 
Patient 
interface 




Compressed gas source 
: -
� .' � baffle 
·.'ii?· 
: �.· ·?; . .. • . . , .  
,11 
� � jetstream 
Figure 1 .4 Conventional jet nebulizer (left) with jetstream flow and baffle in more detail {right). 
Conventional jet nebulizers produce a constant flow of aerosol containing air, resulting in losses of aerosol 
in the environment during periods of exhalation. 
Open vent nebulizers (e.g. Sidestream) continuously entrain air into the nebulizer cup via a special vent. 
Breath assisted open vent nebulizers only take air into the nebulizer cup with inhalation (e.g. Pari LC® 
Plus, Ventstream®). During exhalation, the inlet vent closes and an outlet vent in the exhaust tube opens 
to discharge the used air. When the patient does not inhale, both vents are closed so no drug is lost into 
the environment. 
Breath actuated nebulizers (e.g. AeroEclipse®) build up pressure in the nebulizer cup during periods 
of exhalation which depresses the drug solution in the capillary of the two-fluid nozzle. As a result 
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aerosol generation can only take place during inspiration - thereby also eliminating drug waste during 
exhalation. 
New developments in nebulizer therapy 
A new development in nebulizer therapy is the introduction of a system controlling the supply of air to 
the nebulizer depending on the phase of the inspiratory manoeuvre (eg Akita® Jet with Pari LC®Sprint). 
A plain air bolus can be given before the aerolized drug is released, to prevent the drug of reaching the 
alveolar region, or following the inhalation of the drug an air bolus can push the drugs into obstructed 
airways. 
Other developments have focussed on shortening the nebulization time by using mesh technology. Mesh 
nebulizers either have a vibrating perforated membrane (mesh) in contact with the drug solution, or a 
vibrating piston in the nebulization cup. The oscillation of the mesh (or piston) forces the drug solution 
through funnel shaped pores in the membrane. Mesh nebulizers are efficient, quiet and they can be 
battery operated. Examples are the eFlow®, eFlow® rapid and I-neb. The eFlow® has a very low residual 
volume to reduce drug waste, whereas the eFlow® rapid has a large residual volume so it can be filled with 
the same fill volume as classic jet nebulizers. The large residual volume thus compensates for the more 
efficient nebulization. The I-neb has a so called Adaptive Aerosol Delivery (AAD). adapting the release 
of the next aerosol based on the previous three inhalations, during the first 50-80 °10 of the inhalation. 
This improves drug transport into the peripheral airways and it reduces nebulization time and drug use 
significantly. The latter is especially important for the nebulization of expensive drugs such as iloprost 
for pulmonary hypertension. The I-neb also incorporates software to monitor adherence. Its metering 
chamber can deliver a pre-set volume ranging from 0.25 to 1 .4 ml depending on the drug solution chosen, 
with a residual volume of about 0.1 ml. Nebulizers that only nebulize during (part of) the inspiration are 
also called smart nebulizers. 
A different principle of aerosol generation has been used for the Respimat® Soft Mist™lnhaler. The 
Respimat aerosol generating system takes position in between a pMDI and a classic jet nebulizer. 
It produces an aerosol from an aqueous drug solution by impaction of two fluid jets.25 
How to characterise inhalation aerosols? 
Size is one of the key determinants for the aerodynamic behaviour of aerosol particles and for the amount 
of drug an aerosol particle may carry. For aerosolized solutions, the volume of the droplet and thus the 
amount of drug carried is proportional to the third power of the radius. Small droplets may be numerous, 
but carry little drug; e.g. droplets with a 2.5 µm radius (a 5 µm droplet) carry 125 times the amount of 
drug compared to a droplet with a 0.5 µm radius (a 1 µm droplet). The mass distribution as function of 
the aerodynamic particle diameter for an aerosol can predict the amount of drug that can be deposited 
in large, intermediate or small airways. 
Particle size distributions of aerosols can be measured with cascade impactor analysis (CIA) or laser 
diffraction analysis (LDA).27 Cascade impactors have been considered the gold standard for inhaler testing 
as they classify mass fractions of the drug dose into usually 7 (4-9) aerodynamic size classes. The aerosol 
from the inhaler is drawn through the impactor system with a constant flow rate and forced to undergo 
a series of turns in the airstream. In subsequent stages, each consisting of a nozzle and a collection 
plate, particles with a momentum that is too high to follow the streamlines of air from the nozzle will 
impact on the plate underneath that nozzle (Figure 1.5}. By increasing the air and thus particle velocity in 
subsequent nozzles, classification occurs towards finer particles in subsequent stages. Cascade impactor 
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analysis is the method of choice to assess the aerodynamic particle size distribution from all inhalation 
devices. 
The results from cascade impactor analysis can be processed into cumulative mass distribution curves as 
function of the aerodynamic diameter. From those distribution curves the fine particle fractions (FPFs) or 
Mass Median Aerodynamic Diameters (MMADs) can be derived. Many clinicians emphasize the importance 
of the M MAD; however the M MAD is a mean value and provides no information on the particle size 
distribution. Aerosols with the same M MAD may thus not be comparable. Further, M MAD does not give 
information about the fraction of the dose that has been collected in the impactor. Drug retentions in 
a nebulizer system or losses of drug in a spacer may reduce the amount of drug of which the M MAD is 
measured to a fraction of the label claim. DPls usually contain a drug-carrier mixture. The fraction of drug 
particles released from the carrier particles during inhalation is generally less than 500/o. This may lead 
to an aerosol cloud with a M MAD < 5 µm. The remaining carrier-drug mixture is emitted with a larger 
M MAD, mainly determined by the particle size distribution of the carrier. 
� Noz{J: -�o • • • •  . , . • •• • 
� �  
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Figure 1 .5 The principle of cascade impaction analysis (CIA). Only the smallest particles pass at each level {upper figures, 
left and right and lower figure left. Low right: the Next Generation Impactor (NG!). 
An aerosol from a DPI thus consists of two different drug fractions, each with their own particle size 
distribution. Knowledge of the fine particle dose (FPO) is more relevant for the amount of drugs that can 
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be expected to be deposited in the airways than a single MMAD value. The FPO can be expressed as the 
mass of drug in particles within a certain aerodynamic diameter range. The fine particle 'fraction' (FPF) is 
the fine particle dose expressed as a percentage from either the label claim or the delivered dose to the 
impactor. The delivered dose to the impactor should then also be given and preferably be related to the 
label claim. 
Disadvantages of cascade impactor analysis are that the procedure is time consuming and the distribution 
of the aerosol over a series of different stages makes it difficult to measure single aerosol doses as these 
may be too small to be analysed accurately. Therefore, usually a larger number (5-1 0) of aerosol doses is 
analysed and this analysis results in a mean value for the FOP. Further, in cascade impactor analysis the 
number of classes relevant to inhalation (1 -5 µm) is relatively small. Laser diffraction analysis (LOA) is 
a fast, sensitive and highly reproducible alternative. Particles are passed through a laser beam and the 
light diffracts at different angles depending on the size and optical properties of the particles (Figure 
1 .6). The diffracted light is collected on a series of concentric detector rings and the complex diffraction 
pattern is processed into a volume distribution as function of the particle diameter, assuming that these 
particles are spherical. Disadvantages from laser diffraction analysis are that the data interpretation 
is more difficult than that for data from cascade impactor analysis, as no aerodynamic diameters are 
measured. Laser diffraction analysis yields a volume median diameter (VMD or X50 ; X 10 and X90 define the 
range). X 10 , \0 and X90 are derived from the cumulative volume distribution (Figure 1. 7) with 10, 50 and 
900/o of the volume in particles smaller than those values. 
For aerosol particles with the same density (e.g. spherical droplets from pMDls) with the same density 
(irrespective of size, e.g. spherical droplets from pMDls), the VMD measured by laser diffraction analysis 
equals the mass median diameter. If the aerosol cloud consists of a low concentration of an aqueous 
solution or homogeneous suspension, the VMD even equals MMAD (as measured with cascade impactor 
analysis) as the dynamic shape factor (x) and particle density (p) both equal 1. For non spherical particles, 
as from DPls, laser diffraction analysis can be used to measure dispersion efficacy by comparison with the 
primary particle size as a reference. 
Diffraction 
---::::::::-::::::,,•· ......... 
,- -:.1.-···::::.·:.·:.· · ·- - -------- ------------E--- --=---- -:c=:::==��:t+F�� 
Laser source Measuring area Detector 
Figure 1 .6 {upper left). Diffraction of lightwaves around a small particle B {upper right). Particles of the same size are 
projected on the same part of the detector by a special lens (Fourier lens). 
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Figure 1 .7 A (left). Laser diffraction analysis (LOA) adaptor. B (right) Cumulative volume distribution (closed squares) 
volume frequency distribution as function of the particle diameter (closed circles). X50 or volume median diameter (VMD) is 
pointed out by the arrow. 
The relevance of the inspiratory flow manoeuvre 
1 0  
The way patients inhale has an effect on aerosol generation from a DPI, both on total delivered dose 
and on the Fine Particle Fraction. Further, the inhalation manoeuvre also affects the site of deposition 
in the airways and the fraction of drug deposited. If particles enter the respiratory tract with a high 
travelling speed, they will impact in the upper airways. High flow rates should thus be avoided when 
the lower airways are the target area. 
The effect of flow rate on the site of deposition increases with increasing particle diameter (Figure 1.8). 
In a study with monodisperse particles of three different sizes, losses in the oropharynx are substantial 
at flow rates higher than 30 L/min, particularly for 3 to 6 micron particles.20 On the other hand, small 
particles need a relatively long period of residence time to deposit by sedimentation. The particle's 
settling velocity decreases with the square of the diameter. For particles of 1 micron, the time needed 
to travel a distance of 0.25 mm is almost 8.5 s. For particles in the aerodynamic size range between 1 
and 3 micron this takes considerably less time. Therefore a breathhold pause following deep inhalation 
of at least 5 and preferably 1 0s is necessary. 
Thus, the higher the inspiratory flow, the lower the deposition in the peripheral airways and these data 
plea for a low inspiratory flow rate. However, the energy within the inhaled air stream is also used for 
aerosol generation from DPls. A low inspiratory flow rate may therefore lead to a relative lack of energy 
for effective powder dispersion. Ineffective powder dispersion in turn leads to larger particles in the 
aerosol and a lower fine particle dose. To sum it up, the inspiratory flow should be low enough to allow 
for peripheral deposition, and high enough to disperse the powder adequately and form the optimal 
FPD. 
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Figure 1 .8 Deposition depends on particle size and inspiratory flow, derived from Usmani.20 
The relevance of inhaler resistance 
A DPI can be considered as a resistance to air flow. The flow rate affects the performance of dry powder 
inhalers (effective powder dispersion), but its resistance determines the attainable range of flow rates 
through the device. Importantly, it is not the absolute flow rate that determines the fine particle dose 
from a dry powder inhaler, but the resulting kinetic energy, which also depends on the design of the 
inhaler. Effective inhalers convert the kinetic energy of the air flow into powder dispersion forces. High 
local air velocities within the inhaler are required for this, rather than a high air flow rate through the 
inhaler. The way to achieve high local velocities without a high inspiratory flow rate is to design narrow, 
tortuous channels, turbulent zones or whirl chambers, which all contribute to a higher air flow resistance 
of the inhaler. Therefore, the prerequisite for an effective DPI is to achieve a sufficient  pressure drop 
across the inhaler rather than to achieve a high flow rate through the device. Current  DPls all perform 
well at a pressure drop between 2 and 4 kPa.28 These DPls do have different air flow resistances though, 
and as a consequence the flow rate over the same 4 kPa pressure drop across the DPI may vary from 45 
to 110 L/min .  This will result in different  deposition patterns for the same aerosol particles (Figure 1.8), 
with the highest peripheral deposition fractions at 2 to 4 kPa obtained for the inhalers with the highest 
air flow resistance, leading to the lowest flow rates. 
The driving force for an air flow (<I> ) through the inhaler is a pressure drop (dP) across the inhaler, as 
obtained during inhalation through the inhaler. For DPls, there is a linear relationship between the square 
root of the pressure drop across the inhaler and the flow rate: --..fdP = <I> .R, in which R represents the air 
flow resistan ce. For a given pressure drop dP, the flow rate (<I> ) thus increases with decreasing air flow 
resistance (R). 
A high flow rate can only be maintained for a short period of time. Although patients with a lower vital 
capacity generate lower pressure drops than healthy volunteers across the same air flow resistance, 
they can generate higher pressure drops across higher resistan ces than across low resistance inhalers. 
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A too forceful inhalation will result in an increase in oropharyngeal deposition (Figure 1.8). Aditionally, 
deposition in the lung shifts towards larger airways. If DPls can compensate for these shifts towards 
larger airways and oropharynx at higher flow rates with an increased fine particle dose, the drug dose 
delivered to the smaller, peripheral airways may remain the same. In spite of what is often claimed, DPls 
that release an increased fine particle dose with higher flow rates are therefore to be preferred above DPls 
that deliver a flow independent fine particle dose. Turbuhaler®, Novolizer® and Easyhaler® are examples 
of inhalers with an increase in delivered fine particle dose with increasing flow rate. 
Message in a bottle 
This principle of a pressure drop across lower and higher air flow resistances can be demonstrated with 
a test inhaler with exchangeable air flow resistance, connected to an empty polyethylene terephthalate 
(PET) bottle as a manometer (Figure 1.9). When used with the high air flow resistance, a pressure difference 
across the air flow resistance can be obtained and the water bottle crumples completely. The high air 
flow resistance results from a small orifice and the resulting flow rate is low. The time to achieve pressure 
equilibrium between the lungs and the bottle is then longer. When the air flow resistance is low, because 
of a larger orifice diameter, the attainable pressure drop across the test inhaler with the same inspiratory 
effort is much lower and the time to reach pressure equilibrium is then shorter than with the high 
resistance. This reflects in less crumpling of the water bottle despite a shorter inhalation. 
Besides an appropriate flow rate and a breath hold after maximal deep inhalation, exhalation to residual 
volume prior to inhalation is important to target the peripheral lung. This deep exhalation prior to 
inhalation is important to optimize sufficient refreshment of the alveolar volume. 
Figure 1 .9 This principle of a pressure drop across lower and higher air flow resistances can be demonstrated with a test 
inhaler with exchangeable air flow resistance, connected to an empty polyethylene terephthalate (PET) bottle as a manometer. 
When used with the high air flow resistance, a high pressure difference across the air flow resistance can be obtained and the 
water bottle crumples completely. The high air flow resistance results from a small orifice through which only a low flow rate 
is possible. The time to achieve pressure equilibrium between the lungs and the bottle is therefore relatively long. When the 
air flow resistance is low, because of a larger orifice diameter, the flow rate (at the same inspiratory effort) is much higher. 
Therefore, the time to reach pressure equilibrium on both sides of the the orifice is shorter than with the high resistance 
and the attainable pressure drop across the test inhaler with the same inspiratory effort is much lower. This reflects in less 
crumpling of the water bottle despite a shorter inhalation 
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Drug distribution and drug concentration in the airways 
The surface area of the airways increases from less than 10/o of total airway surface a rea for airway 
generations 0-11 to less than 50/o for airway generations 12-16 and to more than 950/o for the peripheral 
airways, generations 17-23 (Figure 1. 1). Even with an optima l inhalation manoeuvre of an aerosol with 
an optimal particle size distribution, the exponentially increasing airway surface a rea will clea rly lead to 
a considerable decreasing drug concentration towards the a lveoli. 
1 .2 Asthma and COPD 
Astma is a chronic inflammatory disease with reversible airway obstruction based on mucosal oedema, 
increased mucus production and bronchoconstriction. Asthma is clinically cha racterized by episodes 
of wheezing, dyspnoea and/or cough .  Bronchoconstriction and bronchodilator reversibility can be 
demonstrated with pulmona ry function tests. The pathophysiology of asthma includes chronic, mostly 









Figure 1 . 1 0  The inflammatory processes in asthma involve the entire 
bronchial tree up to the alveolar region (presented with permission, 
ITW - Dutch Inhalation Technology Working Group). 
Being an inflammatory disease, anti-inflammatory treatment is the cornerstone of treatment and all 
guidelines recommend inhaled corticosteroids (ICS) as the first choice of maintenance anti-inflammatory 
treatment.31 •32 As the number of ICS receptors increase towards the lung periphery (Figure 1.11)33 ta rgeting 









Figure 1 . 1 1  The number of corticosteroid receptors increases towards the 
periphery of the lung (presented with permission, ITW - Dutch Inhalation 
Technology Working Group}. 
IMPROVING DRUG DELIVERY TO THE LUNGS 24 Towards better inhalation therapy 
Chapterl Introduction and aim 
ICS treatment with extrafine particles aims to treat the entire bronchial tree including the small airways 
better than larger particles would be able to do. Extrafine particles penetrate better into the small airways, 
which is expected to lead to a higher and more homogeneously distributed lung deposition than larger 
particles.20 This might result in asthma control using lower daily doses with fewer side effects. Particle 
size may be of particular importance in young children because of their smaller airways and different 
breathing pattern, with higher breathing frequency and relatively small tidal volume. There are two ICS 
with extrafine particle sizes: extrafine (HFA) beclomethasone di propionate (licensed in Europe for children 
5 years of age and older) and ciclesonide (licensed for children 12 years of age and older). Ciclesonide, 
a pro-drug which is converted in the airways into the active metabolite des-CIC, is thought to have a 
reduced potential for local and systemic side effects. Due to its binding to protein and slow release from 
the protein, it is licensed for once daily use, which may improve adherence. Clinical studies in adults 
suggest that ICS with a large fine particle fraction ( 1-3 µm) might be more effective than ICS with larger 
particles.35-37 A clinically important improvement in quality of life, measured with the Asthma Quality of 
Life Questionnaire, was observed at 12 months for HFA-beclomethasone vs CFC-beclomethasone in half 
the dose equivalent in daily life.35 A study in the General Practice Research Database (GPRD) including 
more than 250/o children aged 5-1 2 years (but children were not separately reported on), found that 
therapy with HFA-beclomethasone resulted in similar or better asthma control than with fluticasone at 
the same or lower prescribed dose.36 Small ICS particles have been demonstrated to be superior to larger 
particles in improving forced expiratory volume in 1 second (FEV,) 38 and bronchial hyperreactivity as 
measured with metacholine.39 
Episodes of bronchoconstriction can be treated with short acting B2 -agonists, which are considered 
first choice rescue treatment. For asthma not controlled by ICS only, adding long acting B
2 
-agonist as 
maintenance treatment is an option.31 •32 
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease in which the whole respiratory 
tract is affected, from the central to the so called small airways of less than 2 mm in internal diameter.40 
Patients with COPD suffer from symptoms resulting from air flow limitation. Treatment varies with COPD­
severity as expressed in GOLD stage 1-4 from short acting bronchodilators as needed to long acting 
bronchodilators with or without ICS (www.goldcopd.org). 
Preferably, devices which are used in asthma and COPD are pMDI ·s with or without spacers, breath 
actuated pMDls and DPls. Nebulizers are only prescribed when there is a need for concomitant oxygen 
supply. 
Administration of bronchodilators with a pMDl-spacer combination is as effective as administration 
with nebulizers as was shown in children with asthma41 •42, adults with asthma42 and adults with mild 
exacerbations from COPD.43•44 
Magnesium sulphate by inhalation has been investigated as an alternative to intravenous magnesium 
sulphate in the treatment of acute asthma exacerbations.45 The mechanism of action is smooth muscle 
relaxation which is additive to the effect of conventional bronchodilators. 
A trend in improvements in pulmonary function and a decrease in hospital admissions compared to 
placebo did not reach statistical significance and currently this treatment is not recommended. 
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1.3 Cystic Fibrosis 
CF is a rare disease with decreased life expectancy due to end stage respiratory failure. 
The pathophysiology of CF is based on a defect in the CFTR gene and the resulting chloride and other 
ion channel defects result in abnormally thick airway secretions. Impaired mucociliary clearance leads 
to further retention of mucus, allowing bacterial colonization, infection and subsequent neutrophilic 
inflammation. The resulting airway damage leads to bronchiectasis. Patients with CF in general have to 
inhale more different drugs as they grow older. 
Inhaled therapy in patients with CF is targeted towards Pseudomonas aeruginosa (P. Aeruginosa}, the 
resulting inflammation and mucus plugs which cause obstruction. A European consensus for inhaled 
medication and inhalation devices for lung disease in CF is available.46 
Inhaled antibiotic treatment in CF started off with low dose gentamycin.47 The second inhaled antibiotic 
was tobramycin, used for Pseudomonas aeruginosa infection. Tobramycin is used for eradication when 
a P. Aeruginosa is isolated for the first time or for maintenance treatment when patients are chronically 
colonized with this micro-organism.48 Also, colistin can be used for maintenance treatment when 
persistent colonization is present. The current eradication standard for P. Aeruginosa is inhalation of 
tobramycin 300 mg twice daily for 4 weeks or inhaled colistin 2 dd 80-160 mg for 3 months combined 
with ciprofloxacin for 3 weeks.46 Next to colistin and tobramycin, azthreonam has become available for 
inhalation (AZLI or Cayston).49 
The most recent development in inhalation of antibiotics in CF, is a tobramycin inhalation powder (TIP), 
which is licensed for maintenance therapy, but not for eradication.50•51 TIP has to be inhaled twice daily 
and during each dosing 4 capsules of 28 mg of tobramycin should be inhaled. Each capsule needs to be 
inhaled twice to minimize retention. Since TIP is very hygroscopic the inhaler is replaced weekly. Other 
inhaled antibiotics in CF under development are fosfomicin/tobramicin and ciprofloxacin.52•53 
Particularly in CF, targeting the drugs to the whole lung may be challenging as the aerosols are more likely 
to deposit in better ventilated, healthier areas of the lung, whereas delivery to more severely affected 
regions is needed. Secretions in the airway will result in a more turbulent flow pattern and in increased 
central airways deposition. The target area for inhaled antibiotics in CF has not been clearly described. 
Besides infection, the exaggerated immune response in the CF airways has been taken responsible for 
ongoing respiratory deterioration in CF. This inflammatory response is often treated with ICS, although 
there are only limited data supporting this.54 ICS are also used in patients with CF and concomitant asthma, 
although it is difficult to diagnose asthma in CF patients. Symptoms and lung function abnormalities may 
be similar. Third, high dose ICS are used in CF patients with allergic bronchopulmonary aspergillosis 
(ABPA). 
Sputum from CF patients contains 3-5 times higher DNA levels than in non-CF individuals because of 
decayed inflammatory cells and bacteria. This makes the sputum more viscous. rhDNase is a drug that 
cleaves neutrophil derived DNA, making the sputum more fluid and therefore has beneficial effects 
in CF. Its efficacy has been demonstrated in patients from the age of 6 years onwards and a reduced 
exacerbation rate and a slight increase in pulmonary function has been demonstrated in patients using 
IMPROVING DRUG DELIVERY TO THE LUNGS 26  Towards better inhalat"on therapy 
Chapterl Introduction and aim 
DNase compared to placebo.ss A 5-80/o overall improvement in FEV, in patients using DNase has been 
shown, although individual response may differ considerably, ranging from marked improvement to even 
deterioration of 200/o in FEV,. Guidelines advise to start from the age of 6 onwards for a three month trial 
period, regardless of the result of pulmonary function tests. In a study comparing DNase delivered from 
2 different nebulizer-compressor systems as an aerosol with either an MMAD of 2. 1 µm or an aerosol of 
4.9 µm, the 2. 1 µm aerosol resulted in a trend to a greater improvement in FEV,, although this was not 
significant.s6 Small airways targeting with a smart nebulizer {Akita) had a more positive effect in adherent 
children compared to larger airway targeting also with Akita. The primary outcome for this study was 
forced expiratory flow at 750/o of forced vital capacity {FEF{750/o)). FEF(750/o) increased significantly by 
0.7 standard deviation (5.20/o predicted) in the large airways group and 1.2 standard deviation (8.80/o 
predicted) in the small airways group. Intention-to-treat analysis did not show a significant difference in 
treatment effect between groups.s7 Usually DNAse is dosed once daily, but a schedule of alternate days 
may be just as effective.sB 
Nebulized hypertonic saline (70/o,) improves mucociliary clearance in patients with CF.s9 On a group level, 
DNAse is more effective than hypertonic saline, but there is variation in individual response.sB Hypertonic 
saline can be used as a cheaper alternative or added to daily DNAse treatment for better c learance of the 
airways.s9 
Bronchodilators can be used for those CF-patients who show a relevant bronchodilatory response, i.e. a 
more than 90/o increase in predicted FEV, after short acting beta-agonists.60 
Other inhalation drugs that are used occasionally in CF or have been under study are other antibiotics 
(liposomal ciprofloxacin), antifungals {amphotericin-B, liposomal amphotericin-B), alternative Chloride 
channel activators {Denufosol), and viral and non-viral agents for gene transfer to the lung.61 •62• 
Unfortunately, although promising in phase 2 clinical trials,63 in phase 3 denufosol did reach up to 
its expectations and failed to show any effect on primary or secondary endpoints when compared to 
placebo. 
Drugs in CF can be administered with pMDl-spacer combinations, breath actuated devices, DPls and 
nebulizer systems. Nebulized drugs in CF are registered with a fixed nebulizer combination and the use 
of unregistered combinations is discouraged. Tobramycin for inhalation solution {TOBI®) is licensed for 
inhalation with a PARI LC® Plus nebulizer and a DeVilbiss® Pulmo-Aide® compressor. A second inhaled 
tobramycin solution {Bramitob®) ,  is also registered with the PARI LC® Plus nebulizer, but together with 
a PARI TURBO Boy® compressor. Aztreonam inhalation solution {Cayston®) is licensed for use with 
the eFlow® nebulizer. If particle size distribution and output would be equivalent with other than the 
registered systems, in vivo equivalence could be anticipated and at least guide the clinician in making 
educated decisions regarding off label drug-device combinations. 
Seven drugs currently in the drug development pipeline for CF will need to be administered by inhalation 
{http://www.cff./research/DrugDevelopmentPipiline/) 
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1.4 Systemic d iseases treated with inhaled drugs and vaccines 
The lung has a large alveolar surface area, which is highly perfused and would therefore be an excellent 
way of administrating drugs to the systemic circulation. In the alveolar region, the barrier for absorption 
is thin and minimal mucociliairy clearance occurs. The lungs are even more permeable to small molecules 
than the gastrointestinal tract.64 The optimal target area within the lungs for the delivery of drugs to the 
systemic circulation is therefore the alveolar region with an estimated resorption surface area of 90 to 120 
m2 in women and men, respectively.65 It is likely however, that systemic drug delivery can also partly take 
place by absorption via the small airways. In general, proteins with molecular weights between 6,000 and 
50,000 Dalton are relatively resistant to most peptidases that are anchored in the plasma membranes of 
all cells and attack peptides at the ends of the amino acid chain, releasing one or two amino acids at a 
time. This results in good bioavailabilities following inhalation for drugs like vaccines, levo-dopa (CVT-
301) or insulin.64 
Peptides and small molecules that are or have been under research for systemic delivery include (but 
are not limited to) 1 4 : fentanyl to treat pain66, dihydroergotamine for migraine67 and interferon beta to 
treat Multiple Sclerosis. Further, inhaled heparin is being developed to inhibit thrombosis68 , as anti­
inflammatory and anti-coagulant agent for the treatment of smoke inhalation in burn victims69 and 
inhaled heparin is also tested to treat Idiopathic Pulmonary Fibrosis.70 
The advantages of inhaled dry powder vaccines, like influenza vaccine in case of an epidemic or pandemic 
outbrake of this disease, are that inhaled medicines are easier to distribute (no cold chain storage), easier 
to administer and thus reduce costs (especially important in low income countries). Moreover, vaccine 
delivery via the respiratory tract, alimentary tract, or skin might elicit mucosa! immune responses on the 
site of virus entry and better cellular immunity, thus improving effectiveness.71 Mucosa! immunization 
might also prove additional advantage compared to the relative ineffective Mycobacterium bovis Bacillus 
Calmette-Guerin (BCG) vaccination; a spray-dried BCG allows efficient aerosol delivery of TB vaccines 
targeted deep into the lung.72 Respiratory administration of measles vaccine proved to be as effective as 
subcutaneous administration and is adaptable to mass campaigns, thereby avoiding the risks associated 
with injections. Measles vaccination by aerosol therefore could help measles eradication.73 
Inhaled insulin has been considered the most promising drug to be used on a large scale for systemic 
delivery but has only shortly been available because of many shortcomings in the devices used.74-76 
1.5 Aims of this thesis 
The main objective of this thesis is  to improve treatment of respiratory and systemic diseases by improving 
inhalation treatment. The conditions for adequate pulmonary drug delivery based on physical laws have 
been discussed above. 
First, current anti-inflammatory treatment in asthma is reviewed (chapter 2). Clinical effects of ICS depend 
on delivered dose and particle size distribution of the aerosol. A high fraction of particles 1-3 µm seems to 
be important as the inflammatory process in asthma involves all airways. Therefore in chapter 3 the particle 
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size distribution and delivered doses from commonly used ICS pMDl's combinations were determined. 
pMDls are almost always used in combination with valved holding chambers or spacers. Spacers decrease 
the dose available for inhalation due to losses in the spacer, but the amount of decrease is unknown for 
all current !CS-spacer combinations. Therefore, to determine the best pMDl-spacer combination and 
define environmental conditions that result in the highest fine particle output, we determined interdevice 
variation and the impact of air humidity and inspiratory flow rate on both spacer output and the particle 
size distribution {chapter 4). The desired target area, best device and inhalation manoeuvre to treat 
Pseudomonas aeruginosa in the CF airway have not been clearly described. The possible answers to those 
gaps in current knowledge are given in chapter 5. New nebulizers became adopted by the CF community 
before registration studies were performed. The hypothesis that the vulnerable mesh technology may lead 
to a decreased output and a change of particle size distribution in daily life compared to using a registered 
drug-nebulizer combination was tested in chapter 6. We determined the effect of inspiratory flow rate 
on output and particle size of newly registered tobramycin and colistin preparations in registered and 
unregistered drug-nebulizer combinations. If particle size distribution and output would be equivalent 
to the registered drug-device systems, in vivo equivalence could be anticipated and at least guide the 
clinician in making evidence based decisions regarding off label drug-device combinations {chapter 7). 
Systemic delivery of drugs is possible if drugs can be targeted to the distal lung region where absorption 
occurs. Inhalation of insulin was one of the most promising examples. However, despite the potential 
advantages of inhaled insulin, e.g. no cold chain storage and no need for needles, the first insulin inhaler 
(Exubera®, Pfizer) was withdrawn from the market after only one year. We hypothesized that the used 
inhaler was too inefficient, large and expensive to serve its purpose. Therefore we aimed to show that 
improved inhalation technology eliminates these drawbacks whereas systemic insulin availability per mg 
inhaled insulin can be doubled {chapter 8) which may also serve as a proof of concept for other systemic 
inhaled medication. 
A summary of the main findings and the implications for clinical practice are given in chapter 9, together 
with a description of common myths in inhalation technology, and directions for future research. 
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Abstract 
Asthma is a disease with chronic inflammation of the airways and anti-inflammatory treatment is a 
logical treatment. Inhaled corticosteroids (ICS) remain the cornerstone of anti-inflammatory therapy in 
recent international guidelines. Asthma cannot be cured by any medication: if the drug is discontinued, 
the disease manifestations return. This has been proven at all ages. In preschool children the diagnosis 
of asthma is difficult to establish. In this heterogeneous group ICS or leukotriene receptor antagonists 
(LTRA) are just as effective as placebo; in the future it will hopefully be possible to describe characteristics 
of responders. LTRA are an alternative in mild asthma, especially when mono-triggered viral related 
wheeze is present. Theophylline is effective and also has bronchodilatory properties, which need to be 
balanced against the relatively frequent side effects. The working mechanisms of anti-inflammatory 
asthma medications including ICS, LTRA, cromones, macrolides and theophylline are described. 
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INTRODUCTION 
Asthma is characterised by bronchial hyper-reactivity, chronic symptoms with intermittent attacks of 
cough and wheeze, skewing of pulmonary T cells to a Th2 phenotype and increased airway eosinophils 
defined as a chronic eosinophilic inflammation of the airways.1 -2 Anti-inflammatory maintenance therapy 
remains the cornerstone of asthma treatment in this era.3-5 Inhaled corticosteroids are considered to 
be the most effective anti-inflammatory treatment, safe in appropriate doses when given to asthmatic 
children and adults, even as long term therapy. 3-5 Actual points of debate include: (1 ) The use and 
indications of ICS in preschool wheezing children; (2) How to monitor the use of ICS based on symptoms, 
lung function, bronchial responsiveness measurement, induced sputum or by means of non-invasive 
exhaled NO measurement; and (3) Should ICS be prescribed in asymptomatic asthmatic children during 
puberty and adolescence? This review will focus on indications, efficacy, monitoring and side effects of 
anti-inflammatory therapy in children with asthma. 
INHALED CORTICOSTEROIDS (ICS) 
Guidelines advise maintenance therapy with ICS for asthmatic children with any of the following 
features: using inhaled B2 agonists three times a week or more; being symptomatic three times a week 
or more; or waking one night a week. In addition, ICS are recommended for consideration in adults 
and children aged 5-1 2 years who have had an exacerbation of asthma requiring oral corticosteroids 
in the last two years.4•5 Corticosteroids diffuse across cell membranes, bind to glucocorticoid receptors 
(GRs) in the cytoplasm, transfer to the nucleus where the receptor-corticosteroid complex binds to 
DNA eventually leading to changes in gene transcription. The desired effect is inhibition of synthesis 
of inflammatory proteins, but the systemic side effects of corticosteroids are also caused by changes 
in gene transcription.6 For many years it was suggested that moderate to higher dosages of ICS (400 
to 1000 mcg of budesonide) proved to be effective as well as safe in children. Even after long term 
therapy with moderate to high doses of ICS growth reduction seemed to be transient and final adult 
height proved to be normal. However, Visser et al [2004] have shown that moderate to high dosages ICS 
may have systemic side effects, serving as a reminder to all clinicians of the importance of minimising 
corticosteroid exposure in growing children.7 
The ICS dose-response curve is rather steep in most asthmatics, meaning that low doses are sufficient 
in most situations. This has led to the view that the lowest effective ICS dose should be found to 
achieve asthma control.3-5 Former guidelines recommended a step down approach, which means that 
after a relatively higher ICS starting dose the optimal minimum dose should be determined.8 Several 
months were needed before this therapeutic optimum was reached. Currently, this approach is no longer 
advised.3-5 Based on clinical symptoms a starting dose is chosen, which in most cases would include a 
daily dose of 200-250 mg fluticasone propionate (FP) or 400 mg budesonide (BUD) / beclomethasone 
(BDP). If clinical remission has been reached after three months of treatment this starting dose should 
be lowered. If the child is not symptom free, the starting dose may be doubled, after issues like therapy 
adherence, adequate inhalation technique and smoking behaviour have been checked.3-5 An alternative 
approach is the use of extra-fine beclomethasone or ciclesonide. Because of small particles these formula 
may give higher peripheral lung deposition, which may be more effective, and as a consequence lower 
ICS doses can be used (i.e. 200 mg daily instead of 400 mg BDP or BUD).9•10 This may be an important 
advantage when treating very young children with small airway diametres. Ciclesonide is a promising 
new ICS which can be prescribed once daily and claims to be ineffective outside the lung.1 1 • 1 2  It has been 
registered in many countries for adults and children over the age of six years. 
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/CS in preschool aged wheezing children 
A recent ERS task force report reviewed the problem of wheezing in childhood in detail. 1 2 An emphasis 
on preschool wheezing reflected the recent changes in the characterisation of wheezing phenotypes 
which have occurred as a result of a number of longitudinal studies. Most reported wheeze occurs in 
acute, short-lived episodes, in association with viral (upper) respiratory infection and in the absence 
of interval symptoms. 1 3•1 4  About 400/o of all preschool children regularly wheeze during common cold 
infections. About two-thirds of these children lose their symptoms and are symptom free after the age 
of six years. Studies of the efficacy of ICS in preschool children have given conflicting results. Some 
studies show that ICS are effective while others find no effect at all. The most plausible explanation 
for these differences is that there is no single wheezing phenotype in young children but several. If 
the diagnosis asthma can be stated with a high level of certainty level in preschool children, then 
a positive response to ICS may be expected. However, if the diagnosis is not clear or less likely, ICS 
are unlikely to be not useful. Schokker et al [2008] found no effect of ICS maintenance treatment in 
2-5 years old children with recurrent wheeze for whom the general practitioner decided to prescribe 
ICS.1 5 In this placebo controlled study with steroid na"ive children, there was no difference between ICS 
maintenance therapy and symptomatic B2 treatment, measured by symptom free days and nights or 
lung function assessed by forced oscillometry. From this, and other studies, it may be concluded that 
ICS are not indicated in most wheezy infants and young children. Many young children are prescribed 
ICS inappropriately. This is both a threat to the child with potential side effects as well as an economic 
burden. Several investigators have tried to define criteria based on which one may conclude whether 
a young child is asthmatic or not, but still it remains extremely difficult to reliably diagnose asthma 
at a young age. 1 2• 1 5  Even if there is a felt to be a high likelihood of asthma and ICS therapy appears to 
be indicated, the question still arises as to whether such a child should be treated with ICS for a long 
period of time. Guilbert et al [2006] have shown that in preschool children at high risk for asthma, two 
years of ICS therapy did not change the development of asthma symptoms or lung function during a 
third, treatment-free year (Figure 2.1).16 In other words, ICS maintenance treatment failed to prevent 
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Figure 2 . 1  In preschool children with a high risk 
for asthma, treatment with fluticasone 100 ug 
2 daily (European label claim, equivalent to BBug 
2 daily US label claim) compared to placebo 
(the shadowed part of the figure) resulted in a 
significant increase in proportion of symptom 
free days during the two years of active treatment. 
Active treatment was then discontinued and the 
children were in observational follow up for an­
other year. The difference in symptom free days 
gradually disappears. Anti-inflammatory treat­
ment with /CS in preschool children at high risk 
of developing asthma takes care of symptoms 
but does not prevent the further development of 
asthma(reproduced with permission, 
Copyright © 2006 Massachusetts Medical Soci­
ety. All rights reserved). 
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ICS in puberty with respect to prognosis in adult life 
Although ICS treatment is the most effective anti-inflammatory asthma therapy and has been prescribed 
for more than thirty years now, there are no data from literature that suggest that permanent remission 
can be reached and that airway remodelling can be prevented.16-1 8 About half of asthmatic children lose 
their symptoms during puberty or adolescence, and maintenance treatment will be stopped either by 
themselves or on medical advice. Have these children really outgrown their asthma or is this symptom 
free period just temporary? Many "ex-asthmatics" will e symptomatic before the age of thirty years 
again. Van der Toorn et al. [2001] have shown that "ex-asthmatic children", who were symptom free 
for many years, and did not require any asthma medication, still had asthma characteristics when 
lung function was measured at the age of twenty years.1 9 In addition, in this cohort the eosinophils 
in induced sputum and exhaled NO values were as high as in symptomatic asthmatics. In bronchial 
biopsies, basal membrane thickness in the asymptomatic group was at least intermediate between 
healthy controls and asthmatics, or comparable with symptomatic subjects (Figure 2.2).1 9 These data 
show that, although these young adults were asymptomatic for many years, they retained typical 
asthmatic characteristics, suggesting that they remain predisposed to developing symptoms of asthma 
in later life. In a later study, Van der Toorn et al. [2005] re-investigated the same patients in order to 
determine whether combination therapy with ICS and long acting B2-agonist (fluticasone-salmeterol) 
lead to improvement in lung function in these "asymptomatic asthmatics" (Figure 2.3).20 These studies 
suggested that asymptomatic adolescents were still at risk, and should be treated with ICS maintenance 
although they seem to have outgrown their asthma. Whether this approach gives rise to a better 
prognosis for lung structure and function during later adult life has not been determined. Regardless 
of the potential merit of therapy, a major barrier remains in motivating asymptomatic adolescents or 
young adults to use medication. 
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Figuur 2.2 Major Basic Protein (MBP) is an eosinohil related protein. The figure shows the MBP density in both epithelium 
(top panel) and sub-epithelium (lower panel) for three groups of study subjects: currently asthmatics (left), "ex­
asthmatics"(adolescents previously under treatment for atopic asthma and now completely free of asthma related symptoms 
and medication for at least 12 months before enrolment) and healthy controls. The clinically cured group still has pathological 
signs highly compatible with asthma! (reproduced with permission-American Thoracic Society) 
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Figure 2.3 Young adults with a history of atopic asthma, 
but without asthma related symptoms and medication for 
at least 12 months and documented bronchial.hyperrespon­
siveness in challenge tests took part in the study. They were 
randomized to receive fluticasone-salmeterol treatment or 
placebo during three months. The active treatment reduced 
BHR in these ontherwise asymptomatic individuals!Each line 
respresents an individual, horizontal bars represent mean 
values (reproduced with permission-Elsevier). 
Active cigarette smoking has been associated with the development of asthma.21 •2 2  International guide­
lines of asthma management emphasise ICS as the most effective anti-inflammatory therapy for chron­
ic asthma.3-5 However, several studies have shown that the efficacy of corticosteroids is reduced in 
asthmatics who are active cigarette smokers (Figure 2.4).23•26 In an observational study in 75 asthmatic 
subjects, of whom 39 were smokers and 78 healthy controls of whom 30 were smokers, Livingston et 
al. [2007] demonstrated that smokers with asthma have an impaired cutaneous vasoconstrictor re­
sponses to topical steroids compared with never-smokers with asthma.27 Besides this systemic effect of 
smoking, it was shown in this study that there is a reduced response to oral corticosteroids in smokers 
with asthma compared with never-smokers, measured by morning PEF, rescue medication use, daytime 
symptoms and asthma control score but not by FEV1 • In a review paper by Thomson et al. [2004] the 
negative influences of active smoking in asthmatics was discussed.28 The authors stated that "Every ef­
fort should be made to encourage asthmatics who smoke to stop, although the effects of smoking ces­
sation upon reversing the adverse effects of tobacco smoke on asthma control, therapeutic response to 
corticosteroids and airway pathology have yet to be fu lly e lucidated. Alternative or additional therapies 
to inhaled corticosteroids are needed for asthmatic patients who are unable to quit smoking".28 Cross 
sectional studies show that children and adults with asthma have on average lower l ung function than 
non-asthmatics.29•30 The annual decline of lung function in adults with persistent asthma is greater than 
in healthy adults, with an even faster decline in women than in men. Dijkstra et al. [2006] have shown 
in a 23 yr fol low-up study that treatment with ICS in adult patients with moderate to severe asthma 
is associated with a reduction in the annual decline in FEV, .31 This was only found in adult men with < 
5 pack years of smoking at follow-up. The effect was dose dependent and was not present in women 
or in men with � 5 pack years of smoking. The decline in FEV1 before start of ICS was not significantly 
different between men and women with < 5 pack years smoking. So, asthmatic women are not only 
more susceptible to cigarette smoke but the efficacy of corticosteroids seems to be less than in men. I f  
adult asthmatic women who actively smoke are so  much more vulnerable to tobacco smoke than men, 
and if smoking abolishes the anti-inflammatory effects of ICS, what wou ld  be the effects of passive 
smoking to asthmatic children, especially girls? It seems biologically plausible that even more negative 
influences on ICS effects in asthmatic girls who are exposed to cigarette smoke occur, although no firm 
data are available in the literature to date. The clinical emphasis should remain in motivating parents of 
asthmatic children to refrain from smoking both for themselves and their children. 
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T FEV, {upper panel) and asthma control score 
T 0 (lower panel) for three groups of adults with FEV1 (L) asthma: smokers, ex-smokers and never-2 5  Vi l T T smokers. Active smoking impairs the efficacy of n l two week treatment with oral corticosteroids 
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/CS and side effects 
ICS proved to be effective and safe in children, both in the short term as well as the long term. In the 
past this view has sometimes led to the prescription of rather high doses of ICS. More recent guidelines 
advise lower doses of ICS to gain optimal asthma control. ICS side effects are dose-dependant, but 
individual sensitivity plays an important role. Although much experience with ICS treatment in children 
has been gained over the past decades, the clinician should always consider potential side effects. 
Well known, and relevant. in children are growth reduction, adrenal suppression, negative effects 
on bone metabolism, and local effects such as candidal infection of the throat and hoarseness of 
the voice.7•32•33 Visser et al. [2004] showed that fluticasone at daily dosages of �500 mcg may have 
negative influence on bone metabolism and growth velocity.7 Although temporary and reversible, this 
indicates that caution should be exercised when considering the prescription of higher dosages of ICS 
in children. However, under-treatment of asthma may also cause growth impairment. Reassuringly, 
long-term treatment with appropriate doses of ICS does not negatively influence final adult height.3•4 
Nonetheless, local side effects may occur even with low ICS dosages. Less well known side effects, that 
are sometimes mentioned, include hypertrichosis, skin bruising and behavioural problems including 
aggression and anxiety. However, in a large study of ICS side effects in the Netherlands, de Vries et 
al. [2008] could not find differences between asthmatic children on ICS and children reviewed in an 
otolaryngology outpatient clinic. Both groups the children had significantly more behavioural problems 
than in a healthy control group.35 
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LEUKOTRIENE RECEPTOR ANTAGONISTS (LTRA) 
Leukotrienes are very potent mediators through interaction with the Cystinyl leukotriene receptor 1 .  
Neither the synthesis nor the leukotriene induced actions are responsive t o  steroid treatment.36 LTRA are 
the first new a nti-inflam matory drugs since the introduction of ICS and  the first to target a specific type 
of mediator. LTRA have both anti-infla mmatory and  bronchodilating properties. Leukotrienes act by 
binding to tra nsmembra ne spa n ning receptors, on multiple cell types, both infla m matory (neutrophils, 
basophils, a nd  eosinophils), as well as structural cells (epithelium, endothelium and smooth muscle). 
They are registered for children from the age of six months to two years upwards, but will be available 
in a sprinkle form for the infa nts in the near future. LTRA are registered for the treatment of allergic 
asthma, exercise induced bronchoconstriction and  allergic rhinitis, both as ad-on a nd (only in mild cases) 
as first line a nti-inflam matory therapy. LTRA are less potent  as an anti-inflam matory preparation than  
ICS, have less bronchodilating potential than salbutamol, but the combined effects for a once daily oral 
drug and  the favourable side effect profile makes LTRA a potentially attractive choice as monotherapy 
in children with mild asthma and rhinitis. For young children,  a useful feature of  montelukast is that 
it is a nti-infla mmatory but lacks the potential side effects of steroids.37 Bisgaard et al. [2005] have 
shown in a multicentre double-blind parallel group study that montelukast was effective in preschool 
children aged 2-5 years with a history of intermittent viral wheeze.38 Children were randomised to 
receive either montelukast or placebo once daily for 12 months. During the study period, montelukast 
significa ntly reduced the asthma exacerbation rate, as well as the use of ICS and  B2-agonist. However, 
these favourable results were not a pplicable to children with symptoms of post- Respiratory Syncytial 
Virus bronchiolitis in children in a study by the same a uthor.39 In a ra ndomised controlled tria l in ninety­
six 2-5 year-old children with asthma-like symptoms, Kooi et al. [2008] could not find significa nt 
differences between maintena nce treatment with fluticasone, montelukast or placebo, which indicates 
that anti-inflammatory thera py in these children is not indicated while symptomatic treatment with 
salbuta mol seems to be sufficient.40 The group is probably too heterogeneous, but so are the children 
that present to clinicia ns with signs and symptoms in the out patient clinic. In future studies, subgroups 
of children who do benefit from anti-infla m matory treatment may be better defined. I n  a recent 
systematic review on montelukast as add-on therapy to ICS treatment in adults with mild to moderate 
asthma the a uthors concluded that montelukast added to ICS improved asthma control com pared with 
ICS monotherapy41 , although the addition of a LABA to ICS is clinically at least as effective as the 
addition of montelukast. LTRA therapy may however have a better long term safety profile, which may 
be even more important  in children tha n in adults. 
MACRO LI DES 
Besides direct anti-microbial activity against gra m-positive cocci and atypical pathogens, macrolides 
also have im mune modifying effects. This has first been demonstrated with erythromycin in diffuse 
pa n-bronchiolitis, and later in cystic fibrosis (CF). Macrolides bind  to a subunit of bacterial ribosomes, 
ultimately leading to inhibition of bacterial protein synthesis and  thereby direct a ntimicrobial activity.42 
The role of chronic infection with Chla mydia- and Mycopla ma pneumoniae in the persistence or severity 
of asthma has been demonstrated.43 The other proposed mecha nisms in asthma  besides this direct 
antimicrobial activity are effects on bronchial cells and  on cells of the in nate immune system.44 Both 
in CF and  in diffuse pa n-bronchiolitis improvement has been reported with a ntibiotic levels below the 
minimal inhibitory concentrations of several bacteria, suggesting an a nti-infla m matory activity as the 
putative mechanism of im provement. Not surprisingly, a Cochrane review found insufficient  evidence 
to support or to refute the use of macrolides in patients with chronic asthma due to the small numbers 
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of patients' studied.45 In the recent international guidelines on treatment of asthma a place for the role 
of macrolides has not been specified.3-5 
CROMONES 
The cromones, cromolyn sodium and nedocromil sodium, are mast cell stabilizers. Their effect is caused 
by phosphorylation of a cell membrane protein that is responsible for the termination of mediator 
release from mast cells, thereby turning off a very early stage of the asthmatic inflammatory response. 
Secondly, cromones are chloride channel blockers. When the opening of chloride channels with cell 
activation is prevented the subsequent calcium channel opening resulting in mast cell degranulation 
does not occur. However, their anti-inflammatory effect is weak46 or nonexistent.47 More importantly, 
publication bias is suggested by using a so called funnel plot showing an under representation of small 
studies with negative results. Therefore, beneficial effects of sodium cromoglycate as maintenance 
therapy in childhood asthma may have been overestimated.48 
THEOPHYLLINE 
I t  has been suggested that "The use of theophyll ine to treat asthma has undergone several cycles of 
enthusiasm and unpopularity over the past 50 years''.49 Currently, theophylline seems to be increasing in 
popularity again.3-5 I t  is relatively cheap and is taken orally, but the major l imitations of the drug are its 
narrow therapeutic index and wide inter-patient pharmacokinetic variability. As a result, dos ing must be 
individually titrated to steady-state serumconcentrations to achieve both benefit and safety. In patients 
receiving theophylline monotherapy, sustained release doses providing a peak serum concentration of 
10 to 20mg/L (mcg/ml) are best documented to improve symptoms and reduce the need for rescue 
therapy. Theophylline has bronchodilatory properties, though not as strong as long acting inhaled beta2 
agonists. Antiinflammatory and immunomodulating effects have been described with serumlevels of 
5mg/L. Therefore, serumconcentrations of 5 to 10 mg/L may be adequate for some patients, particularly i f  
they are also receiving ICS. The molecular mechanisms for the anti-inflammatory action of theophylline 
are unclear, but the end result is suggested to be decreased inflammatory gene expression.50 
OTHER ANTI-INFLAMMATORY DRUGS: BEYOND THE GU IDELINES 
Metotrexate51 and cyclosporine52 have been used with a small but significant effect in the treatment of 
severe, persistent asthma in children. For others including chloroquine, azathioprine, dapsone, antiTNF­
alfa, interferon-gamma and simvastatine there is a lack of studies to give guidance on the effects of use 
in children. Potential new cytokine therapeutic drugs and targets in asthma are reviewed elsewhere.53 
CONCLUSIONS 
ICS remain the most powerful anti-inflammatory drugs balanced against safety in asthma. 
Antileukotrienes may be an alternative when an oral drug is needed in case of mild asthma, especially 
when viral infections are the most important trigger. On a group level, neither ICS nor LTRA were 
different from placebo in 2-5 year old children: children appear to get better with time alone. Cromones 
seem to be of l ittle value when studied on a group level. Theophylline is limited by its risk of side 
effects and the need for serum levels leaving it at best as a non-preferred alternative. Macrolides are of 
potential interest because of the combination of anti-infectious and anti-inflammatory properties in 
difficult to treat asthma but they can not be recommended as mainstream therapy at this point in time. 
It is worth noting that asthma cannot be prevented or cured by any of the currently available anti­
inflammatory therapies. Nonetheless, when treatment is stopped, the disease manifestations return. 
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Abstract 
Introduction 
Recent developments concerning pressurized metered dose inhalers (pM Dls) with inhaled corticosteroids 
(ICS) are the introduction of ciclesonide and the replacement of propellants. As the results of in vivo 
studies depend on pMDI  performance, it is necessary to evaluate pM Dls in vitro for delivered dose and 
particle size distributions 
Methods 
Fluticasone 125 µg, budesonide 200 µg, beclomethasone HFA 100 µg, and ciclesonide 160 µg were 
compared for delivered dose and particle size using laser diffraction analysis with inspiratory flow rates 
of 10, 20 and 30 1/s. 
Results 
The volume median diameter of fluticasone was 3.5 µm, budesonide 2 .8 µm, beclomethasone and 
ciclesonide both 1.9 µm. The mouthpiece retention was up to 300/o of the nominal dose for beclomethasone 
and ciclesonide, 11- 190/o for the other pMDls. Lifespan, flow rate, and air humidity had no significant 
influence on particle size distribution. The delivered dose of beclomethasone, budesonide, and ciclesonide 
remained constant over the lifespan. The delivered dose of fluticasone 125 decreased from 1060/o to 630/o; 
fluticasone 250 also decreased whereas fluticasone 50 remained constant. 
Conclusions 
There is a significant difference in median particle size distribution between the different ICS pMDls. Air 
humidity and inspiratory flow rate have no significant influence on particle size distribution. Ciclesonide 
160 and beclomethasone 100 deliver the largest fine particle fractions of 1. 1-3.1 µm. The changes in 
delivered dose during the lifespan for the fluticasone 1 25 and 250 may have implications for patient 
care. 
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Chapter 3 Comparative in vitro evaluation of four corticosteroid metered dose inhalers: 
consistency of delivered dose and particle size distribution 
For the treatment of asthma the inhalation of medication is preferred and its effectiveness is widely 
appreciated. 1 •2 The preferred size of the inhaled particles for deposition in both central and peripheral 
airways is claimed to be 1 -5 µm for adults,3 and 1 . 1 -3 µm for children.4•5 The delivered dose as percent­
age of the label claim as well as the particle size distribution (PSD) within the delivered dose has major 
influence on the site and amount of drug deposited in the airways. 
Recent developments include the switch from chlorofluorocarbon (CFC) to hydrofluoroalkane (HFA) 
containing formulations for environmental reasons. This switch resulted in dramatic changes in plume 
properties6 and particle size distributions in the aerosol.7 For instance, for beclomethasone dipropionate 
(BOP) the same serum levels from a CFC-MDI as from only half the dose with an HFA-MDI after inhalation 
have been reported.8 As the results of in vivo studies are largely dependent on pMDI performance, a 
change in pMDI should be thoroughly investigated to interpret in vivo studies with caution. 
Furthermore ciclesonide (CIC), a new inhaled corticosteroid, was introduced. Ciclesonide is a prodrug 
which is converted into the active metabolite in the airways. Its high protein binding allows its use 
only once daily. It has been formulated as an aerosol solution for a pMDI with a hydrofluoroalkane as 
propellant, and most of the particles produced are claimed to be between 1 and 5 µm.9 
To the best of our knowledge, no studies have been published in which the consistency of delivered dose 
and physical properties of the aerosol of ciclesonide are compared with other aerosols. Information about 
delivered dose and PSD is essential for both in vitro studies and clinical trials. 
This prompted us to compare the ciclesonide 1 60 µg/dose pMDI with three other widely used pMDls 
containing ICS: fluticasone 1 25 µg/dose, budesonide 200 µg/dose, and beclomethasone 100 µg/dose on 
their fine particle doses ( 1 -5 µm) and the influence of lifespan of the pMDI, flow rate, and relative air 
humidity on the aerosol properties. 
MATERIALS AND METHODS 
Pressurized metered dose inhalators were obtained from the local hospital pharmacy. The pMDls tested 
were: fluticasone dipropionate 1 25 µg/dose (FP, Flixotide®, GlaxoSmithKline); budesonide 200 µg/dose 
(BUD, Pulmicort"', AstraZeneca); ciclesonide 1 60 µg/dose (CIC, Alvesco®, Nycomed); and beclomethasone 
di propionate 1 00 µg/dose (BDP, Ovar"', Teva). The CIC and BDP pMDls are CFC-free and contain clear drug 
solutions; FP contains a CFC-free suspension whereas BUD contains a suspension in a mixture of CFC 
propellants. Table 3.1 compares some properties of the pMDls studied. 
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Name Shape of Dimensions Distance of Propellants/solvents 
mouthpiece mouthpiece nozzle to 
(mm) mouthpiece 
end (mm) 
Fluticasone Oval 1 5 x10 21  Tetrafluorethane 
flattened 
sides 
Budesonide Oval 18x1 3 27 T rich lorofl uormethane 
Dichlorodifluormethane 
Beclomethasone Circu lar 1 6  diameter 33 Norflurane / ethanol 







Table 3.1 Some physical properties of the metered dose inhalers and actuators studied, measurements in millimetres. 
MEASUREMENT OF DELIVERD DOSE 
pMDls were connected to a filter system with Gelman glass filters A/E, P/N 61663 ; diameter 50 mm 
(Gelman Sciences, Ann Arbor, Michigan, USA). The filter system was supplied with a flow control unit and 
a solenoid valve with timer to set the flow rate to 20 I/min and suction time to 3 s. The suspension pMDls 
were shaken for at least 10 s before doses were fired with the mouthpiece in a coupling flange with seal 
to prevent suction of false air and loss of aerosol. Time between firing of subsequent doses was at least 
60 s to prevent excessive cooling of the pMDls. 
For three different devices (of the same batch) per type of inhaler, 15 individual doses were collected 
in the filter and analysed subsequently :  five doses were taken from the beginning, five from the middle 
and five towards the end of the lifespan of the pMDI. The remaining doses in between were collected 
in groups of 5-40 and analysed together. The first ten doses of each new pMDI were wasted. Filter and 
mouthpiece retentions were dissolved in ethanol (analytical grade) and the drug solutions were analysed 
with a spectrophotometer (Unicam UV 500, ThermoSpectronic, UK) at 236 nm for fluticasone, 244 nm for 
budesonide, 243 nm for ciclesonide, and 239 nm for beclomethasone after it was checked with standard 
drug solutions added to filter depositions, so that the propellants in the drug formulations did not disturb 
the spectrophotometrical analysis. Checks have also been done on filter adsorption and the release of 
ethanol soluble components from the plastic mouthpiece parts. 
PARTICLE SIZING IN THE AEROSOLS 
For measurement of the particle size distributions (PSDs) in the aerosols from the pMDls we used a 
laser diffraction apparatus (Sympatec Helos BF Magic) with inhaler adapter (Inhaler 2000, Sympatec, 
Clausthal-Zellerfeld, Germany). The inhaler adapter has a flow controller and solenoid valve with timer to 
adjust to the desired inspiratory flow rate and suction time. The flow rate was measured with a venturi­
meter. Unless indicated otherwise, suction of the aerosol through the laser beam was at a constant flow 
rate of 10 I/min during 3 s. This was decided after it was checked with time sliced measurements that 
this time is sufficiently long enough to draw the entire aerosol from the pMDI through the laser beam. Al l  
measurements were started on an optical signal on detector channel 30 (for fine particles) of 0.20/o. The 
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relative humidity in the laboratory (at a room temperature of 20-22 °C) was varied between low (approx. 
300/o), median (approx. 550/o) and high (approx. 750/o) to investigate the effect of ambient conditions on 
the particle size distribution. 
A 100 mm (R3) lens was used with a measuring range of 0.5-1 75 µm and calculations were made with 
the Fraunhofer theory after it was checked that no overestimation of fine particles occurred. Ghost peaks 
from propellant(s) were removed with forced stability. No sheath or counter flow through the adapter was 
added to the aerosol cloud and the distance from the exit of the mouthpiece to the laser beam was fixed 
to 50 mm after it was checked that this yields realistic size distributions. The pMDI was fired manually and 
the particle size distributions in the aerosol were measured for five doses taken from the beginning, five 
from the middle and five towards the end of the lifespan of the pMDI. Additionally, the effect of flow rate 
(10, 20, and 30 1/s) on the PSD was determined. Data per flow rate are the mean of 3 series of 5-10 doses 
in which each series is for a different pMDls from the same lot. PSDs are presented as X10-, \0- and \0-
values derived from the cumulative volume distribution curves as a function of the particle diameter. 
Statistics were performed using SSPS for Windows (version 1 3.0) and all tests were performed two sided, 
a p < 0.05 was considered statistically significant. 
RESULTS 
Figure 3.1 shows the mean metered dose (with maximum and minimum values obtained) as percent of the 
label claim from the three different devices of the same batch for all four pMDls. In Figure. 3.1 the mean, 
maximum and minimum per device are for all doses, except for the first ten which were intentionally 
wasted. As expected there is a spread in metered dose for every individual pMDI. The variation is 
particularly extreme for at least two of the FP pMDls, varying from 620/o to 1 580/o, respectively from 720/o 
to 1 620/o of the label claim for the devices 1 and 2, this is statistically significant. The mean metered 
dose is approximately 100/o higher for CIC than for the other pMDls, but the mouthpiece retention in this 
inhaler is higher too: 300/o versus 11 -1 90/o for the other pMDls. As a result, the delivered dose from CIC 
is more or less the same as that from the FP and BUD pMDI: on average 850/o of the label claim. Only the 
BDP pMDI has a slightly lower delivered dose of 700/o of the label claim. 
121 delivered dose 
150 �.--�-------i • mouthpiece retention Figure 3.1 Mean metered dose (for all doses) as 
percent of label claim for three different devices of 
the same type taken from the same lot with spread 
bars indicating the maximum and minimum values 
obtained. 
FP = fluticasone 125 µg/dose; 
BUD = budesonide 200 µg/dose; 
BOP = beclomethasone 100 µg/dose; 
CIC= ciclesonide 1 60 µg/dose. 
Figure 3.2 a-d shows the consistency of the delivered doses for all devices within their lifespan. It can be 
seen that there is a small, not clinically significant spread between the delivered doses of BDP and CIC and 
that two BUD pMDls exhibited a low output at the start after having already wasted the first 10 doses, one 
of them was statistically significant. The delivered dose of FP pMDI decreased statistically significantly 
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with the number of doses taken to less than 70°/o of the output in the first actuations. Because we were 
surprised by this result we studied twelve additional FP 125 µg pMDls taken from different lots, and also 
measured (in duplo) the delivered dose of FP 50 µg and 250 µg for comparison. 
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Figure3.2 a-d: Delivered dose in µg at the start (5 1-55), the middle (M 1-M5) and the end (E1-E5) of the lifespan of the same 
device. FP = fluticasone 125 µg/dose; BUD = budesonide 200 µg/dose; BOP = beclomethasone 100 µg/dose; CIC = ciclesonide 
1 60 µg/dose. 
Figure 3.3 sum marises the mean values with spread bars showing maximum and minimum doses 
obtained. It was found that the output of FP 50 remains constant. However, the delivered dose of FP 
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Figure 3.3 Changes in the delivered 
dose from fluticasone (FP) 50, 125 
and 250 µg with the cumulative 
number of doses taken from the same 
device. Data points for FP 125 µg are 
the mean of 15  devices (from five 
different batches); those for FP 50 and 
250 µg are the mean of two devices 
(from different batches). Spread bars 
indicate the maximum and minimum 
values obtained. 
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Characteristic values (X10, X50 and X90) from the cumulative volume distributions in the aerosol are 
presented in Figure 3.4 The X50 of FP (3.5 µm) is significantly greater than all others, and the X50 of BUD 
(2.8 µm) is significantly greater than those of BDP and CIC ( 1.9 µm for both devices). Also the spread 
in droplet size is much smaller for BDP and CIC. FP 125 µg showed a great inter-device spread in size 
distribution; mean values for the median droplet diameter varied between 2. 1 and 3.8 µm for individual 
devices from different batches, this is statistically significant. For BDP and CIC the inter-device variation 
with respect to PSD was negligible, whereas the X50-value for BUD ranged from 2.7 to 3.0 µm which is 
statistically significant. The data in figure 3.4 are for one particular device producing a representative 
aerosol and each data point in figure 3.4 is the mean of five doses taken from the start (S), middle (M) 
or end (E) of the inhaler's lifespan. We also checked the size distributions in the aerosols from the FP 50 
and 250 µg pMDls and found that the FP 50 µg has a much smaller median diameter (X50 is 2.7 µm) than 
the FP 125 µg. In contrast, the FP 250 appeared to deliver significantly larger particles with a median 
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Figure 3 .4 Particle size 
distribution of within lifespan 
of the pMDI for fluticasone (FP) 
125 µg, budesonide (BUD) 200 µg, 
HFA beclomethasone (BOP) 
100 µg, and ciclesonide (CIC) 
160 µg at a suction of 10 I/ 
min through the laser beam. 
S, M and E refer to doses taken at 
the start, middle and end of the 
lifespan respectively. 
Figure3.4 also shows that the PSDs of all four pMDls remained rather constant within their lifespan. 
The relative air humidity within the range from 30 to 750/o had no significant influence on particle size 
distribution. For FP and BUD the inter-device variations were significantly larger than for BDP and CIC. 
The influence of the flow rate on the particle size distribution in the aerosol is shown in Figure 3.5. This 
figure demonstrates the small effects of the flow rate on the PSD for all 4 tested devices within the range 
between 1 0  and 30 I/min. Due to differences in metered dose, mouthpiece retention and size distribution 
in the aerosol, different fine particle mass fractions (FPF < 5 µm as percent of label claim) may be 
expected. This is shown in Figure 3.6. 
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- Figure 3.5 The particle size distribution in the aerosol 
as function of the flow rate . 
FP = fluticasone 125 µg/dose; 
BUD = budesonide 200 µg/ 
dose; BOP = beclomethasone 
100 µg/dose; 
CIC = ciclesonide 160 µg/dose. 
All three pMDls of the same type showed a very high consistency in mean delivered fine particle mass 
fraction, the fraction < 5.0 µm being highest for the CIC pMDI. The aerosols from the FP and BUD pM DI 
contained only very few particles < 1  µm but for the BOP and CIC pMDI nearly 150/o of the delivered 
aerosol was in the particle range of <1 µm. There were also considerable differences for the fraction 
3. 1-5 µm, between FP and BUD on the one hand (respectively 290/o and 240/o of the label claim) and BOP 
and CIC on the other (approx. 100/o for both). For the fraction 1. 1-3. 1 µm the CIC pMDI scored best (550/o), 
followed by BOP (440/o), BUD (420/o) and FP (390/o). 
1 00 
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Figure 3.6 The size distribution within the fine particle fraction as percent of label claim based upon the mean delivered dose 
from the pMDI at 20 I/min. FP = fluticasone 125 µg/dose; BUD = budesonide 200 µg/dose; BOP = beclomethasone 100 µg/dose; 
CIC = ciclesonide 160 µg/dose. 
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To our knowledge, this is the first study to compare the in vitro performance of four different ICS pMDls 
including FP, BUD, BDP, and CIC at three different flow rates and taking lifespan and ambient humidity 
conditions into account. Most previous studies dealt with single pMDls. 1 0-1 5 Terzano studied the particle 
characteristics of FP, BDP, and flunisolide in vitro at two different flow rates (30 and 60 l/min). 1 6  Feddah 
compared the in vitro performance of three ICS DPls with pMDls containing the same drugs (FP, BUD and 
BDP) in an impactor at three different flow rates (30, 60 and 90 I/min) but their study did not include 
BDP and CIC. 1 7  Dalby, Barry and Stein also compared the performance of three different pMDls, but their 
comparisons included other types of drugs, like salmeterol, salbutamol, and cromolyn sodium. 1 0-20 
Figure 3.1 shows that none of the pMDls tested delivered a mean dose corresponding with the label claim. 
The spread found in delivered dose was relatively high for FP and also significant for BUD. For the BUD 
pMDI this was the result of a random variation, showing a few extremes towards lower values varying 
between 520/o and 790/o of the label claim (Figure 3.2b}. However, for FP a gradual and significant decrease 
in delivered dose was obtained over the lifespan of the pMDI. This decrease appeared to be consistent for 
15 devices taken from five different batches as shown in Figure 3.3. On average (for all fifteen devices) 
the mean of the doses 11-20 from this pMDI was 1060/o of the label claim versus only 630/o for the mean 
of the doses 92- 100. This reduction is not only statistically significant, but also of clinical importance. We 
did not find an explanation for the inconsistencies found. However, these results point at the importance 
of knowing which doses from FP and BUD are used for in vitro studies as well as for clinical trials. 
For all four types of pMDls the delivered dose is lower than the metered dose due to some retention in 
the mouthpiece. As summarised in Table 1 mouthpieces have different shapes and dimensions; only those 
of CIC and BDP are the same. We found a 150/o reduction for the mouthpiece retention of BDP and CIC 
by shortening the distance of the nozzle to the mouthpiece end to 21.5 mm. Shortening also appeared 
to influence the PSD in the aerosol. For BDP the X50-value decreased from 1.95 to 1.79 µm; for CIC the 
decrease was from 2.02 to 1.8 µm. Mouthpiece shortening may also have consequences for the deposition 
in the mouth and valved holding chambers however. The net result of all these effects has to be studied. 
Regarding the particle size distributions in the aerosols (Figure 4, Figure 5 and Figure 6) previous findings 
obtained with cascade impactor analysis are confirmed. 10• 1 7• 1 9·20 BDP and CIC pMDls deliver much finer 
particles than FP and BUD pMDls. The data in Figure 6 suggest that BDP and CIC produce the highest 
mass fractions within the size rang of <3. 1 µm and therefore are most appropriate for use in children 
because of their smaller airways. The relatively high fraction of particles < 1. 1  µm in the aerosols from 
the BDP and CIC is likely to be exhaled to a large extent again, unless a relatively long breathhold period 
is established. 21 ,22 
The PSDs for all four pMDls do change statistically significant, but we do not think this is clinically 
relevant within their lifespan, nor when the flow rate or relative humidity is varied between 10 and 30 I/ 
min, respectively 30 and 750/o. 
In contrast with most previous studies we used a laser diffraction technique for the characterisation of 
the particle size distribution in the aerosol. With the laser diffraction technique the size distribution of 
individual doses can be measured more reproducibly than with impactors, which suffer from variable 
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losses in the valve, actuator, and USP throat.20 Therefore, the laser diffraction technique enables a better 
assessment of the spread in the fine particle dose in the emitted aerosol. There is a discrepancy between 
previously published data from cascade impactor analysis and the laser diffraction data in this study for 
the same pMDls. For instance, we found a volume median diameter of 1 .9 µm for BDP (Figure 4). Leach 
and Stein referred for BDP to an average particle size of approximately 1 µm; and from their cascade 
impactor data mass median aerodynamic diameters (MMADs) of 0.9- 1 .0 µm can be calculated. 7•20 The 
reason for the different results may be losses in the induction port. For BDP these losses are within the 
range from 20 to 300/o of the label claim (at approx. 30 I/min). Partly as a result of that, cumulative fine 
particle fractions collected in the impactor were only between 40 and 500/o of the label claim.20 With the 
laser diffraction technique there are no losses in an induction port and the mean delivered dose for BDP 
in our study was more than 700/o. Possibly classification occurs in the throat of an impactor, as a result of 
which the size distribution within the remaining aerosol fraction is changed. Moreover, the evaporation 
during longer travelling distance in cascade impactors is likely to result in an overestimation of the fine 
particles. There are more basic differences between cascade impactor and laser diffraction technique, but 
it is very unlikely that the differences in median diameters obtained with both techniques are the result 
of that. 
CONCLUSIONS 
In this study we show that the in vitro evaluation of ICS pMDls under well-controlled conditions is 
mandatory for adequate evaluation of drug delivery studies in patients. We have demonstrated that 
the performance may vary over the lifespan of the pMDI and the fine particle fraction differs relevantly 
between different !CS. Design, such as the length of the mouthpiece, significantly influences dose delivery. 
We found that the delivered dose of FP 1 25 and 250 decreased significantly during its lifespan, and in some 
of the BUD pMDls the first delivered doses were significantly lower. Although our data are consistent, they 
have to be confirmed by others and the clinical relevance should be investigated. The particles of CIC and 
BDP are the most appropriate for paediatric use. Our results partly confirmed earlier studies. 
Before testing a combination of valved holding chambers and pMDls, the performance of the pMDI itself 
should be known in relation to the environmental conditions and the inspiratory flow rate. Furthermore it 
is important to realise that there may be a significant inter-dose spread as well as inter-device variations 
regarding delivered dose and PSD. Particularly an inter-device spread makes it necessary that the same 
pMDI is used for comparison of data obtained with and without holding chamber. Knowledge of in vitro 
performance is essential to value important in vivo studies. 
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Chapter 4 High air humidity increases delivered total and fine particle dose 
of inhaled corticosteroids from valved holding chambers 
Abstract 
Background 
Optimal clinical effects of inhaled corticosteroids (ICS) in patients with asthma depend on their 
deposition in both large and small airways. This requires a high fine particle dose in the aerodynamic 
size range 1-3µm. We studied the effect of relative air humidity, lag time and flow rate on the delivered 
fine particle dose from 6 ICS pressurized metered dose inhalers (pMDl)-valved holding chamber (VHC) 
combinations. 
Methods 
Fluticasone 125 µg, budesonide 200 µg, beclomethasone dipropionate 100 µg and ciclesonide 1 60 µg 
were delivered by pMDls without VHCs and with fully primed VHCs. Aerosol doses were collected on 
filters at low (25-350/o), medium (55-650/o) and high (74-800/o) relative air humidity and analysed using 
UV absorption. Particle size distributions of the aerosols were measured using laser diffraction with a lag 
time of O to 20s after firing the pMDls. Suction flow rates were 10, 20 and 30 L/min. 
Results 
Increasing relative air humidity from 300/o to 800/o increased total delivered dose from VHCs by a factor 
1.4 (mean value of all combinations; p<0.002 ;  range 1.0-2.0) without significantly changing the particle 
size distributions. Fine particle doses from VHCs at medium relative humidity were 16.90/o of label claim 
from pMDI for fluticasone (Volumatic®) ,  18.60/o for budesonide (Nebuhaler®), 24.50/o for beclomethasone 
(AeroChamber®), 36.60/o for ciclesonide (AeroChamber®) ,  all comparisons p<0.001. Suction flow rate did 
not change the Volume Median Diameter (VMD) of ICS from VHCs. The VMD reduction after 20 seconds 
lag time was less than 50/o (mean value). 
Conclusions 
High air humidity leads to an increased delivered total and fine particle dose ( 1-3 µm) from VHCs 
compared to low humidity. The subsequently higher ICS deposition in large and small airways may 
lead to better asthma control. We recommend using ICS from VHCs in humid environments, like in a 
bathroom. 
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Asthma is an inflammatory d isease affecting both large and small ai rways. 1 -2 Targeting the small 
ai rways with inhaled corticosteroids (ICS) is regarded the important challenge of ICS treatment,3-7 in 
particular as the number of ICS receptors increases towards the lung periphery.8 Clinical stud ies sug­
gest that ICS with a large fine particle fraction (1-3 µm) might be more effective than ICS with larger 
particles.9-1 2  This is compatible with the observation that 1.5 µm ICS particles provide higher periphe­
ral and higher total l ung deposition than particles of >3 µm.13 
Adequate inhalation technique is required for optimal inhaled d rug treatment. Valved hold ing chambers 
(VHCs) are used to overcome frequently encountered coordination problems with the use of a pressurized 
metered dose inhaler (pMDI). Additional advantages of VHCs are that they allow for the retention of 
large particles in the VHC 14 and reduce the speed of the aerosol particles in the mouth and throat 
region 1 5, resulting in lower oropharyngeal deposition. 
A disadvantage of VHCs is that they may reduce the total dose available for inhalation due to d rug 
deposition onto the inner wall of the VHC caused by electrostatic charge deposition, sedimentation by 
gravity, and inertial deposition due to the high plume velocity. 1 6- 1 8  This reduction of total dose is less 
when the VHC is washed or primed. 1 9.2° Relative humid ity can affect electrostatic charge, but to what 
extent is yet unknown. Fu rther, a lower inhalation flow rate and longer lag time between dose fi ring 
and inhalation from the VHC may decrease the fine particle dose from VHCs. These three factors, i.e. 
relative air humidity, inhalation flow rate and lag time, may thus reduce cl inical efficacy of ICS when 
administered with a pMDI-VHC combination. Therefore, we studied these three factors on both total 
dose and fine particle dose delivered from six pMDI-VHC combinations and compared delivered dose 
from the VHC to label claim and delivered dose directly from the pMDI. 
Our u ltimate goal was to find the best combination and the best circumstances for optimal (fine particle) 
output, which may contribute to improved treatment of patients with asthma. 
MATERIALS AND METHODES 
pMD/s and VHCs 
The hospital pharmacy provided pMDls; the manufacturers provided the VHCs studied. The ICS tested 
were fluticasone dipropionate (FP) 125 µg/dose:120 doses (Flixotide®, GlaxoSmithKl ine) ; budesonide 
(BUD) 200 µg/dose: 200 doses (Pu lmicort® , AstraZeneca) ; ciclesonide (CIC) 160 µg/dose: 200 doses 
(Alvesco®, Nycomed) ;  beclomethasone dipropionate hyd rofluoralkane (H FA;  BDP) 100 µg/dose: 60 doses 
(OVAR®, Teva). The beclomethasone and ciclesonide pMDl's have d rug solutions in HFA with ethanol 
as co-solvent and yield fine particle aerosols: (volume median diameter for both d rugs is 1 .9 µm as 
measured with laser diffraction technique.21 The fl uticasone pMDI with an ethanol-free HFA suspension 
and the budesonide pMDI with a suspension in a mixture of CFC propellants, yield larger particle aerosols 
(volume median diameter 3.5 µm en 3.0 µm respectively.21  We included fine and larger ICS aerosols in 
ou r study to investigate the influence of the particle size distribution on the output from VHCs. The 
suspension pMDls were shaken for at least 10 seconds before doses were fired. Time between firing of 
subsequent doses was at least 60 seconds to prevent excessive cooling of the pMDls due to propellant 
evaporation. The first ten doses of each new pMDI were wasted. The total number of doses used for each 
part of the study is summarised in the data collection protocol (Table 4.1). 
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VHCs used were Volu matic® (Al len 8: Hanburys Ltd) with fl uticasone, Nebu ha ler® (AstraZeneca) with 
budesonide and AeroChamber P lus® (Trude l l  Med ica l I nternationa l )  with beclomethasone, c ic leson ide, 
fl uticasone  a nd budeson ide. The VHCs were either used new (unwashed, non-pr imed), fu l ly primed (> 20 
doses) or washed by d i pp ing in  a fresh, m i ld  so l ution of l iqu id  d ish detergent in  l u kewarm clea n water 
fo l lowed by d rying to a i r. After the study was comp leted, the anti-static AeroChamber Pl us F low-Vu® 
beca me ava i lable.  This VHC was tested unprimed and  unwashed as i nstructed in the patient i nformation 
l eaflet. 
Combinat ion :  FP+VOL FP+AC BUD+NEB BUD+AC BDP+AC CIC+AC 
1 .  Effect of relative air humidity on delivered dose from VHC 
Flow rate: 20 L/m i n ;  suction  t ime: 12 s; relative air h umid ity: 25-350/o; 55-650/o and 75-800/o; lag time: 3 s 
N u mber of doses* 498 486 603 648 1 026 
2 .  Effect of lag t ime on  del ivered dose from VHC: 
Flow rate: 20 L/m i n ;  suction  time: 1 2  s; relative air h um id ity: 500/o; lag t imes: 1 ;  3 ;  5; 10 and 20 s. 
N u mber of doses* 1 05 1 05 1 00 1 05 
3. Effect of washing and priming on delivered dose from VHC 
Flow rate :  20 L/m in ;  suction time: 12 s; relative a i r  h umidity :  300/o; lag t ime: 3 s. 
N u m ber of doses* 90 90 
4. Effect of flow rate on particle size distribution from p MDls and VHCs 
Flow rates: 10; 20 and 30 L/m in ;  suction times: 3 s (pM Dls) and  5 s (pMDl+VHC) ; lag time:  3 s 
N u mber of doses* pMD I :  60 
pMD l+VHC: 
45 
pMD I :  60 
pMDl+VHC: 
45 
pMD I :  60 
pMDl+VHC: 
45 
5. Effect of lag time on particle size distribution from VHC 
pMDI :  60 
pMDl+VHC: 
45 
pMD I :  60 
pMDl+VHC: 
45 
Flow rate: 10 L/m in ;  suction  t ime: 5 s; relative air h um idity: 500/o; lag t imes: 1 ;  3; 5; 10 and 20 s 
N u mber of doses* 60 60 60 60 60 
468 
1 1 0  
90 




*The tota l n umber of doses used depends on the number of doses in the pMD I ;  the first and last ten doses of each pMDI  
were excluded. The tota l n umber of  doses from pMD ls used i n  this study:  551 4 
Table 4. 1 Data collection protocol. 
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MEASUREMENT OF DELIVERED DOSES 
pMDls and VHCs were connected to a filter system with glass filters (Gelman Sciences, Ann Arbor, 
Michigan, USA). The filter system was supplied with a flow control unit and a solenoid valve with timer 
to set the desired flow rate and suction time. Suction time was adjusted to assure complete emptying of 
the total system (Table 4. 1). Single breath inhalation from a VHC is currently advised in clinical practice 
whenever possible instead or tidal breathing.22 
Drug deposits on filter were analysed with a spectrophotometer (Unicam UV 500, ThermoSpectronic, U K) 
after dissolution in ethanol or water. The procedure was checked with standard drug solutions added 
to filter depositions, to make sure that the propellants in the drug formulations did not disturb the 
spectrophotometrical analysis. Checks and, if necessary, corrections were also done on filter adsorption 
and the release of ethanol soluble components from the plastic mouthpiece parts. We alternatingly 
measured 9 subsequent doses together from the pMDI  and 9 together from the pMDI  with VHC because 
of the previously reported large variation in delivered dose from pMDls.21 Each 10th dose was used 
to analyse the mouthpiece retention from the pMDI. We did so for all doses from the pMDI with two 
different devices from the same batch and averaged all data of two duplicate pMDI-VHC combinations. 
We also assessed delivered dose from unwashed, unprimed VHCs and compared them with washed 
VHCs. 
MEASUREMENT OF PARTICLE SIZE DISTRIBUTION 
Particle size distributions in the aerosols from the pMDls and pMDI-VHCs, were measured with laser 
diffraction technique (HELOS BF MAGIC) using an inhalation adapter (INHALER 2000, both Sympatec, 
Clausthal-Zellerfeld, Germany). The inhalation adapter used has a flow controller and solenoid valve 
with timer to adjust the desired inspiratory flow rate and suction time. A 1 00mm (R3) lens was used 
with a measuring range of 0.5 to 1 75 mm. All measurements were started on an optical signal on 
detector channel 30 (for fine particles) of 0.20/o. Calculations were made with the Fraunhofer theory 
after checking that no overestimation of fine particles had occurred. Ghost peaks from propellants were 
removed with forced stability. Further details are described in our previous study.21 With laser diffraction 
technique Volume Median Diameters (VM D  or X50) are derived from the cumulative volume distribution 
curves and X,o as well as X90 define the size range of the aerosol. We did not aim to measure the absolute 
aerodynamic size distributions in the aerosols. Our aims were focussed on measuring the changes in the 
size distribution as function of the relative air humidity, flow rate and lag time, with and without VHC. 
Laser diffraction was used as these aims cannot be met in the same way and for the large number of 
doses with cascade impactor analysis. 
All laser diffraction measurements were performed at medium relative humidity since humidity had a 
negligible effect on particle size distributions. The fine particle fractions were defined as the volume 
fractions between 1 .0-3.0 µm. 
To study the effect of the inspiratory flow rate on the volume median diameter, suction of the aerosol 
through the laser beam was set at a constant flow rate of 10, 20 or 30 L/min during 3 seconds for pMDls 
and 5 seconds for VHCs. Time-sliced measurements showed that 5 seconds at 1 0  L/min are sufficient to 
obtain a representative measurement of the particle size distribution in the aerosol. 
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The distance from the exit of the pMDI  or VHC mouthpiece to the laser beam was fixed at 50 mm. 
A longer distance did not change the particle size distribution, which suggests that droplet evaporation 
or particle growth did not occur. 
DELIVERED TOTAL DOSE FROM VHC AND RELATIVE AIR HUMIDITY 
Measurement of the effect of relative air humidity on delivered doses from (fully primed) VHCs was 
performed at a flow rate of 20 L/min. Humidity values were 25-350/o (low), 55-650/o (medium) and 75-
80 0/o (high) in a room with temperature varying between 1 8.5 and 20.5 °C. All doses from two different 
pMDls from the same batch were used for each pMDI-VHC combination at each humidity-condition 
and the data per combination (and condition) were averaged. After the study was completed, the anti­
static AeroChamber Plus Flow-Vu® became available. The delivered dose from this antistatic device was 
compared with that from the previously used AeroChamber® for CIC and BDP at low (250/o) and medium 
(650/o) RH. CIC and BDP were used anticipating that the effect of electrostatic charge is largest for the 
smallest particles. 
EFFECT OF LAG TIME AND VHC PREPARATION ON DELIVERED DOSE VHC 
Total delivered dose from the fully primed VHCs as function of the lag time between firing of a dose 
and suction (1 ; 3; 5; 1 0  and 20 s) was measured at a flow rate of 20 L/min and at medium humidity. 
We also assessed the total delivered dose from unwashed and unprimed VHCs and compared them with 
washed VHCs 
EFFECT OF FLOW RATE ON PARTICLE SIZE DISTRIBUTION 
The effect of the inspiratory (suction) flow rate on the volume median diameter in the aerosols from 
pMDls and pMDI-VHC combinations, was studied with constant flow rates of 10, 20 or 30 L/min at 
medium humidity. 
EFFECT OF LAG TIME ON PARTICLE SIZE DISTRIBUTION 
To study the effect of the lag time (1 ; 3; 5; 10  and 20 s) between firing of a dose and suction on the 
particle size distribution of the aerosol from the VHC at medium humidity, the inspiratory flow rate was 
set at 1 0  L/min. 
FINE PARTICLE DOSE 
The fine particle dose was calculated on the basis of measured delivered dose on filter and the fine 
particle fraction measured with laser diffraction analysis 
STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS, version 1 4. We used the Kruskall-Wallis test for comparison 
of more than two groups. Differences between 2 groups were analysed by means of the Mann-Whitney 
U test. A p-value of < 0.05 was considered significant. 
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The impact of relative humidity on delivered total dose from pMDI-VHC combinations 
VHC output, expressed as percentage of pMDI output, increased with higher relative air humidity, 
except for budesonide with AeroChamber®. The overall mean VHC output, expressed as percentage of 
the delivered dose from the pMDI without a VHC, increased from a mean of 340/o in all combinations at 
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Figure 4.1 Delivered doses from primed and washed VHCs as a percentage of the delivered doses from the pMDls, for three 
different relative humidity (RH) ranges. Each bar is the mean of two devices from the same batch over the total lifespan (i.e. 
200 doses per device for HFA-BDP and BUD; 120 for FP and 60 for CIC}. The Kruska/1-Wallis test ·was used for comparison of 
the 3 tested humidity ranges. 
AC =AeroChamber®,Plus; BOP = beclomethasone; BUD = budesonide; CIC = ciclesonide; FP = fluticasone; NEB= Nebuhaler®; 
pMDI = pressurised metered dose inhaler; RH = relative humidity of the air; VOL=Volumatic ® 
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sig n ifica nt for a l l  combinations, except for budeson ide  with the AeroChamber® (Figure 4. 1 and  Table 
4.2). VHC output for fl uticasone  + Vol umatic® i ncreased with 1 020/o from low to h i g h  relative h u m id ity 
(p = 0.001 ) ,  for fl uticasone  + AeroChamber® with 640/o (p = 0.001 ) , for cicleson ide  + AeroChamber® 
with 570/o (p < 0.001 ), for beclomethasone + AeroCha m ber® with 540/o (p < 0.001 ) whereas the change 
for budeso n ide + Nebuha ler® was lowest with 1 00/o (p = 0.002). 
BOP  a n d  C IC  in the antistatic Aerochamber® Pl us F low Vu™ a lso showed an i ncrease i n  de l ivered dose 
with i ncreas ing h um id ity: CIC output increased from 440/o to 71 0/o and  BPD from 1 40/o to 61 0/o from 
low to m ed i u m  h u mid ity. 
Drug-VHC Humidity VHC output p-value between 
O/o from pMDI relative humidity ranges 
mean (Cl) 
FP-VOL All p = 0.001 
Low 22.9 (19.0-26.8) low-medium 0.005 
Medium 38.0 (28.5-47.5) low-high <0.001 
High 46.2 (40.9-51.5) medium-high >0.1 
FP-AC All p = 0.001 
Low 18.7 (12.2-21.2) low-medium >0.1 
Medium 19.5 (15.1-24.0) low-high 0.001 
High 30.7 (26.8-34.6) medium-high 0.003 
Bud-NEB All p = 0.002 
Low 44.2 (42.6-45.8) low-medium >0.1 
Medium 45.7 ( 44.4-4 7 .1) low-high 0.001 
High 48.8 (47.2-50.4) medium-high 0.019 
Bud-AC All p = 0. 13 
Low 34.6 (29.3-40.2) 
Medium 28.4 (26.5-30.3) 
High 30.2 (28.4-32.0) 
BOP-AC All p < 0.001 
Low 39.4 (37.3-41.5) low-medium <0.001 
Medium 55.5 (52.7-58.3) low-high <0.001 
High 60.5 (58.2-62.8) medium-high 0.018 
CIC-AC All p < 0.001 
Low 44.3 (42.7-45.9) low-medium 0.001 
Medium 58.0 (54.4-61 .6) low-high 0.001 
High 69.5 (64. 1 -74.9) medium-high 0.021 
Table 4.2 The impact of relative humidity on the pMDl+VHC output compared to the output from 
pMDls without VHC. Cl = 95% confidence intervals. 
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DELIVERED FINE PARTICLE DOSE FROM pMDls AND pMDI-VHC COMBINATIONS 
Aerosols from pMDI-VHC combinations had (on average) a slightly smaller volume median diameter 
(VMD) than the aerosols directly from the pMDls, except for the ciclesonide - AeroChamber® combina­
tion (Figure 4.2). In addition, the fraction of particles < 1 . 1 µm increased for all pMDls when delivered 
from the VHC (Table 4.3). However, this hardly affected the volume percentages between 1.0 and 3.0 µm 
which are most relevant for peripheral lung deposition as well as the most homogeneous drug deposi­
tion over the whole lung.13 Only fluticasone with Volumatic® showed an increase in fine particle dose 
(FPD) from 42.90/o (for pMDI) to 49.90/o for pMDI plus primed VHC (p<0.01 ) (Table 4.3). The differences 
in delivered doses and in particle size distributions between the pMDls alone and the pMDI-VHC com­
binations resulted in different delivered fine particle doses (Table 4.3). The fine particle dose at medium 
humidity, using a fully primed or washed VHC, ranged between 440/o (fluticasone-Volumatic®) and 600/o 
(ciclesonide-AeroChamber®) of the fine particle dose directly from the pMDI. 
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Figure 4.2 Volume median diameters in  the aerosols from fully primed VHCs (shaded bars) a t  three different flow rates com­
pared to the volume median diameters in the aerosols directly from the pMDls {black bars). All bars are the mean of three series 
of ten subsequent doses taken from two different pMOls (totalling 60 laser diffraction measurements per bar). Five seconds 
suction time at a medium relative humidity. 
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pMDI Fluticasone Budesonide Beclomethasone 
1 25 µg 200 µg 1 00 µg 
VHC Volumatic® Nebuhaler® AeroChamber ® 
A. Volume percentage < 5 µm in delivered dose (0/o) 
from pMDI 76.69 83. 1 1  95.90 
from primed 86.46 86. 1 7 1 00 
VHC new 82.51 86.98 1 00 
B. Volume percentage < 1 . 1 µm in delivered dose (0/o) 
from pMDI 0.25 4. 1 2  1 8.87 
from primed 0.58 1 0.35 27.07 
VHC new 0.96 1 0.38 30.91 
C. Volume percentage 1 .0-3.0 µm in delivered dose (0/o) 
from pMDI 42.92 50.91 62. 1 0  
from primed 49.86 50.53 63 . 1 7 
VHC new 47.90 50.53 62.27 
Table 4.3 Particle size fractions from pMDI and from pMDI-VHC combinations 
Ciclesonide 
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Comparison of particle size fractions in delivered dose from pMDI with fully primed VHC and with new (unwashed, non­
primed} VHC at medium humidity. Results are expressed as a mean of 3-5 doses for pMDI and 10-25 doses for pMDI-VHC 
combinations (at 10 L/min). Primed VHCs compared with unwashed, non-primed VHCs did not differ from each other regard­
ing volume percentages within delivered dose. 
IMPROVING DRUG DELIVERY TO THE LUMGS 68 Towards better inhalation therapy 
Chapter 4 High air humidity increases del ivered total and fine  particle dose 
of inhaled corticosteroids from valved holding chambers 
EFFECT OF INSPIRATORY FLOW RATE AND LAG TIME  
The inspiratory flow rate did not significantly change the volume median diameter (VMD) of the aerosols 
(Figure 4.2), and neither did the lag time between the release of aerosol in the VHC and the start of 
suction. The overall mean reduction in VMD after 20 seconds was less than 50/o (Figure 4.3). 
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Figure 4.3 Relative changes in the volume median diameters of the aerosols from VHCs as function of the lag time between 
firing a dose and aerosol suction from the VHCs at a constant flow rate of 70 L/min (5 s}; testing at medium relative humidity. 
All data points (mean of 2 series of 5 subsequent doses taken from two different pMDls for t >  7 second} are expressed as a 
percentage of the volume median diameter obtained after 7 second lag time. 
The mean reduction in delivered dose after 10 seconds lag time compared to 1 second lag time was 
20.10/o. This reduction was 12.70/o for ciclesonide + AeroChamber®, 15.40/o for fluticasone + Volumatic®, 
15.80/o for beclomethasone + AeroChamber®, 24.70/o for budesonide + AeroChamber® and 32.70/o for 
fluticasone + AeroChamber®. The mean reduction increased to on average 300/o when a longer lag time 
of 20 seconds was applied (Figure 4.4). 
PRIMING AND WASHING OF THE VHC 
Priming was complete after firing at least 10 doses into the AeroChamber® and this was the same for 
all three pMDls tested (data not shown). The experiments were conducted at low humidity, under which 
conditions the effect of priming and washing on the delivered dose is highest. Priming after washing in 
a soap solution and drip drying had no additional effect. 
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Figure 4.4 Output from VHCs after increasing lag time, expressed as percentage of dose output after a lag time of 1 second 
between firing a dose and start of suction. 
DISCUSSION 
The major finding of this study is that a higher relative air humidity increases the drug output from 
fully primed and washed VHCs, even up to a double dose difference for the fluticasone + Volumatic® 
combination (Figure 4.1, Table 4.2). The particle size distribution does not change with increasing 
humidity, thus a higher output translates directly to a higher fine particle dose. Higher humidity also 
increases the output from the new antistatic AeroChamber®. 
A second important finding of our study is that the fine particle dose delivered from fully primed VHCs 
at medium relative humidity may be as low as only 440/o to 6O0/o of the FPO directly from the pMOI 
without VHC (Table 4.4). This corresponds to losses in the VHC of FPO between 4O0/o and 560/o. At low 
humidity these losses are even considerably higher. Low humidity frequently occurs in daily life and 
our data suggest that the resulting lower drug dose output from VHCs can be overcome by inhaling 
medication in a moist environment, like in the bathroom. Finally, our results indicate that VHCs retain 
particles of all sizes and not exclusively the largest particles, although the volume median diameter 
decreases slightly for most combinations compared to that in the aerosol directly from the pMOI  (Figure 
4.2). The flow rate has no significant influence on the volume median diameters of ICS from VHCs 
(Figure 4.2). 
We found that VHC output increases when humidity is higher. This novel finding seems in contradiction 
with former studies that showed lower delivered doses to the lung with higher humidity.23-25 However, 
these studies were performed with experimental setups for mechanically ventilated patients and 
included heating and humidifying of air (up to 10O0/o relative humidity). Furthermore, tubes with 
narrow internal diameters, as well as Y-pieces and T-junctions were used to split and mix air streams by 
compression and suction. In our study, we collected the aerosol on a filter immediately downstream of 
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the mouthpiece and also measured PSD close to the mouthpiece of the VHC. We regard droplet growth 
as an unlikely explanation for the higher VHC output at high humidity as this would not influence the 
drug dose measured on the filters. Neither did we find a shift in the particle size distribution towards 
larger droplets at higher air humidity. 
Where we found losses in the VHC between 40 and 560/o at medium humidity, and even higher losses 
at low humidity, other authors have shown reductions between 0 and 53 0/o of the label claim.26-30 In  
these studies the definition of  fine particle fractions varied between particles of  1 to  5 µm to  'smaller 
than' 4.7- 5.8 µm. In our study we defined fine particles as particles from 1 .0-3.0 µm, as these are the 
most relevant for peripheral lung deposition. Furthermore, in some other studies the effect of relative 
air humidity was not taken into account or reported. 
The 200/o reduction in dose output from a VHC after 1 0  s in our study was substantially less than the 500/o 
reduction described in an earlier study.31 This discrepancy may be due to other conditions during testing, 
such as humidity, which was not reported in the latter study. In our study, we did not find a gradual 
decrease in output as function of the lag time (Figure 4.4). This may be caused by the large variation in 
delivered dose from the same pMDI as well as the inter-device variation as previously described.21 
A lag time of 20 s between firing and inhalation of a dose resulted in a mean output reduction of 300/o 
for all pMDI-VHC combinations tested. For fluticasone and budesonide with volume median diameters 
(VMD) of 3.5 and 3.0 µm from the pMDI respectively, aerosol losses in the AeroChamber® were higher 
(30-400/o) with 20 s lag time than for beclomethasone and ciclesonide with VMDs of 1 .9 µm (20-300/o) 
respectively (Figure 4.4). 
The higher retention for aerosols with larger VMDs in the same VHC within the same lag time may 
be caused by sedimentation. However, the mean VMD decreased less than 50/o after 20 s lag time and 
the reduction in delivered dose of fluticasone after a 20-second lag time was the same for the large 
Volumatic® and the small AeroChamber® (Figure 4.3). We hypothesise that the sedimentation of larger 
droplets keeps the entire aerosol in motion thereby leading to sedimentation deposition of smaller 
particles as well. 
Pre-treating VHCs by washing them in mild ionic detergent, followed by drying to the air has been 
presented as an effective, economical alternative to priming with medication. 19•32 This study underscores 
the usefulness of washing instead of priming since we found that priming with ICS after washing had 
no additional effect on reduction of VHC losses. 
We showed that VHC retention may be considerable and is not exclusively confined to large particles 
of ICS in our study. In general, we hypothesize that the reasons for losses of drug in the VHC are 
sedimentation (caused by gravity), impaction (influenced by the high initial plume velocity as well as 
during suction from the VHC), particle-wall contact by aerosol circulation in the VHC and/or electrostatic 
charge (influenced by VHC material, VHC preparation such as priming or washing, relative air humidity 
and chemical properties of the drug formulation). The increasing fine particle output with increasing 
humidity is also true for the new anti-static AeroChamber Plus Flow-Vu®. 
Why is a large fine particle fraction important? As peripheral airway inflammation is central in asthma 
and the highest density of steroid receptors in the lung is found in the small airways, a higher total and 
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peripheral lung deposition of ICS most likely will improve asthma treatment. 1 •2•8•33• 1 9  Small articles in a 
narrow size distribution (1-3 µm) result in a higher total and more homogeneous lung deposition than 
a wider fraction of particles 1-5 µm.1 3 ·34·35 Particles < 1 µm are mainly exhaled, whereas more than 300/o 
of the particles > 3 µm may be deposited in the oropharynx. 1 3  
The higher lung deposition resulting from a larger mass fraction of fine particles when VHCs are used at 
high humidity may improve lung function 1 1 • 1 2•36, quality of life 9, and asthma control. 10 
Taken together, low air humidity has a relevant and significant negative effect on fine particle output of 
a (fully primed and/or washed or antistatic) VHC. In both d ry cold and dry hot climates, the efficacy of 
the therapy may be improved by administrating the medication in a moist environment (e.g. a bathroom). 
This is as effective as doubling the dose, and much cheaper. Adding a VHC to a pMDI reduces both total 
and fine particle dose delivered, but not specifically the largest particles only. We recommend a careful 
selection of pMDI-VHC combinations when designing new clinical studies and to record humidity as 
well. In general, unregistered pMDI-VHC combinations should not be used without previous (in vitro) 
investigation of delivered fine particle doses. The highest fine particle dose output from VHCs obtained 
in our study was with beclomethasone and ciclesonide, both used with the AeroChamber®. 
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Sir, 
We have read the European consensus article about inhaled medication and inhalation devices in CF 
therapy with great interest and would like to congratulate the authors on a great achievement. 1 The aim 
of inhaled antibiotic therapy in CF is to reach the best clinical response with a minimum of side effects. 
On three important topics regarding inhaled antibiotics no recommendations were made. With this letter 
we would like to put these issues forward as areas for future research, both bench- and bed-side, as well 
as to hypothesize on the answers. 
WHICH AREAS TO TARGET? 
Cystic fibrosis is thought to be a disease starting in the small airways on the basis of infant pulmonary 
function tests2 and imaging studies.3 Pseudomonas aeruginosa (Psa) is regarded as the most important 
pathogen in adult CF patients. A recent study demonstrates that Psa is present in both conductive and 
respiratory airways.4 Psa is very capable to develop resistance to virtually all anti-pseudomonal agents 
through the selection of genetic mutations.1 
Aminoglycosides are the most frequently used inhaled antibiotics in CF lung disease and they need high peak 
levels (far above the Minimal Inhibitory Concentration, M IC) to make use of the reported post-antibiotic 
effect of this class of drugs. Efficacy of aminoglycosides is predicted best by the peak concentration (CmaJ 
to M IC ratio5·6 and a CmaJM IC ratio greater than 10 is advised. A concentration gradient can be a risk 
for resistance development and the lowest drug concentration obtained in the lungs must be sufficiently 
high above M IC. According to criteria from the European Society of Clinical Microbiology and Infectious 
Diseases (EUCAST, www.eucast.org) Pa strains with M IC < 2 mg/L for tobramycin are considered sensitive 
to this type of antibiotic. Thus, to obtain an effective therapy, based on MIC and advised Cm)MIC ratio, 
tobramycin concentrations of > 20 mg/L in all airways may be necessary. 
WHICH PARTICLE SIZE TO DELIVER? 
In patients with stable asthma, Usmani et al. showed in a radio-isotope study that about 500/o (+/- 50/o) 
of the real dose of monodisperse particles in the size range between 1 .5 and 6 micron can be deposited in 
the lungs. These deposition fractions were reached with a slow inhalation (mean of 30.8 L/min), followed 
by a breath hold period.7 The other 500/o of the dose is not deposited in the lungs, but either predominantly 
exhaled (especially the smaller particles) or deposited in the oropharynx. There is an increase in peripheral 
lung deposition from 10 to 250/o of the real dose for particles with decreasing particle size from 6, to 
1 .5 µm. So, smaller particles can give considerably higher peripheral lung deposition which is in agreement 
with prediction from computational lung deposition studies. 
Airway generations (gens) 1 7  to 23, frequently referred to as the respiratory airways, contribute more than 
950/o to the total airway surface area. In contrast, the transitional airways (gens 1 2- 1 6) add only 40/o and 
the conducting airways (gens 1 - 1 1 )  cover less than 1 0/o  to the total area.8 Although the definitions used by 
Usmani et al. in their study for central, intermediate and peripheral airways are not completely comparable 
to these definitions for conducting, transitional and respiratory airways, it is clear that differences in the 
mass median aerodynamic diameter (MMAD) result in extreme differences between drug concentrations 
in different lung regions. Only approx. 250/o of the real dose of 1 .5 µm particles deposits on 950/o of the 
total lung surface area (in the peripheral lung) versus 3 1 0/o  of the real dose on the complementary 50/o 
of the total surface area (in the central and intermediate lung). This yields a difference in concentration 
almost by a factor 25. For larger particles or higher flow rates, the differences are even greater. A fall in 
concentration from upper to lower lung is therefore inevitable, but particles in the aerodynamic size range 
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between 1 and 2 µm yield clearly more homogeneous drug concentrations within the whole lung than 
particles in the size range between 2 and 4 µm, or even larger. Therefore, fine particles ( 1-2 µm) seem 
preferable for design of future delivery devices for antibiotics in CF, whereas they should be inhaled with 
a slow inhalation manoeuvre (inspiratory peak flow rate � 30 L/min). 
WHICH DEVICE TO USE? 
On the basis of the small airway involvement in CF and the exponentially increasing surface area of the 
airways towards the alveoli, the peripheral airways should be targeted for inhaled antibiotics. Targeting 
should be with small particles ( 1-2 µm) and slow inhalation (30 L/min). The aerosol administration devices 
for antibiotics in CF should be selected with the objective to fulfil these requirements. 
The authors describe studies with various administration devices in respect of total lung dose and mention 
values ranging from 3 to 730/o.1 Differences in the site of deposition may be expected from using the Pari 
LC ® Plus with a 'suitable' compressor for TOBI® (Pari TurboBoy® N) or the eFlow ® rapid. Under laboratory 
conditions (suction rate 30 L/min), the MMAD's from these devices are 2.8 and 3.5 µm respectively.9 
Also the subfractions of fine particles (particularly 1-2 micron) are different (22.6 and 14.40/o of the 
emitted dose at 30 L/min respectively). This will result in a different distribution over the airways (even 
if total lung deposition is the same) from both devices.5 A larger difference may result when the average 
inspiratory flow rate through the eFlow is higher than that through the LC Plus® (peak inspiratory flow 
rates may vary between 17 and 90 L/min for adult patients breathing through a nebulizer device.10 The 
relevance of such variations to the efficacy of the treatment has to be investigated in clinical studies 
by comparison of the effect of the same drug administered with different MMAD's and different flow 
rates. A breathhold period after inhalation is important when using a DPI in order to achieve significant 
deposition by sedimentation. When the prerequisites of MMAD and flow manoeuvre are considered, both 
a dry powder inhaler or a nebulizer-system may be appropriate. 
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Abstract 
Background: 
Nebu l ized antibiotics a re importa nt i n  the treatment of cystic fibrosis. The Pa ri eFlow® ra pid with 
vibrati ng  mesh is often used off- labe l  for the admin istration of tobramycin (TOB I®) because of a reduced 
nebu l ization time and easier hand l ing compa red to a classic nebu l izer-compressor combination. Mesh 
techno logy may be vul nerab le ,  however. Therefore, we i nvestigated partic le size d istri bution and output 
as wel l as  changes i n  the performance of the eFlow before and after 6 months of use, i n  compa rison with 
the Pa ri LC® Plus nebul izer p l us Tu rboboy® compressor. 
Methods: 
Size d istri butions in the aeroso ls and nebu l ization times for TOB I® were measu red with laser d iffraction 
tech n ique ;  del ivered doses by weig h ing. 
Results: 
New eFlows produce considerab ly la rger droplets (X 
50
= 3.5 µm) from TOB I® than  new LC Plus nebu l izers 
( X 
50
= 2.8 µm). After use, the X 50 i ncreases for both systems (to 3.7 and 3.3 µm,  respectively). The re lative 
spa n of the size d istribution { (X90-X10)/X50 } changes from 1 .26 to 1 .28 µm for eFlow and from 2. 1 9  to 
2.45 µm for LC Pl us. The tota l nebul ization time doub les for LC Pl us, whereas in 51 0/o of a l l  experi ments 
the eFlow switched off after 10 m in ,  result ing in incomplete dose de l ivery. For the eFlow, changes d u ring  
use a re re lated to clogg ing of orifices. Once be ing clogged, on ly replacement of  the mesh restores the 
orig ina l  performance. 
Conclusions: 
New eFlows produce larger d rop lets and in a na rrower size range compa red to new LC P lus nebul izers for 
TOB I® , and  therefore both devices a re not equ iva lent. Theoretica l ly a l a rger  portion of the aeroso l from 
eFlow is l i kely to be deposited in the upper a i rways. The performance of both tested nebul izers decreases 
after 6 months of use. For the eFlow, t imely rep lacement of the mesh is necessa ry. These i n  vitro resu lts 
underscore the importance of reg istration stud ies of new d rug-device comb inations. 
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In patients with cystic fibrosis (CF) inhaled tobramycin is widely used to suppress Pseudomonas 
aeruginosa with the aim to preserve lungfunction and to prevent pulmonary exacerbations. 1 -3 A special 
tobramycin solution for inhalation (TSI: TOBI®) was developed for use with the Pari LC® Plus (LC Plus) with 
an appropriate compressor.4 Nearly a decade after the FDA approved TOBI® with a DeVilbiss Pu Imo-Aide® 
compressor ( 1997), the new Pari eFow® rapid (eFlow) with vibrating mesh technology5 was cleared for 
the U.S. (2004) and the European markets (2005). Immediately afterward, the registered eFlow was in use 
for the aerosolization of TOBI® in many different countries, although the combination of drug and device 
has not officially been approved and registered. The manufacturer of both devices showed in an in vitro 
deposition study (with the Andersen impactor) that LC Plus and eFlow produce aerosols with different size 
distributions from this drug solution.6 Reduced nebulization time and ease of handling, both increasing 
patient compliance, were important stimuli for this off-label use. The difference in median droplet size and 
size distri-bution between LC Plus and eFlow may have consequences for the site of deposition and safety, 
however. Although no firm recommendation for the target area can be found in the literature7, it has been 
shown that most adult CF patients have recurrent upper airway infection with Pseudomonas aeruginosa 
from which colonization of lower airways occurs8 up to (and including) the alveoli.9•1 0  In addition to the 
difference in droplet size distribution between the LC Plus and eFlow, concern has been raised about the 
durability of the eFlow in daily practice due to expected vulnerability of the mesh, particularly in relation 
to cleaning and sterilization procedures. Therefore, the aim of this study was to verify the difference 
in performance of new devices as presented by the manufacturer and to investigate whether changes 
occur in the performance of both devices in daily practice (6-month therapy) when being used for the 
administration of TOBI®. Such changes could have relevant implications for lung deposition, and may 
further increase the difference between the aerosols from the eFlow and the LC Plus. 
Laser diffraction technique was chosen because laser diffraction data are already available for the LC Plus 
from a previous study. 1 1  To make the results more comparable, used eFlow and LC Plus nebulizers were 
collected from the same group of patients. 
MATERIALS AND METHODS 
Study design 
Fifteen adult cystic fibrosis patients in The Netherlands using a nebulizer for the administration of TOBI® 
were advised by their physician to change over to the eFlow for the administration of TOBI® and asked 
to volunteer in the study. The costs for these new devices were refunded by Chiron (now Novartis, East 
Hanover, NJ). The 10 patients who used a LC Plus nebulizer until then, handed it in for performance testing. 
They were given appropriate instructions on cleaning, and provided with a disinfection device. After 6 
months of use (three cycles of 28 days TOBI® treatment) they handed in their eFlow for performance 
testing with a questionnaire regarding experiences, cleaning procedures, and other drugs nebulized with 
the device. 
On returning their used eFlow (series 1), all patients received a new (substitute) device, also financially 
provided by Novartis. Collected (used) eFlows were checked on proper cleaning of the devices before 
starting the performance testing. Because some meshes appeared to be visibly polluted, it was decided 
to extend the study: all patients were asked to hand in their substitute eFlows for performance testing 
again after another 6 months use, and 8 out of 15 patients agreed to do so (series 2). Before the patients 
started using their substitute devices, even more emphasis was put on correct cleaning and handling 
compared to the first series. 
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The patients participating in this study were advised by their physicians to change over to the eFlow for 
therapy (compliance) related reasons and not asked to change over for this performance testing study. 
Therefore, this study is considered an observational study without intervention, and approval from an 
ethical committee according to the the (Dutch) Law on Medical Scientific Research involving Human 
Beings (WMO) was not necessary. The median period of use for the collected LC Plus nebulizers was 6 
months. 
MATERIALS 
TOBI® ampoules, exposed to room temperature 15 min before use, were supplied by Red Swan pharma 
logistics (Utrecht, The Netherlands). Nebulizers and Petra disinfection apparatus were supplied by Novartis. 
eFlows (both new and used) were tested with a Pari mouthpiece with an exhalation filter in agreement 
with daily practice. Two used eFlows from the first series of 15 were returned without the vibrating mesh, 
and were therefore excluded from the testing program. One of the visibly polluted devices from the second 
series was also tested after the mesh was replaced by a new one. The 10 used LC Plus nebulizers were 
tested in combination with a Pari TurboBoy® N compressor. This compressor from the same manufacturer 
compl ies with the specifications mentioned for the aerosolization of TOBI® Uet flow is 4 L/min). Using 
the TurbuBoy® N also enables comparison with data presented previously for new LC Plus nebulizers.11 
Actually, the same compressor device was used for the new and used nebulizers after it was checked so 
that the jet flow was still the same and meeting the specifications of the manufacturer. 
MEASUREMENT OF PARTICLE SIZE DISTRIBUTION IN THE AEROSOL 
Particle size distributions in the aerosols were measured with a H ELOS Compact/KA laser diffraction 
apparatus (Sympatec, Germany) at a constant flow rate of 30 L · min- 1 using a 100-mm lens (measuring 
range from 0.5 to 175 µm), an INHALER 2000 adapter, and the Fraunhofer theory for the calculations.12 
All eFlows (new and used) were tested three times, using three different TOBI® ampoules; used LC Plus 
nebulizers were tested in duplicate. The first test with used devices was as collected from the patients. 
Between the tests, the devices were cleaned according to the procedures prescribed to the patients. A 
series of measurements of 10 sec each was started from the beginning of the nebulization process with 
interval times of 20 sec. Data from the eFlows were collected until the devices stopped nebulization (on 
detection of a minimum liquid level, or after 10 min). Measurement of LC Plus was continued into the 
phase of sputtering, but the data obtained during sputtering were omitted from processing. Cumulative 
volume distribution curves (as function of diameter) were averaged per ampoule first, and next, the mean 
of three ampoules per device was calculated in order to obtain an overall mean size distribution per 
device. 
Data are presented as cumulative volume distribution curves (Figure 6.1), or as characteristic values (X10 ; 
\0 = VMD and X90) derived from these curves (Figure 6.2 and Table 6.1). The variations given in Table 6.1 
and spread bars in Figure 6.2 represent the highest and lowest X50 values obtained within all individual 
series ( 10 sec measurements) per device. The spread bars in Figure 6.1 represent the standard deviation for 
the averaged values per time interval. Because the cumulative volume distribution curves were not log­
normal, geometric standard deviations (GSD's) could not be calculated. Instead, relative spans (RS) of the 
size distributions { RS = (X90-X10)/X50} are presented (Table 6. 1). The mouthpieces of the nebulizers were 
positioned less than 5 mm from the laserbeam to exclude droplet evaporation. Unpaired Student t-tests 
were performed for statistical analysis. 
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NEBULIZATION TIMES AND DELIVERED DOSES 
Total nebulization times (until switching off for the eFlow and the start of sputtering for the LC Plus, 
respectively) were recorded for individual ampoules and averaged per device. Delivered doses (in mg drug 
solution) were calculated from differences in weight before and after nebulization. Delivered weight 
may overestimate delivered drug dose because of evaporation in the LC plus nebulizer cup (not for the 
eFlow).13 Mean optical concentrations in the aerosol cloud were recorded to detect changes in the output 
rate, indicative for dry running of the LC Plus nebulizers and severity of clogging of the vibrating meshes 
in the eFlows. 
RESULTS 
Particle size distributions in the aerosols 
Figure 6.1 shows the volume median droplet diameters (VMD = X50) with standard deviations and optical 
concentrations (Capt) in the aerosols from new nebulizers as function of the nebulization time. The 
curves represent the mean of five devices. For both types of nebulizers, the droplet size distribution is 
constant except for the first 10 sec of nebulization and after the optical concentration starts to decrease 
significantly. Table 6.1 compares the overall mean data for new and used devices and shows that the 
volume median diameter for TOBI® from a new eFlow is approximately 240/o higher than that from a new 
LC Plus (p < 0.05). However, the RS of the size distribution is narrower for the eFlow than for the LC Plus 
(p < 0.05). 
The interdevice variation before and after use is shown in Figures 6.2 A (for eFlow) and B (for LC Plus). The 
spread bars in Figure 6.2 A and B indicate the maximum and minimum values obtained within the three 
ampoules. The relative standard deviation (RSD in X50) was found to increase from 2.80/o for new eFlows 
to 6.70/o (series 1 )  and 8.40/o (series 2) for used devices and from 2.90/o (new) to 11.40/o (used) for LC Plus, 
respectively (all p < 0.05). Table I shows that overall mean values for X50 and RS both increase for eFlow 
(as well as for LC Plus) during use and both increases are significant (p < 0,05). 
Figure 6.3 A shows the array of round orifices of an unused vibrating mesh. For polluted meshes (Figure 
6.3 B and CJ, orifices were either still more or less completely open, or practically totally clogged (as in 
Figure 6.3 CJ. The fraction of more or less totally clogged orifices in a severely polluted mesh was over 
500/o (Figure 6.3 BJ. 
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Figure 6.1 Volume median droplet diameters 
(X50-values) and optical concentrations (Capt) 
in the aerosols from a new eF/ow and a new 
LC Plus nebulizer {plus TurboBoy N compressor}, 
respectively, as function of the nebulization time 
(mean of five devices). The spread bars indicate 
the standard deviations .
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Figure 6.2 Comparison of characteristic values (X10. Xso. and X90} from the cumulative volume distributions (as function of the 
diameter} for the aerosols from new and used eFlow (A} and LC Plus nebulizers (BJ. The spread bars (X50} indicate maximum 
and minimum values obtained within individual series. 
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NEBULIZATION TIMES AND 
DELIVERED DOSES 
Table 6. 1 shows that the mean nebulization 
time for the eFlow devices increased during 
use from 6.7 to (on average) 8.9 min (p < 0.05). 
This increase does not reflect the dramatic 
difference in delivered solution weight between 
new and used devices, as the eFlows used in 
this study were programmed to switch off 
automatically after 10 min. It was found for 
the 21 used eFlows, each of them tested three 
times with three different ampoules (63 
measurements in total), that during 32 
measu rem en ts (510/o) the device was switched 
off prematurely. This percentage was higher 
for series 1 (560/o) than for series 2 (420/o), 
possibly as a consequence of putting more 
emphasis on the need for correct cleaning 
when the devices of series 2 were handed to 
the patients. In total, eight devices switched 
off prematurely for all three ampoules (see 
Table 6. 1). As a consequence, part of the dose 
was not delivered. Actually, the delivered dose 
for both series of used devices varied from 1. 15 
(220/o) to 4.21 g (790/o) out of the (on average) 
5.3 g TOBI® solution. For new devices, the 
variation was only between 3.67 (690/o) and 
4.02 g (760/o) of the real dose. When a polluted 
mesh was replaced by a new one (as for one of 
the severely polluted devices in series 2), the 
nebulization time (7.5 min) and the delivered 
dose (3.76 g) were restored to original values. 
In contrast with the nebulization times for the 
eFlow, these data for LC Plus depend on the 
inhalation manoeuvre and will be different 
with tidal breathing compared to a constant 
flow rate. This may result in a more than 
doubled nebulization time with (in vivo) tidal 
breathing. In addition, the effect of 6 month 
use is a twofold increase in nebulization time 
for LC Plus {Table 6. 1). The flow rate with 
Figure 6.3 Scanning electron microgrophs of a new 
(A) and a heavily polluted used mesh (B and CJ from 
the eF/ow. 
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which the aerosol is drawn from the nebulization cup determines the fraction of particles deposited on 
the baffle and inner walls of the cup, and thus, the refl ux of drug solution. Therefore, nebulization times 
and delivered doses for the LC Plus in Table 6. 1 are only useful for comparative evaluation between new 
and used devices. Additionally, delivered drug dose cannot be derived from weight loss of the nebulizer 
cup because of liquid evaporation: drug concentration in the nebulizer cup during nebulization may 
increase up to nearly 1400/o of the original value.13 It was found that total nebulization time for the LC 
Plus at a constant flow rate increases considerably more than that for the eFlow, because the LC Plus does 
not switch off after 1 0  min. 
Relative 
span of the 
Volume median size Total nebulizntio11 Average Number of 
diameter (Xso) distribution Delivered dose timea output mte eFlows switched 
Device (micron) (X.90-XmlXsoJ (g drug solution) (min) (g/min) off pre111aturelyb 
eF!ow new 3.5 (3.3-3.7) 1 .3 3.85 (3.67-4.02) 6.7 (5.5-8.0) 0.58 15/0/0 
eF!ow used, series 1 3.8 (3.3-4.3) 1 .3 3.35 (1 .65-4.21) 9.0 (5.5-10) 0.37 39/22/6 
eFlow used, series 2 3.5 (2.8-4.0) 1.3 3.48 (1.15-4.09) 8.7 (6.5-10) 0.40 24/10/2 
LC Plus new 2.8 (2.7-3.0) 2.2 3.44 (3.41-3.50) 6.9 (6.8-6.9) 0.50 
LC Plus used 3.3 (2.8-4.2) 2.5 4.19 (3.61-4.44) 13.0 (8.0-20.5) 0.32 
°યForeF/ow: time reduced due to devices switching off automatically after 10-min nebulization time. bfhe first figure indicates 
the total number of ampoules tested (three per device); the second figure indicates to the total number of switchings off; the 
third figure indicates the number of devices for which none out of three ampoules was completely nebulized. 
Table 6.1 Comparison of overall mean median diameters (X5J ,  relative spans of the size distributions {(X90-X,J/X50 }, delivered 
doses (g drug solution}, total nebulization times (min}, and output rates (g drug solution per minute) for new and used eFlows 
and LC Plus nebulizers. 
Results between brackets are the lowest and highest values observed. 
PATIENT COMPLIANCE 
Although all patients in the study indicated to have cleaned their eFlow with great care and consistency 
(warm water detergent), most eFlows were returned with polluted meshes. The same was true for the 
devices of the second series, despite more emphasis on good cleaning procedures, particularly after 
the last use. The majority of patients (850/o in series 1 ;  750/o in series 2) also used their eFlow for the 
administration of other medicaments than TOBI®. They nebulized salbutamol, ipratropium, terbutalin, 
colistin, DNAse (Pulmozyme), acetylcistein and/or saline. 
DISCUSSION 
The objectives of this study were to verify differences in droplet size distribution between eFlow and LC 
Plus (for TOBI®) and to investigate possible changes in the performance of the vibrating mesh technology 
applied in the eFlow during (6 months) use in daily life (CF patients). With respect to the latter, the 
outcome of the study is that particularly the interdevice variation increases during use. Surprisingly, the 
changes in performance for the eFlow are less extreme than those concluded for the LC Plus (based on 
comparison of previous data for new LC Plus nebulizers and new data for used devices in this study). 
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This study has also confirmed that the VMD's in the aerosols from new eFlows (3.52 µm from laser 
diffraction analysis) and the new LC Plus nebulizers (2.84 µm) are not the same. Pari presented for TOBI® 
a mass median aerodynamic diameter from the Andersen cascade impactor (at 28.3 L/min) of 3 .95 µm 
for the eFlow and 3.5 µm for the LC Plus, while using the same compressor we used in this study.6 The 
differences between our study and data from Pari® cannot be explained easily. Contributing factors are 
that different measurement principles have been used and that different conditions such as relative air 
humidity may have been different. However, the difference in median diameter between the eFlow and 
LC Plus is consistent for both studies. The difference in median diameters between eFlow and LC Plus 
(by 240/o in this study) raises concern about the site of deposition in the human lung, and therefore, the 
therapeutic effect and safety. Based on the impaction parameter (IP = p.X5tU, where p is the particle 
density and U is the particle velocity), the difference is even 540/o. In terms of fine particle fraction, the 
fraction <3. 1 micron is 250/o lower from eFlow than from LC Plus. In daily life, this difference may be 
even greater, because the manufacturer of TOBI® recommends using a compressor with a jet flow within 
the range from 4 to 6 L/min. In the present study, a compressor with a jet flow of 4 L/min was used, 
and from previous investigations it is known that higher jet flows result in smaller droplets.1 1 • 1 4- 1 6  Hence, 
based on in vitro deposition data, the eFlow does not seem to be equivalent to the LC Plus. The volume 
median diameters of used eFlows and LC Plus nebulizers differ less from each other ( 130/o) than those of 
new devices (240/o) because the increase in volume median diameter during use is higher for the LC Plus 
( 15.50/o) than that for the eFlow (5. 10/o). 
For nebulized antibiotics a high drug concentration on the site of infection is required. As already mentioned 
in the introduction, Pseudomonas infection may involve the whole lung. Consequently, the whole lung 
has to be treated with the antibiotic drug. Based on the exponentially increasing inner surface area of the 
airways from the lobar bronchi to the alveoli, an increasing amount of drug is necessary toward the lower 
airways in order to obtain a more or less equal drug concentration throughout the entire lung. According 
to various lung models1 7  the conducting airways (generally 0- 11) contribute only approximately 10/o to 
the total airway surface area, versus 40/o for the transitional airways (generally 1 2- 16) and 950/o for 
the respiratory airways (generally 17-23). Hence, on the basis of the surface area distribution and the 
desired equal drug concentration, the amount of drug to be deposited in the respiratory airways needs 
to be 24 times higher than that in the conducting and transitional airways combined (generally O to 16). 
However, when aiming at deposition in the respiratory airways, losses occur in the preceding conducting 
and transitional airways. According to lung deposition models1 8, these losses exceed the approximately 
50/o that is needed in these regions. This supports the idea that antibiotics for equal distribution over the 
entire lung have to exhibit the appropriate particle size for deposition in the respiratory airways, or the 
concentration in the deep lung will be much lower than that in the conducting and transitional airways. 
From both deposition modelling1 0-20 and in vivo deposition studies21 , it is known that the optimal particle 
size for peripheral lung deposition at moderate flow rates (30-60 L/min) is rather between 2 and 3 µm 
than between 3 and 4 micron. Peak inhalation flow rates during tidal breathing as measured with a 
pneumotachograph may be in the range of 30 to 90 L/min for CF patients.22 Because it is known that 
mean flow rates are approx. 700/o of peak flow rates23 , this reduces the expected range of mean flow rates 
through the eFlow to 20-60 L/min. As an overall conclusion, it seems rational to expect that the ratio of 
aerosol deposition in the conducting and transitional airways to that in the respiratory airways is higher 
from the eFlow than from the LC Plus. Therefore, it is recommended that a comparative in vivo deposition 
study is conducted to verify this expectation. 
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The reasons for a change in median droplet size during use of the eFlows have not been investigated. It 
has been observed though, that the wetting of the mesh and the adherence of expelled gas bubbles to 
the mesh surface change during use. This could influence the droplet formation process and the influence 
could depend on the mesh pollution. The size distribution in a wet aerosol is also affected by droplet 
coalescence and evaporation, which depend on the droplet concentration in the aerosol. For the eFlow, 
this droplet concentration is related to the number of open orifices. Clogging (Figure 6.3 BJ appeared to 
reduce the optical concentration (Copt) from 800/o for new meshes to less than 200/o for strongly polluted 
meshes. When clogging of an orifice occurred, it seemed to be more or less complete (Figure 6.3 8-C}, 
although it is expected that also partially clogged orifices do not produce droplets because the resistance 
to flow through an orifice increases exponentially with its diameter. Above a certain threshold value for 
the resistance, no droplets will effectively be formed. This may explain why the effect of mesh pollution 
on output rate is much greater than that on particle size distribution in the aerosol. Despite the emphasis 
put on good cleaning procedures in the instructions for use, mesh pollution was visible for nearly all 
collected eFlows, but the devices of series 2 showed less clogging than the devices of series 1 (with only 
one exception). Considering that more emphasis was put on correct cleaning at the start of series 2, it 
must be concluded that cleaning and maintenance have a great effect on mesh pollution. In this respect, 
the mesh technology is vulnerable. Pollution may also have been influenced by unintended nebulization 
of other drug solutions than TOBI® with the same device. Cleaning of a polluted mesh during performance 
testing appeared hardly effective in regaining the original eFlow performance. Only in a few examples it 
was observed that the second and third experiment of used devices (after cleaning) yielded slightly better 
results than the first. However, replacement of a polluted mesh fully restored the particle size distribution 
and nebulization time to values for a new device. Pari® has recently developed an "easy care cleaning aid" 
for this purpose, but data about use in daily practice and efficacy have not been published yet. Possible 
reasons for differences in performance between new and used LC Plus nebulizer cups have been explained 
and discussed before. 1 1  
For the eFlow, the increase in  nebulization time eventually leads to  automatic switching off after 10 
min. This implies that part of the dose is not administered to the patient and this has resulted in extreme 
variation in delivered dose in this study (Table 6.1). In a recent personal communication with Pari we were 
informed that the time for automatic switch-off will therefore be prolonged to 20 min. This change in 
technical specification may indeed decrease the variation in delivered dose, but it will also increase the 
necessity to measure the nebulization time because of the observed increase in inter device variation due 
to mesh pollution. Nebulization of other drug solutions than TOBI® with the eFlow should be strongly 
dissuaded. Although we could not find clear correlations between the degree of clogging and the type 
of drug solutions nebulized in this study, neither with the cleaning methods applied, it may well be that 
mesh pollution is influenced by these parameters. Apart from possible consequences for mesh pollution, 
the droplet size distribution may vary with the properties of the drug solution. 1 4 Moreover, not all drug 
solutions are supplied in the same large volume as TOBI®. Considering the high residual volumes left in the 
medicament chamber after the eFlow is switched off (upon detection of minimal level), the delivered dose 
may vary quite substantially with the volume of the drug solution inserted in the medicament reservoir. 
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CONCLUSIONS 
LC Plus nebulizers and eFlows produce aerosols with different droplet size distributions for TOBI®: the 
median droplet diameter from a new eFlow is 240/o larger (fine particle fraction < 3. 1 micron is 250/o lower) 
and the difference between the devices becomes even greater when a compressor with a higher jet flow 
is used. In addition, the size distribution is narrower from the eFlow. This is likely to have consequences 
for the drug deposition in the respiratory tract and the finding underscores the importance of extensive in 
vitro (and in vivo) testing before selecting formulation-nebulizer combinations for clinical use.24•25 During 
use, median droplet diameters appear to slightly increase for both devices, but the observed increase was 
somewhat higher for the LC Plus than for the eFlow. Therefore, the aerosols from used devices are more 
comparable than those produced by new devices. During use the interdevice variation and nebulization 
time increased for the eFlow, which seems most likely to be the result of mesh pollution (clogging of 
orifices). This occurred despite good emphasis on the cleaning instructions, and there may have been 
an influence on clogging from nebulizing other drug solutions than TOBI® with the same device, like 
Pulmozyme. Mesh pollution changed the output rate quite dramatically, and the decreased output rate 
in combination with automatic switch-off after 10-min nebulization time resulted in an unacceptable 
variation in delivered dose. Therefore, timely replacement of polluted meshes is mandatory. 
These in vitro data suggest that the eFlow is not equivalent to the LC Plus for TOBI® administration, but 
a clinical effectiveness study (including assessment of adhearance) should be performed to confirm that 
conclusion. 
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Optical concentration in the aerosol. Capt is a measure for the light extinction, which is 
influenced by the droplet density and the droplet size distribution in the aerosol 
Geometric standard deviation (for log-normal distributions) 
Mass median aerodynamic diameter 
Relative span of the size distribution; ratio of (X90-X10) to X50 (alternative for geometric 
standard deviation for skewed distributions) 
Volume median diameter 
Diameter derived from the cumulative volume distribution curve: 100/o of the volume is in 
particles smaller than X,0 (micron) 
Diameter derived from the cumulative volume distribution curve: 500/o of the volume is in 
particles smaller than X
50 
(micron) 
Diameter derived from the cumulative volume distribution curve: 900/o of the volume is in 
particles smaller than X90 (micron) 
IMPROVING DRUG DELIVERY TO THE LUNGS 89 Towards better inhalation therapy 
Chapter 6 Changes in performance of the Pari eFlow® rapid and Pari LC® Plus 
during 6 months use by CF patients 
REFERENCES 
Moss RB: Long-term benefits of inha led tobramycin 
i n  adolescent patients with cystic fibrosis. Chest 
2002 ; 1 2 1  :55-63. 
2 Ramsey BW, Dorki n HL, Eisenberg JD, G ibson RL, 
Harwood I R, Kravitz RM, Schid low DV, Wi lmott RW, 
Astley SJ, McBurn ie MJ, Wentz K, and Smith AL: 
Efficacy of aerosolized tobramycin in patients with 
cystic fibrosis. N Eng/J Med 1 993;328:1 740- 1 746. 
3 Ramsey BW: Management of pu lmonary disease 
in patients with cystic fibrosis. N Eng/J Med. 1 996; 
335 : 1 79-1 88. 
4 Cheer SM, Waugh J, and Noble S: I n ha led 
Tobramycin (TOBI®) A review of its use i n  the 
management of Pseudomonas aeruginosa infections 
in  patients with cystic fibrosis. Drugs 2003 
63 :2501 -2520. 
5 Lass JS, Sant A, and Knoch M: New advances i n  
aerosol ised drug de l ivery: vibrat ing membrane 
nebul izer technology. Expert Opin Drug De/iv 2006; 
3 :693-702. 
6 Pari techn ica l information leaflet for eFlow® rapid : 
http://www.pari.de/deutsch/300/31 0/31 30/1 3/PDF/ 
NL.pdf. Accessed Juen 1 8, 2008. 
7 Denn is JH ,  and Pieron CA: I nha l ed a ntibiotic therapy 
in evidence: what del ivery device? J Cyst Fibrosis 
2002 ; 1  (Suppl 2) :209-21 4. 
8 Taylor RF, Morgan OW, Nicholson PS, Mackay IS, 
Hodson M E, and Pitt TL: Extrapu lmonary sites of 
Pseudomonas aeruginosa in adu lts with cystic 
fibrosis. Thorax. 1 992;47 :426-428. 
9 Ader F, Le Berre, R, Faure K, Gosset P, Epau lard 0, 
Toussa int B, Polack B, Nowak E, Viget NB ,  Kipnis E, 
and Guery BP: Alveolar response to Pseudomonas 
aeruginosa: role of the type I l l  secretion system. 
Infect lmmun 2005;73 :4263-4271 . 
1 0  Restrepo C l ,  Dong Q ,  Savov J, Mariencheck WI ,  and 
Wright  JR: Surfactant protein D stimu lates 
phagocytosis of Pseudomonas aeruginosa by a lveo lar 
macrophages. Am J Respir Cell Mo/ Bio/ 1 999 ; 
21 :576-585. 
1 1  de  Boer A H ,  Hagedoorn P, and Frij l i n k  H W :  
The choice o f  compressor for the aerosol isation of 
tobra mycin (TOBI®) with the Pari LC Plus™ reusable 
nebu l izer. lntJ Pharm 2003 ;268 :59-69. 
IMPROVING DRUG DELIVERY TO THE LUNGS 90 Towards better inhalation therapy 
1 2  d e  Boer AH, Gjaltema D ,  Hagedoorn P, Schal ler M, 
Witt W, and Frij l i nk  HW: Design and appl ication of 
a new modular adapter for laser diffraction charac-
terisation of inha lation aerosols. lntJ Pharm 2002 ; 
249:233-245. 
1 3  Le Brun PPH, d e  Boer AH, Gja ltema D ,  Hagedoorn P, 
Heijerman HGM, and Frij l i nk  HW: Inha lation of 
tobramycin in cystic fibrosis. Part 1 :  the choice of a 
nebul izer. Int J Pharm 1 999 ; 1 89 :205-21 4. 
1 4  McCa l l ion ONM, Taylor KMG, Thomas M,  and Taylor 
AJ : The influence of surface tension on aerosols 
produced by medica l  nebul izers. lntJ Pharm 1 996; 
1 29 : 1 23-1 36. 
1 5  Corcoran TE, Dauber J H ,  Ch igier N ,  and I acono AT: 
Improving drug del ivery from medica l nebul izers: 
the effects of increased nebu l izer flow rates and 
reservoirs. J Aerosol Med 2002 ; 1 5:271 -282. 
1 6  Standaert TA, Bohn  ES, Aitken ML, and Ramsey B :  
The equ iva lence of compressor-flow relationsh ips 
with respect to jet nebu l izer aeroso l ization charac-
teristics. J Aerosol Med 2001 ; 1 4:31 -42. 
1 7  Morrow PE, a n d  Y CP: Models o f  aerosol behaviour 
in a i rways. In :  F Moren, MT Newhouse, and MB 
Dolovich MB (eds). Aerosols in Medicine. Principles, 
Diagnosis and Therapy. Elsevier, Amsterdam; 1 985, 
pp. 1 49-1 68. 
1 8  Gerrity TR : Pathophysiological and disease constraints 
on aerosol del ivery. I n :  Da lby PR (ed). Respiratory 
Drug Delivery. Boca Raton, FL: CRC Press; 1 990, pp. 
1 -38. 
1 9  Clark AR, and Egan  M :  Mode l l i ng the deposition of 
inha led powdered drug aerosols. J Aerosol Sci 1 994; 
25: 1 75- 1 86. 
20 Schu lz H: Mechan isms and factors affecting intra-
pulmonary particle deposition : impl ications for 
efficient inha lation therapies. Pharmaceut Sci Technol 
Today 1 998;1 :326-344. 
21 Usmani OS, Biddiscombe MF, and Barnes PJ: Regional 
lung deposition and bronchod i lator response as a 
function of beta2-agon ist particle size. Am J Respir 
Crit Care Med. 2005; 1 72 : 1 497- 1 504. 
22 Denyer J, Dyche A, and N ikander K: Breathing 
patterns in adult patients. J Aerosol Med 1 997 ;20 
(Abstract). 
Chapter 6 Changes in performance of the Pari eFlow® rapid and Pari LC® Plus 
during 6 months use by CF patients 
23 de Boer AH, Winter HM I ,  and Lerk CF: I nha lation 
characteristics and the i r  effects on i n  vitro drug 
del ivery from dry powder inha lers. Part 1. I nha lation 
cha racteristics, work of breath ing and vol unteer's 
preference in dependence of the i nhaler resistance. 
lntJ Pharm 1 996;1 30:231 -244. 
24 Berl inski A, and Waldrep JC: Aerosol characterization 
of nebu l ized i ntranasa l g lucocorticoid formu lations. 
J Aerosol Med. 2001 ; 1 4:237-244. 
25 Smith EC, Denyer J, and Kendrick AH : Comparison 
of twenty-three nebu l izer/compressor combinations 
for domici l i a ry use. Eur Respir J 1 995;8 : 1 2 14- 1 221 . 
IMPROVING DRUG DELIVERY TO THE LUNGS 91 Towards better inhalation therapy 





<C :c u 
Do the aerosol 
properties of 
i nha led antib iotics 
used i n  Cystic Fibrosis 
vary between drug 
so lutions and 
jet nebu l izers? 
Bart L. Rottier 
Francesca Scotti 
Paul Hagedoorn 
Henderik W. Frijlink 
Eric J. Duiverman 
Anne H. de Boer 
submitted 
IMPROVING DRUG DELIVERY TO THE LUNGS 93 Towards better inhalation therapy 
Chapter 7 Do the aerosol properties of inhaled antibiotics used in Cystic Fibrosis 
vary between drug solutions and jet nebulizers? 
Abstract 
Background: 
Nebulized tobramycin and colistin are widely used against Pseudomonas aeruginosa (Psa) in the airways 
of cystic fibrosis patients. Psa is present in both large and small airways and thus, the entire lung needs 
to be targeted. Effective targeting depends on drug mass output, particle size distribution and inhalation 
manoeuvre. Therefore, antibiotic formulation, nebulizer, jet pressure and inspiratory flow rate may all 
influence the particle size distribution in the aerosol but to which extent is unknown. In this study the 
aerosol properties of four antibiotic products using four nebulizer systems at different jet pressures were 
assessed 
Methods: 
Two available tobramycin solutions for inhalation (TOBI®, Bramitob®) and two colistin brands (Colistin® , 
P romixin®) restituted as solution were tested with Pari LC® plus, Pari LC® sprint, Pari LC® Sprint Star and 
Ventstream® with jet pressures of 1, 1.5, 2 and 2.5 bar. Differences in the particle size distribution of the 
aerosols were measured with laser diffraction technique. 
Results: 
All four nebulizers deliver finer aerosols when the jet pressure or the suction flow rate is increased. Volume 
median diameters for TOBI at 2.5 bar jet pressure and suction flow rate 20 L/min from LC® Sprint Star 
( 1.82 µm) and Ventstream® (1 .73 µm) are considerably smaller than those from LC® Plus (2.21 µm) and 
LC® Sprint (2. 15 µm). There is no difference in particle size distribution between all four drug solutions 
from the same nebulizer type at the same jet pressure. 
Conclusions: 
For fine aerosols, a jet pressure of 2.5 bar is optimal and Ventstream® results in smallest VMD. Especially 
for less powerful compressors, the choice of a nebulizer is important. Regarding particle size distributions, 
the tested tobramycin and colistin solutions are the same from the same nebulizer used with the same 
jet pressure. 
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Lung disease remains the major cause of morbidity and mortality in cystic fibrosis (CF). The airways of 
800/o of patients with cystic fibrosis (CF) will eventually become permanently infected ('colonised') with 
Pseudomonas aeruginosa (Psa). 1 Chronic infection with Psa is associated with an accelerated decline of 
lung function and should therefore be treated.2-3 The antibiotics colisthimethate sodium, tobramycin and 
more recently, aztreonam have all been used as inhaled antibiotics to suppress Psa in the CF airways. 1 •4•5 
Both tobramycin and colisthimethate sodium have also been successfully used in an effort to eradicate 
Psa from the airways, at least temporarily, in cases of intermittent Psa colonization.1•6•7 As Psa is present 
in all airway generations, including the peripheral airways up to the alveoli, the target area for inhaled 
antibiotics should therefore be the whole lung.8 A droplet size in the range of 1 -3 µm is expected to be 
the most effective as this size range will give the most homogeneous distribution over the airway tree 
when inhaled with a relatively slow inspiratory flow rate (30 L/min).9 In vivo deposition studies with 
particles in this size range showed that approximately a half to one third of the lung dose is deposited in 
the peripheral lung and the remaining part in the central and intermediate lung. 10  With the exponentially 
increasing airway surface area from the central lung towards the alveoli, this will result in a comparable 
decrease in antibiotic concentration from the central lung to the peripheral airways. 10 As the efficacy 
of aminoglycosides depends on a high peak level, preferably a factor 1 0  above the Minimal Inhibitory 
Concentration (MIC) against Psa1 1 • 1 2, high peripheral deposition is even more important. 
Tobramycin solution for inhalation (TOBI®: 300 mg/5 ml ) is registered in combination with the Pari LC® 
Plus reusable jet nebulizer and a suitable compressor resulting in a flow rate of 4-6 L/min. Another 
tobramycin solution is Bramitob® (300 mg/4 ml), also registered in combination with a Pari LC® Plus 
reusable nebulizer and the Pari Turboboy N® compressor. 13 According to registration texts, colisthimethate 
sodium is available as Promixin®, to be nebulized with a ·suitable compressor-nebulizer system· and 
Colistin®, registered with ·a compressor providing a flow over the nebulizer of 6-8 L/min' or the eFlow 
rapid®. Although drugs may be licensed with certain systems, new nebulizers are commonly used without 
registration and patients may switch to another drug without switching to the prescribed nebulizer 
system for that new drug. The reasons for doctors or patients to use other than registered combinations 
may be expected increased adherence and improved peripheral airway deposition and thereby, increased 
effectiveness 14 ; shorter administration time 1 5, portability and low noise level or a combination of all these. 
However, switching from nebulizer system may lead to the generation of larger droplets with decreased 
peripheral airway deposition as consequence. 1 6  
The in vitro performance of  different nebulizers with regard to particle size distribution (PSD) in combination 
with the two available tobramicin and colisthimethate sodium inhalation solutions for off-label nebulizers 
has not been systematically reported. Therefore, the first aim of this study was to investigate the effect of 
nebulizer and compressor choice and use on the aerosol properties of the four drug solutions. If different, 
a switch from one combination to the other may have consequences for the lung deposition of the drug. 
The outcome of the study may then guide clinicians in deciding which systems and antibiotics can be used 
and interchanged freely when used with same breathing characteristics. 
A second aim was to find the most effective nebulizer-pressure combination based on the smallest volume 
median diameter in the aerosol. 
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MATERIALS AND METHODS 
Materials 
The jet nebulizers used in this study were Ventstream (Philips Respironics, UK, supplied by Romedic 
BV, The Netherlands) , LC® Plus (Pari GmbH, Germany, supplied by Romedic BV, The Netherlands). LC® 
Sprint and LC® Sprint Star (both Pari GmbH, Starnberg, Germany, supplied by Pari Benelux, Brussels). All 
nebulizer cups were washed before use to remove fatty coatings. Multiple nebulizer cups of the same 
type were used after it was checked with water that they produced comparable aerosols under the 
same circumstances. For the LC family mouthpieces exist with and without exhalation valve. After it 
was checked that the presence of the valve does not influence the aerosol properties, only mouthpieces 
without valve were used to make sure that no false air along this valve contributes to total suction flow 
rate. Parts of the nebulizer cups were marked to assist reproducible re-assembly for further testing after 
cleaning. Compressors used in the study were TurboBoy N® (Pari GmbH, Starnberg, Germany) and CR60 
(Philips Respironics, supplied by Romedic, the Netherlands). 
TOBI® (300 mg/5ml) (supplied by Novartis, Arnhem, The Netherlands and Bramitob® vials (supplied by Chiesi) 
were stored in the refrigerator and exposed to room temperature 1 5  minutes before use. TOBl®contains 
300 mg tobramycin and 11,25 mg sodium chloride dissolved in 5 ml water filled in ampoules. The solution 
is adjusted to pH 6. Bramitob® (300 mg/4ml) is a solution of tobramycin in water without additives. 
Colistin® (supplied by Grunenthal GmbH, Aachen, Germany), colistimethate sodium, is delivered as a 
dry powder i n  amounts of 80 mg. Each dose is accompanied by a vial with a 3 ml 0.90/o aqueous sodium 
chloride solution to dissolve the powder. 
Promixin® (supplied by Romedic, The Netherlands) is colistimethate sodium, also supplied as 80 mg 
powder doses. According to the instruction a dose of Promixin® was dissolved in demineralized water. 
Methods and study design 
A constant jet pressure from the pressure mains of 1.0, 1 .5, 2.0 and 2.5 bar was used for each nebulizer 
(Figure 7.1). Pressures were controlled with a pressure regulator having a digital manometer for accurate 
and reproducible adjustment (Rototherm 0-6 bar, the British Rototherm Co. Ltd, U K). A constant 
pressure enables to test nebulizer performance over a wider range of values than with compressors. 
As nebulizers have different air flow resistances, jet pressures from the same compressor are different. 
This makes comparison of nebulizer performance at the same jet pressure generated with compressors 
difficult. Furthermore, pressurised air from the mains excludes a decrease in compressor performance 
as a possible cause for changes in particle size distribution over time. In order to rule out a potential 
difference between particle size distribution from pulsatile air pressure generated with compressors and 
continuous a ir flow from the mains, the performance of the same nebulizer cups with both air sources 
was compared at precisely the same pressures. For this comparison, the mean values of the pulsatile jet 
pressures generated by the Turbo Boy N® and CR 60® compressors in combination with the LC® Plus and 
Ventstream® nebulizers were measured. Next, exactly the same pressures were adjusted with a constant 
air pressure from the mains for these nebulizers. 
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Compressors 
(pulsating flow) 
• Tu rboboy® N 
• CR 60® 
Nebulizers: 
• PARI LC® Pl us 
• Ventstream® 
Inhalation flowrate and drug 
• 20 I/min water 
• 20 I/min TOBI® 
Figure 7 .1 Experimental set up 
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Mains 
(constant flow) 
• 1 ,0 bar 




• PARI LC® Plus 
• PARI LC® Sprint 
• PARI LC® Sprint Star 
• Ventstream® 
Inhalation flowrate and drugs 
• 1 0 I/m in :  TOBI® 
• 20 I/m in :  TOB I®, Bramitob®, Col istin® and Promixin® 
• 30 I/min : TOBI® 
• 20 I/m in :  water measurements 
Measument of the particle size distributions in the aerosol 
Particle size distributions were measured with laser diffraction technique (HELOS BF MAGIC) using an 
inhaler adapter (INHALER 2000), both from Sympatec, Clausthal-Zellerfeld, Germany. A 100mm lens was 
used with a measuring range of 0.5 to 175 µm and the Fraunhofer approximation theory for computation 
of the size distributions from the complex diffraction patterns. For the theoretical background regarding 
the Fraunhofer and Mie theory a reference is made to the literature.17 Briefly, the Mie theory would be 
more appropriate for assessment of the aerodynamic size distributions, but using this theory requires 
exact knowledge of the complex refractive index of the drug solutions. However, this refractive index 
changes during the nebulization process as the drug concentration increases due to evaporation and 
therefore, the Mie theory can not be applied properly. Further, as the study is a comparative evaluation 
between different drug solutions, nebulizers and conditions, differences in size distributions between 
different experiments are more relevant than absolute aerodynamic values. During nebulization of 
tobramycin solutions, size distribution measurements with a duration of 10 seconds were repeated with 
thirty seconds interval after an initial lag time of 10 s to stabilise the nebulizer performance. During 
nebulization of the colistin solutions, the interval time was reduced to 15 s because of the much shorter 
total nebulization times. Measurements were continued until sputtering of the nebulizer or a rapidly 
decreasing optical concentration. 
For the comparative evaluation study, 4 types of nebulizers were tested at 4 different jet pressures with 
all 4 antibiotics at a suction flow rate of 20 L/min. Relative air humidity and temperature were recorded. 
A change in performance of the nebulizers was checked regularly with the nebulization of water 
throughout the study. 
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Data are presented as volume median diameter (VMD) as derived from the cumulative volume distribution 
curve as function of the laser diffraction diameter. Unpaired student t-tests were performed for statistical 
analysis. P < 0.05 was considered statistical ly significant. 
RESULTS 
Differences in the volume median diameter (VMD) between the different nebulizers for TOBI®. 
The mean Volume Median Diameter (VMD) of the TOBl®-aerosol over total nebulization time, obtained 
at the same constant jet pressure of 1 bar and a suction flow rate of 20 L/min is significantly smaller for 
LC® Sprint Star (2.88 µm) and Ventstream® (2.36 µm) than for LC® Sprint and LC® Plus (3.75 and 3.65 µm 
respectively, p< 0.001 ) (Figure 7.2). The VM Ds produced by Ventstream® and LC® Sprint Star also differ 
significantly (p<0.001 ). The LC® Sprint is meant to replace the LC® Plus and both types of nebulizers 
produce the same droplet size distribution indeed. Each bar in Figure 7.2 is the mean of five complete 
nebulization runs (vials) unti l sputtering of the device obtained according to the measuring times and 
interval times between the measurements as described in the section materials and methods. Hence, the 
total number of measurements for each inhaler in Figure 7.2 varied between 39 (for the LC® Plus) and 99 
(for the LC® Sprint Start, depending on the time till sputtering and thus, the number of measurements 
per run. The spread bars in Figure 7.2 represent max-min for the mean values of the five runs. Relative 
standard deviations were of the same order of magnitude for all four nebulizers, 6.7 ; 5.8 ; 6.6 and 6.20/o for 
LC® Plus, LC® Sprint, LC® Sprint Star and Ventstream® respectively (n = 5). For the LC® Plus and LC® Sprint 
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Figure 7 .2  Volume median diameter (VMD) in  the aerosol for TOBI® at  1 bar (constant) jet pressure and a suction flow rate of  
20 L/min. Mean VMD-values over total nebulization time till sputtering for five TOBI® vials. The spread bars indicate the spread 
(maximum and minimum values obtained between the five vials). Differences between VMD of LC® Plus/LC® Sprint and LC® 
Sprint starNentstream® P< 0.00 1) 
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For the LC® Sprint Star and Ventstream®, changes in the VMD during the nebulization process were 
considerably smaller. The most constant size distribution per vial was measured for the Ventstream®. 
Figure 7.3 also shows that the variation in size distribution for the LC® Plus becomes larger with i ncreasing 
nebulization time, i.e. when the amount of drug solution in the nebulization cup becomes less. It is 




) increases with increasing volume median 
diameter. For TOBI® from the nebulizers in this study, the increase in span as function of VMD is linear 
from 4.77 micron for the Ventstream® to 7.78 µm for the LC® Plus at 1 bar jet pressure (20 L/min suction 
flow rate). The relative span { (X90-X10)/X50 for TOBI® from all four nebulizers is almost the same however: 
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Figure 7 .3  Changes (and spread} in  the volume median diameter during the first 2.5 min of  nebulization for TOBI® from the 
LC® Plus at 2 bar jet pressure and suction rates of 10, 20 and 30 L/min. Each curve is the mean of 3 vials. Spread bars in the 
curve for 10 L/min are indicative for all flow rates and represent the maximum and minimum values obtained at each moment 
during inhalation. 
The influence of jet pressure and nebulizer on volume median diameter 
Figure 7.4 shows the volume median diameter in the aerosol for TOBI® at a suction flow rate of 20 L/min 
as function of the constant jet pressure. The volume median diameter increases more or less exponentially 
with decreasing jet pressure. The order of nebulizers from larger to smaller volume median diameter is 
LC® Plus/LC® Sprint (X50 decreasing from 3.50 to 2.20 µm between 1 and 2.5 bar) ; LC® Sprint Star (X50 
decreasing from 3.00 to 1.82 µm between 1 and 2.5 bar) and Ventstream® (X50 decreasing from 2.50 to 
1.70 between 1 and 2.5 bar). On average, the VMDs for the Pari nebulizers (LC® Plus, LC® Sprint  and LC® 
Sprint Star) decrease to the same extent (with 390/o between 2.5 and 1 bar). The Ventstream® is slightly 
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less jet pressure dependent with a decrease of 31 °/o between the same extremes for the jet pressures. With 
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Figure 7.4 Effect of constant jet pressure on the volume median diameter of TOBl®at a suction rate of 20 L/min for all four 
nebulizer types. 
Effect of jet pressure source (from mains or compressor) on volume median diameter 
Mean jet pressures measured during nebulization of TOBI® at a suction flow rate of 20 L/min for the 
LC® Plus were 1 .74 and 2.67 bar for the TurboBoy N® and CR 60® compressor respectively. Those for the 
Ventstream® nebulizer for the same compressors were 1.03 and 1.65 bar. Volume median diameters in 
the aerosols produced by both nebulizers depended on the jet pressure in the same manner as depicted 
in Figure 7.4 with higher jet pressure leading to a smaller VMD. Minor differences were found between 
constant and pulsatile jet pressure but the differences were smaller than the spread (max-min) shown in 
Figure 7.2. As the difference between highest and lowest VMD 's decreases with increasing jet pressure as 
shown in Table 7. 1, the source (mains or compressor) for the jet flow results in random but no systematical 
differences in VMD. 
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Bar Ventstream ® LC® Plus Ventstream® 
VMD Max - Min VMD Max - Min  
1 3.65 0.67 2.36 0.39 
1 .03 2.54 0.40 2.34 0.23 
1 .65 2.1 9 0.04 1 .9 1  0. 1 9  
Table 7 . 1  Mean VMD (µm) and absolute spread {difference between minimum and maximum values obtained} in VMD at 
different jet pressures. VMD and absolute spread for jet pressures (bar) > 1 bar are for all experiments {both constant and 
pulsatile pressure). 
Effect of suction flow rate on volume median diameter 
An increase in suction flow rate from 1 0  L/m in to 30 L/m in  leads to a s l ight decrease in VMD for TOBI® 
from the Pari LC® P lus (Figure 7.5). The effect is independent of the jet pressure with which the aerosol 
is produced. 
The influence of the drug solution on the size distribution in the aerosol 
Al l  four  d rug so lutions (2 d ifferent antib iotics) appear to yie ld  the same size d istribution when they a re 
de l ivered with the same nebu l izer and  jet pressure at the same suction flow rate of 20 L/min.  Lower 
rather tha n h igher  jet pressures a re l i ke ly to emphasize differences i n  aerosol characteristics {Table 7.1). 
Therefore, the vol ume median d iameters in the aerosols from a l l  fou r  antibiotics and fou r  nebu l izers a re 
shown produced at a low jet p ressu re of 1 bar (Figure 7.6). Al l d ifferences between the VMD-va lues from 
the same nebu l izer a re with in the spread shown in Figure 7.2. Therefore, d ifferences have to be considered 
i nsign ificant and due to the variation in nebu l ization rather  than  due to d ifferences in  physico-chemica l  
properties o f  the d rug sol utions. 
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Figure 7 .5 Effect of suction flow rate on the volume median diameter of TOBI® from the LC® Plus nebulizer at 2 bar constant 
jet pressure (air from the mains) and in combination with the CR60® and TurboBoy N® compressors, yielding 2.67 and 1 .14 bar 
jet pressure respectively. 
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Figure 7 .6 Volume median diameter of all four drug solutions from all four nebulizers operated at 1 bar (constant) jet 
pressure at a suction flow rate of 20 L/min. 
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Most importantly this study shows that the VMDs for TOBI®, Bramitob®, Colistin® and Promixin® are the 
same when the same nebulizer is used at the same jet pressure. Another important finding is that the size 
distribution (VMD) of the aerosol from the same drug solution may change considerably when a different 
nebulizer is used at the same jet pressure. 
This means that the four drug solutions in this study can be exchanged for used with the same nebulizer 
without reaching another target area. In contrast, changing the nebulizer for the same drug solution may 
yield a much finer or coarser aerosol. Considering that antibiotics need to reach the whole lung including 
the peripheral airways for which small particles in the size range between 2 and 3 micron are more 
preferable than particles of 3 to 4 micron, the Ventstream® nebulizer seems most suitable for inhaled 
antibiotics in CF, closely followed by the Pari LC® Sprint Star. Nebulization with the Pari LC® Plus and its 
successor Pari LC® Sprint results in larger VMDs and must therefore result in lower peripheral antibiotic 
concentrations compared to both other nebulizers in this study. 
Although the VMD from Pari LC® Plus and Pari LC® Sprint (both 3.5 µm) is only 1 7  to 40°/o higher 
than VMD from Pari LC® Sprint Star (2.5-3.0 µm) and Ventstream® (2.5 µm) at 1 bar jet pressure, the 
difference between the extremes (LC® Plus and Ventstream®) is by a factor 2 expressed in terms of the 
impaction parameter. This impaction parameter (IP = p.D2.U, where p is the particle density and U is the 
particle velocity) predicts the chance of inertial deposition in the upper airways by inertial impaction. 
The resulting higher value for the impaction parameter may cause a considerably increased impaction of 
antibiotic aersosols in the upper respiratory tract from, Pari LC® Plus and Pari LC® Sprint with an increased 
penetration into the central and decreased penetration into the peripheral lung as consequence. 
The differences in VMD from the tested nebulizers are likely to result from differences in nebulizer design, 
especially that for the nozzle and baffle. A difference in design of the nozzle geometry can also be 
concluded from the difference in jet pressures obtained with the same compressors (Table 7.1) for the Pari 
LC® Plus and Ventstream®. For both compressors across the Ventstream® nozzle a lower pressure drop was 
found than across the LC® Plus nozzle. This, in spite of a considerably lower VMD from the Ventstream® . 
The spread bars in Figure 7.2 are partly the result of changes in the volume median diameter in the 
aerosol during the nebulization process (Figure 7.3). Prolonged nebulization (as shown in Figure 7.3 for 
the LC® Plus with TOBI®) does not consistently result in smaller particles. Also increased VMDs with 
increased nebulization times have been observed, e.g. for the LC® Sprint Star. These variations in VMD 
within total nebulization time do therefore unlikely result from changed physico-chemical properties 
of the drug solution, as could be caused by evaporation or cooling. The spread tends to increase with 
increasing nebulization time (Figure 7.3) and to decrease with increasing jet pressure {Table 7.1). Further, 
the differences between maximum and minimum values in Table 7.1 include all experiments at the same 
jet pressure. Therefore it was concluded that there is no significant effect of the jet flow source on the 
droplet size distribution. 
As found before, the size distribution in the aerosol decreases with increased jet pressure (Figure 7.4). 1 8  
A higher jet pressure decreases droplet size due to improved break-up of the liquid jet and a shift in the 
cutpoint of the baffle towards smaller droplets.1 9  Almost the same VMD can be obtained from the Pari LC® 
Plus and LC® Sprint at 2 bar as from the Ventstream® at 1 bar. Further advantages of a higher jet pressure 
are a higher reproducibility of nebulization {Table 7.1) and a much shorter nebulization time. 
IMPROVING DRUG DELIVERY TO THE LUNGS 1 03 Towards better inhalation therapy 
Chapter 7 Do the aerosol properties of inhaled antibiotics used in Cystic Fibrosis 
vary between drug solutions and jet nebulizers? 
In contrast with the jet pressure, the effect of the inspiratory (suction) flow rate on the size distribution 
in the aerosol is relatively small (Figure 7.5). Previously, it was found for TOBI® from the Pari LC® Plus that 
the effect of suction flow rate decreases with increasing jet pressure.21 This finding seems to be confirmed 
for VMD from the CR60® compressor (2.67 bar) compared to VMD from the TurboBoy N® compressor 
(1.74 bar) and 2 bar from the mains respectively, but not for VMD from 2 bar compared to VMD from the 
TurboBoy N® compressor. This may be due to the relatively small difference in VMD between 1.74 and 2 
bar and the relatively large spread between duplicate measurements at the same jet pressure. 
What are the clinical implications of the results of this study? As Psa is present in the whole lung, all 
airways, central as well as peripheral, should be reached with the antibiotic drugs. In order to do so, the 
target should be the lower airways as the upper and central airways will receive drug deposition from 
losses underway. Studies show that this aim can best be reached with particles in the aerodynamic size 
range of 1 to 3 micron. 1 9  With the exponentially increasing lung surface area from the trachea to the 
alveoli, it is clear that the highest possible peripheral deposition has to be the objective in order to obtain 
the most homogeneous drug distribution in the whole lung. This study provides a tool to the clinician 
to be informed about VMDs of antibiotics in CF therapy from different nebulizers depending on the jet 
pressure with which they are operated. This enables the clinician to make a well balanced decision for 
the type of nebulizer-jet pressure combination to be used by a particular patient. As compressors may 
decrease in performance over time, measurement of generated jet pressure by a patient's compressor in 
the outpatient clinic should be tested on a regular basis. 1 6  This can guide the clinician in estimating which 
VMD can be expected for the nebulizer used by the patient. 
Laser diffraction technique was used to measure the particle size distributions in the aerosols from the 
nebulizers. The main advantage of laser diffraction technique compared to cascade impactor analysis is 
the possibility to follow the size distribution during the entire nebulization time by interval measurements. 
This makes laser diffraction technique appropriate for measuring changes and fluctuations in the size 
distribution during nebulization. This gives a much better insight in the variations which appear to be the 
result of both spread within the same measurement and spread between measurements (vials). The fast 
measurement with laser diffraction technique also enables to complete a large number of experiments, 
which makes this technique very suitable for comparative evaluation studies. 
How do the results of this study relate to existing literature? The Pari company reports an MMD of 3.8 µm 
for the Pari LC® Plus, 3.5 for the Pari LC® Sprint and 3.1 µm for the Pari LC® Sprint Star, all tested with a 
0.90/o saline solution using a 1.2 bar compressor and a constant suction flow rate of 20 L/min as measured 
with Mastersizer X laser diffraction.20 These MMDs are in good agreement with the VMDs provided in 
Figure 7.5 for TOBI® in spite of differences in the properties of the solutions (a low concentrated saline 
solution compared to higher concentrated tobramicin solutions). Our findings are in contrast with the 
European consensus of inhaled medication and inhalation devices for patients with CF, in which it is stated 
that due to a lower surface tension nebulization of colistimethate sodium results in smaller droplets. 1 3  
An acknowledged limitation of this study is that nebulizer output (rate), which is a result of both 
nebulization and evaporation, was not formally assessed. 
IMPROVING DRUG DELIVERY TO THE LUNGS 104 Towards better inhalation therapy 
Chapter 7 Do the aerosol properties of inhaled antibiotics used in Cystic Fibrosis 
vary between drug solutions and jet nebulizers? 
In summary, we demonstrated that the nebulization of TOBI®, Bramitob®, Colistin® and Promoxixin® with 
the same nebulizer using the same jet pressure results in the same volume median diameter. To obtain an 
aerosol with the highest fine particle fraction and highest expected total and peripheral lung deposition, 
Pari LC® Sprint Star and Ventstream® perform best, especially with a jet pressure of 2 bar or higher. 
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Abstract 
Background 
Patients accepted the first insulin dry powder (Exubera!>) poorly as the inhaler was large, expensive, 
available in 2 dose strengths only and complex to use. We aimed to show that improved inhalation 
technology eliminates these drawbacks whereas systemic insulin availability per mg inhaled insulin can 
be doubled. 
Methods 
Fine particle doses ( 1-3 µm) of Exuberai; from the Exubera® inhaler ( 1  and 3 mg) and a novel disposable dry 
powder inhaler (Twincer™ : 1-1 2 mg) were measured in vitro using laser diffraction and cascade impactor 
analysis. Equivalent insulin doses from both devices were subsequently computed and used to treat a 
13-year old girl with type 1 diabetes mellitus. Inhalation flow manoeuvres were recorded. Serum insulin 
levels were measured. 
Results 
Based on in vitro data, use of the Twincer™ allowed a 420/o lower insulin dose compared to the Exubera® 
inhaler to obtain the same fine particle dose ( 1-3 µm). Insulin serum concentrations for the 13-year old 
girl (t = 30 min) per mg inhaled insulin were 7.7 mlU/L when using the Exubera® inhaler and 14.4 mlU/L 
from the Twincer™ . 
Conclusions 
Systemic availability per mg insulin can be doubled by using the Twincer™ compared to the Exubera® 
inhaler. With the Twincer™ , doses up to 12 mg can be administered in one inhalation. Improved consistency 
of delivered fine particle dose and hence safety, higher dose flexibility, cost reduction, and patient comfort 
may fulfil all technical prerequisites for pulmonary delivery of systemically acting drugs, which may 
facilitate a comeback of inhaled insulin 
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INTRODUCTION 
The International Diabetes Federation estimates that nowadays 285 million people around the world 
have diabetes.1 Patients needing short acting insulin could inhale this with a dry powder inhaler instead 
of taking subcutaneous injections. Despite the potential advantages of inhaled insulin, e.g. no cold chain 
storage of the drug and disposal of needles, the first insulin inhaler (Exubera®, Pfizer) was withdrawn from 
the market after just over one year. All other inhaled insulin developments were subsequently terminated, 
except for the MannKind Technosphere® Technology. Reasons for withdrawal of Exubera® were amongst 
others poor patient acceptance2-5, high costs compared to insulin injections6 and safety concerns.7•8 The 
Exubera® inhaler {Figure 8. 1 A) was a large device and required a large sequence of actions to complete 
before a dose of insulin could be inhaled. Size and lack of simplicity are drawbacks since devices need 
to be small and simple for good patient acceptance. Insulin inhalers furthermore should allow a wide 
range of doses to be taken in one inhalation. For Exubera®, only two doses were available in two different 
blisters.8•9 The high costs involved might be reduced by using cheaper inhalers, simple formulation 
technologies and by increasing the fine particle dose per mg of insulin. The safety concerns with Exubera® 
involved small lung function changes (for forced expiratory volume in 1 s (FEV,)) and carbon monoxide 
diffusing capacity (DLCO) in 1-3 year studies, that all returned to normal after cessation of inhaled insulin 
treatment.8 If indeed relevant, changes in lung function may be reduced by increasing deposition efficacy 
in the target area, which decreases total lung dose. Updated label information by Pfizer and the Food and 
Drug Administration (FDA) regarding newly diagnosed lung malignancies, all in ex smokers, caused the 
termination of all competitor developments.7 
Figure 8.1 A (left) and B (right) 
A: The Exubera® inhaler 
demonstrated by a volunteer 
B: The Twincer™. 
Do these reasons for termination of Exubera® imply that there is no future for inhaled insulin?1 0  The 
answer depends on the extent to which previously mentioned improvements relative to Exubera® can be 
realised and the resolution of the safety issues. (Ex)smokers are possibly to be excluded from new trials 
with inhaled insulin. Clinical studies with MannKind's Technosphere® insulin (Afrezza®) are in a final 
stage of the FDA approval process. An alternative for inhaled insulin is developed using inkjet technology, 
but in vitro data from these developments have not been published in the scientific domain so far. 11 
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We therefore aimed to show with the Twincer™ dry powder inhaler that improved inhaler technology can 
fulfil all necessary prerequisites for a comeback, including the same insulin plasma concentrations when 
giving only half the dose as with the Exubera® inhaler. 
MATERIALS AND METHODS 
We designed a stepwise approach and determined 1) the delivered doses at different flow rates; 2) 
the dispersion efficacy and reproducibility of the Exubera® formulation by both inhalers; 3) expected 
equivalent doses for both inhalers based on equivalent delivered fine particle dose; 4) lung deposition 
efficacy based on resulting insulin levels. 
The Twincer™ (Figure 8. 1 BJ is a disposable high dose inhaler developed for the administration of 
colistimethate sodium in CF patients.12 The inhaler is also suitable for highly effective pulmonary delivery 
of a large number of other drugs that need to be administered in high doses. Injection moulded Twincers 
were supplied by lndes (Netherlands). PVC coated alu-alu blisters of 280 mm3 (Tommy Nielsen, Denmark) 
were used as dose compartments. The Twincer™ blisters were filled with insulin powder formulation from 
3 mg Exubera® blisters ; weighing was on a 5 decimal analytical balance. Exubera® inhalers and insulin 
blisters ( 1  + 3 mg) were purchased from EuroCept Pharmaceuticals (Netherlands). 
Dispersion efficacy and reproducibility of the Exubed' formulation 
Efficacy and consistency of insulin powder dispersion by the Exubera® ( 1  and 3 mg blister) and the 
Twincer™ inhaler ( 1-12 mg doses) were studied with laser diffraction technique, using the primary particle 
size distribution of the Exubera® formulation from RODOS dispersion (3 bar) as reference. A HELOS BF 
MAGIC (Sympatec, Germany) laser diffraction apparatus was used with 100 mm lens (measuring range 
0.5 to 175 µm). Dispersion testing was at a single flow rate of 55 L/min (2.3 kPa) for the Exubera® low 
resistance inhaler, and at 35 (2 kPa) and 55 L/mi_n (4 kPa) through the Twincer™ respectively. 
Delivered fine particle dose and assessment of equivalent doses 
Delivered fine particle doses from the Exubera® inhaler and Twincer™ were analysed with cascade impactor 
technique (MSLI, apparatus 4 described by the USP/NF 2007). Flow rates were the same as mentioned 
for laser diffraction analysis and inhalation times were set to 3 s. Fine particle doses from both inhalers 
within the aerodynamic size range 1-3 µm were computed because this size fraction is considered most 
appropriate for deposition in the peripheral airways where absorption of insulin must occur.8•1 3  From the 
delivered fine particle doses, equivalent nominal doses from the Exubera® inhaler and Twincer™ were 
assessed. 
In vivo insulin levels 
A 13-year old girl was referred to our hospital because of brittle type 1 diabetes (T 1 D). T 1  D was diagnosed 
at the age of 11 years. She was treated with by continuous subcutaneous insulin infusion from the age 
of 12 years onward. Episodes of hyperglycaemia and ketoacidosis developed gradually with increasing 
frequency despite an increased insulin dose (5 E/kg/24 hrs). Insulin resistance was considered, but 
attempts to reduce subcutaneous insulin resistance by adding heparin to the insulin and administration 
of immunoglobulins were not successful. Next, a trial with Exubera® to improve diabetic regulation was 
unsuccessful. We hypothesized that improved inhaler technology and the resulting improved alveolar 
deposition would increase the insulin serum concentrations. The patient was trained to perform a maximal 
exhalation prior to steady and deep inhalation. Of each inhaler type, one device was instrumented to 
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record the flow manoeuvres in vivo. The flow curves as function of inhalation time were integrated to 
obtain the inhaled volumes. After inhalation, a breath hold period (5-10 s) was applied for both devices. 
Insulin doses were inhaled at 10 am, noon and 2 pm on 3 successive test days, using both inhalers in an 
alternating way on top of unchanged subcutaneous pump insulin infusion and a standardized carbohydrate 
intake. The equivalent nominal dose was based on the glucose level prior to inhalation. Glucose and free 
insulin levels were determined at t=0, 30, 60 and 90 minutes after inhalation. The samples were treated 
with polyethylene glycol to precipitate anti-insulin antibodies. The doses administered with the Exubera 
inhaler were derived from registered dose recommendations for Exubera® in relation to the measured 
glucose levels7 those from the Twincer™ were based on the computed in vitro dose equivalence with 
the Exubera® inhaler. We obtained patient and parental consent for treatment, which was carried out in 
accordance with the principles of the Declaration of Helsinki as revised in 2000. 
RESULTS 
We measured that a 1 mg Exubera® blister contains on average 1 .8 mg powder versus 5.5 mg in the 3 
mg blister. Both the efficacy and the reproducibility of dispersion of the Exubera® insulin formulation 
are much higher with the Twincer™ than with the Exubera® inhaler {Figure 8.2). This results in a much 
higher fine particle fraction (FPF) in the aerodynamic size range 1-3 µm with the Twincer™ than with the 
Exubera® inhaler, being 38.80/o and 21.20/o of the real dose for a 3 mg blister respectively. For the 1 mg 
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Figure 8.2 Efficacy and reproducibility of dispersion by the Twincer™ and Exubera® inhaler for five successive (3 mg) doses, 
both at 55 L/min as expressed with the cumulative volume distribution. The arrows point to the Volume Median Diameter 
(VMD). The X-axis is logarithmic. 
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MMAD = mass median aerodynamic diameter for FPF < 5 µm from cascade impactor analysis 






The volume median diameter in the aerosol from laser diffraction for the Twincer™ was 2.7 µm and 
independent of the dose weight (between 1 and 12 mg) (Figure 8.3 A} and the flow rate (35-55 L/min). 
In contrast with the Exubera® inhaler, although also flow independent, the median diameter was 3.6 µm 
for the 1 mg blister and 5.4 µm for the 3 mg blister (Figure 8.3 B}. The emission time and the volume 
needed to inhale all insulin form the inhaler for the 3 mg blister at 55 L/min were considerably less for 
the Twincer™ than for the Exubera inhaler (approx. 1.2 versus 3.7 s for the emission times, equalling 1.05 
and 3.4 L of inhaled air respectively). On the basis of the in vitro deposition data in the impactor we 
calculated that a 1 mg blister ( 1.8 mg powder) from the Exubera® is equivalent to 1 . 11 mg powder from 
the Twincer™ and a 3 mg blister (5.5 mg powder) to 3.02 mg powder from the Twincer™ . This is a mean 
dose reduction by a factor of 1.7 (420/o). 
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Figure 8.3 A Volume median diameter in the aerosol from the Twincer™ as function of the Exubera® insulin dose weight at 35 
and 55 L/min respectively. Each bar represents the mean of two measurements. 
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Figure 8.3 B Volume median diameter in the aerosol from the Exubera® inhaler using 1 and 3 mg blisters at three different 
inspiratory flow rates. Each bar represents the mean of five blisters. 
With both inhalers, serum insulin concentrations were highest after 30 minutes. The overall mean values 
for the 3-day treatment demonstrate that the doses needed when using the Twincer™ were 500/o lower 
than when using the Exubera® inhaler. Serum insulin concentrations per mg inhaled insulin were 7.7 from 
the Exubera® inhaler and 14.4 (mlU/L) from the Twincer™ {Table 8.2). 
� 
Inhaler Mean dose weight Mean flow Mean breathe Mean insulin Plasma 
administered (mg) rate hold period plasma cone. per mg 
(L/m) (s) concentration Exubera® 
(mlU/L) formulation 
after 30 min (t=30 min) 
Exubera® 14.2 32.9 5.6 110 7.7 
Twincer rM 7. 1 30.7 7.5 103 14.4 
Table 8.2 in vivo serum insulin from the Exubera® inhaler and the Twincer™. 
DISCUSSION 
The principle finding of this study is that that the systemic availability of inhaled insulin can be doubled 
when increasing the fine particle dose by using more effective inhaler technology {Table 8.2). More studies 
are needed, yet this proof of concept study provides suggestive evidence that inhaled insulin can be a 
realistic therapeutic alternative for patients with true needle phobia or when there are major needle site 
problems. 
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The difference in volume median diameter between the aerosols from the Twincer™ and Exubera® inhaler 
(e.g. 2.7 µm and 3.6 µm respectively, for the 1 mg blister, Figure 8.4) is the main reason for the higher 
efficacy of the Twincer™. The 330/o larger vo lume median diameter (X50) from the Exubera® equals a 780/o 
higher impaction parameter (IP = p.X5/U),  in which p is the particle density and U the particle velocity. 
This impaction parameter is a predictive parameter for i nertial deposition in the larger airways. Particles 
that are only slightly smaller will have substantially higher deposition in the peripheral ai rways where 
absorption of insulin must occur.8•1 3  The MMAD presented i n  Table 8. 1 for the 3 mg blister (2.5 µm) is 
smaller than that from previous in vitro deposition studies with the Exubera system (3.5 µm 14) .  Direct 
comparison of these two MMAD values is not possible however, as we computed the MMAD for the fine 
particle dose < 5 µm, whereas Harper et al did not specify the fraction for which they computed the 
MMAD. 
The even slightly greater improvement i n  systemic availability (2x) compared to the in vitro deposition 
efficacy (1 .7x) may be explained by a much shorter emission t ime from the Twincer™ than from the 
Exubera® inhaler. For effective systemic del ivery via alveolar absorption the entire dose should preferably 
be delivered within  the fi rst litre of inhaled air to transport the aerosol to the peripheral airways. If the 
aerosol is diluted in a larger volume (as for the Exubera® i nhaler), part of the dose may not reach the 
alveolar absorption area and total residence time in the lungs may be too short for effective sedimentation. 
A breath hold of 5- 10  seconds following inhalation further improves deep lung deposition. 
Our results suggest that inhaled i nsulin can be a realistic alternative for patients with T l  D needing 
a pre-meal bolus of insul in .  Pharmacokinetic characteristics of i nhaled insulin with rapid absorption 
and rapid elimi nation compared to subcutaneously admin istered insulin closely mimics endogenous 
prandial i nsulin release. 1 5 The higher in vitro fi ne particle dose from the Twincer™ in the 1-3 µm range 
compared to the Exubera inhaler corresponds well with the increased systemic availability of i nsulin in  
vivo. This particle fraction of  1-3 µm is regarded optimal for  peripheral ai rways deposition . 1 3  A lower 
i nsulin dose with a cheap i nhaler device might sign ificantly reduce costs as well. Other advantages are 
that the Twincer™ is smal l ,  disposable and easy to use. Dose flexibility can be increased to 12 mg without 
affecting dispersion efficacy. Regardi ng safety, the conclusions for different products (Exubera®, AERx®, 
AIR®, Afrezza®) after 1 to 3 year use of these systems are that lung function changes are relatively small, 
non-progressive and reversible. Reported lung function changes may also be attributed to Tl DM being a 
m icro angiopathic disease also affecti ng the lung. 16 Although a causal relation between i nhaled insul in  
and the development of lungcancer has not been demonstrated, an i ncreased concentration and duration 
of exposure of the alveolar epithel ium and underlying con nective tissue to insuli n  should possibly be 
avoided. 1 5• 1 7  With a more homogeneous distribution with a higher small particle fraction, local insul in  
concentrations may be lower and the transfer time from alveolus i nto the ci rculation may be shorter. 
We hypothesize furthermore that he reported lung function changes may partly have been caused by the 
excipients used in the insul in  formulations. Exubera® contained mannitol, glycine, sodium citrate and 
sodium hydroxide. The Technosphere® formulation (Afrezza®), the only remain ing system in development, 
consists of highly porous fumaryl diketopiperazine self-assembling crystals  with a large surface area to 
which insulin is absorbed. Regardi ng long term safety, excipient-free insuli n  might be preferable. 
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The importance of this study is that we have shown that improved efficacy and consistency of lung 
deposition, increased dose flexibility, cost reduction and increased patient comfort are all feasible with 
improved inhaler technology. This concept was applied in one girl with T 1  D with success. Future studies 
in larger groups of patients have to show the implication for implementation in the management of T 1  D 
including long term safety issues. This may fulfil all technical prerequisites for pulmonary delivery of 
systemically acting drugs and a comeback of inhaled insulin for selected patients. 
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GENERAL DISCUSSION 
9.1 Inhaled drug delivery: many variables and their interactions 
The ultimate aim of this thesis is to improve treatment of (respiratory) diseases by improving inhalation 
treatment. Inhalation of aerosolized drugs has resulted in better clinical control of prevalent pulmonary 
diseases like asthma and COPD. Inhalation therapy has also led to an important increase in life expectancy 
and quality of life for patients with Cystic Fibrosis. Further, the pulmonary route has proven to be suitable 
for systemic drug delivery, e.g. for insulin and vaccines. A high fine particle fraction is necessary for 
optimal targeting of the peripheral ai rways for respi ratory diseases as well as for systemic treatment and 
the delivery of vaccines by inhalation. However, despite clear advantages of inhaled therapy and ongoing 
device and drug formulation development, incomplete understanding of the many factors that influence 
drug deposition in the respiratory tract has been a limiting factor in achieving optimal inhalation therapy 
so far. 
The results of our studies clearly demonstrate that relevant improvements are both possible and necessary. 
In this thesis, we have provided insights in factors contributing to lung deposition. Fi rst, we showed that 
the choice of drug and device combination significantly influences the (fine) particle output from a pMDI. 
The output of fluticasone 250 and 125 µg/dose pMDls decreases with the number of delivered doses 
(chapter 3). 1 Fine particle dose when pMDls are used with valved holding chambers (VHCs or spacers), 
as recommended in children, may vary from 170/o to 370/o of label claim only depending on which pMDl­
spacer combination is chosen (chapter 4). Second, increasing air humidity leads to up to a 500/o higher 
output from VHCs without a change in particle size distribution and thus results in a higher fine particle 
dose (chapter4}. For nebulized drugs, a relevant increase in fine particle output can be obtained by a higher 
jet flow through the nebulizer system (chapter 7). Third, systemic absorption of insulin can be doubled by 
using an appropriate device which enables adequate inhalation and delivers a higher fine particle fraction 
in the initial phase of inspi ration compared to an earlier insulin inhaler (chapter B}. Treatments are time 
consuming. The results in chapter 6 additionally show that lack of adherence to cleaning regimes may 
lead to a large and clinically relevant decrease in output from nebulizer systems.2 Finally, we show that 
two marketed tobramycin solutions with different drug concentrations and different excipients do not 
differ significantly in aerosol properties when nebulized with different nebulizer-compressor systems. 
Therefore, these products are widely exchangeable when used with the same system. For 2 different 
suspensions of colistin, results were similar (chapter 7). 
The studies above give insight in some characteristics relevant to the choice of aerosol generation device, 
envi ronmental ci rcumstances and drugs. However, reaching the exact target area in the lung for drug 
deposition with a sufficient fine particle dose requires more than the appropriate selection of the drug 
and the device needed. Many variables are involved in inhalation therapy and many interactions between 
these variables exist (Figure 9.1). 
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Figure 9.1 interaction of the 
many variables in drug delivery 
in the airways. 
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The health care provider has to select the drug and an appropriate device for inhalation, depending on 
the type of disease, disease severity, age and skills of the patient. The health care provider then has to 
instruct the patient about the best procedures for the chosen inhalation device and the patient has to be 
motivated to comply with these instructions. For nebulizers and spacers this also includes the need of 
cleaning. In chapter 1 basic principles of inhalation therapy are discussed. 
Inhalation manoeuvre 
Exhalation to residual volume before inhalation and a breathhold pause (theoretically as long as possible, 
in practice 5 to 10 seconds) after maximal inhalation may result in a peripheral lung deposition of 250/o. 
This sequence is essential for optimal use of dry powder inhalers and also recommended for children using 
a pMDl-spacer combination whenever possible.3 .4 Exhalation to residual volume results in maximal air 
refreshment of the most distal airways with inhalation. Slow to moderate inhalation flowrates decrease 
impaction in the upper airways. The breathhold results in more time for sedimentation to occur. This 
manoeuvre is optimal for drug delivery in the small airways and in the alveolar region. 
Inhalation device 
The intrinsic inhaler resistance of a DPI affects the peak flow rate and duration of inhalation. Over 
a low resistance inhaler, the instruction to inhale forcefully will lead to increased drug losses in the 
oropharyngeal region by inertial impaction. Only if the DPI compensates this with a higher fine particle 
dose at higher flowrates, the distribution of deposition in the smallest airways may remain similar. For 
pMDls, drug losses in the oropharynx or spacer may increase by a high aerosol plume velocity resulting 
in increased impaction. For deep lung penetration of the drug, the aerosol emission time from a DPI or 
nebulizer has to be short and early during inhalation as only the fraction of the dose delivered within the 
first half of the inhaled volume will be effectively transported into the alveoli and most distal airways. 
Drug formulation 
The drug formulation itself can have a great effect on the properties of the aerosol and the dose delivered 
to the patient. From adhesive mixture types of powder formulations, generally less than 500/o of the dose 
is released as particles with the appropriate aerodynamic size distribution. Surface tension and viscosity 
influence the size distribution of the droplets from nebulizers and may change during the nebulization 
process due to evaporation and temperature changes. Relative air humidity may also have an effect on 
hygroscopic powder formulations in DPls, especially when stored under moist conditions over longer 
periods. 
In conclusion, many human-drug-device interactions exist and these may all result in increased or 
decreased deposition in the target lung area, subsequently leading to increased or decreased symptom­
or disease control. These interactions will be addressed in the next parts of this chapter, focusing on 
target area, fine particle dose and drug distribution, patient related factors and methods to measure 
effectiveness of inhalation therapy. 
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9.2 Target area 
To improve drug delivery to the lungs in pulmonary 
or systemic diseases, first the target area needs to 
be defined and 3 issues need to be addressed. 
To start, it is necessary to define the target 
area to which the drugs need to be delivered. 
This target area depends on the location of the 
disease process (e.g. the site of inflammation or 
infection), the presence of drug receptors (e.g. 
steroid receptors) and effector tissue (e.g. smooth 
muscle). 
Second, the chosen target area is the principal 
determinant of the preferred aerodynamic 
particle size (distribution) and optimal inspiratory 
flow manoeuvre . 
Third, devices need to be developed and selected 
that facilitate patients from a wide age range 
to use the device correctly, resulting in optimal 
output and deposition at the most favourable 
inspiratory manoeuvre. 
Asthma and COPD 
Asthmatic inflammation is present in both large 
and small airways5•6 with an increasing number of 
ICS receptors towards the periphery.7 In asthma, 
all airways thus need to be targeted with ICS with 
emphasis on the peripheral airways. The target area 
for beta-2-agonists in asthma is predominantly 
determined by the airway generations where 
smooth muscle contraction leads to airway 
narrowing. Although smooth muscle is present 
all the way down to the respiratory bronchioli, in 
airways distal to generation 1 4, other stretching 
and pulling factors play a role in keeping the 
airway opened. Down to generation 7, airways 
are to some extent protected from narrowing 
due to smooth muscle contraction by cartilage. 
Therefore, the target area for bronchodilators are 
the airways from generation 7 to14.8 
Chronic obstructive pulmonary disease (COPD) 
is an inflammatory disease where the whole 
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Clinical effect 
respiratory tract is affected from the central to 
the so-called small airways of less than 2 mm 
in internal diameter.9 Depending on severity as 
expressed in GOLD stage 1-4, treatment varies 
from short acting bronchodilators as needed to 
long-acting bronchodilators with or without ICS 
(www.goldcopd.org). The target area for both ICS 
and long acting bronchodilators in COPD is there­
fore similar to that in asthma. 
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CF 
In CF lung disease, infection (e.g. by Pseudomonas aeruginosa, aspergil/us fumigatus), viscous sputum and 
inflammation play an important role and may be targeted by inhaled antibiotics or antifungals, DNAse 
and hypertonic saline, and ICS respectively. Small airways in CF are involved in the disease process from 
birth onward, as indicated by trapped air on CT scans 10 and by increased FRC as measured with pulmonary 
function tests in young children, which reflect inflammatory processes and mucus plugging. 1 1 •1 2  
Pseudomonas aeruginosa (PA}, if present, resides in both conductive and respiratory airways. 13 Therefore 
the target area for nebulized antibiotics in CF are all airways and a high fine particle fraction is needed to 
target these all. For the treatment of PA in the airways with aminoglycosides this is even more important 
as the efficacy of aminoglycosides is predicted best by the peak concentration (CmaJ to Minimal Inhibitory 
Concentration (MIC) ratio and a Cm)MIC ratio greater than 10  is generally advised. For tobramycin 
this means that a concentration of 20 mg/L in the airway may be necessary, underscoring the need for 
targeting the small airways to reach this high concentration in the light of an exponentially increasing 
airway surface area (chapter 5). 1 4 
Viscous mucus is present in all airways in CF and airway obstruction starts, in young children already, 
in the small airways. Mucolytics therefore need to target the entire bronchial tree, and in particular the 
small airways. 
In summary, all airways may need to be targeted with anti inflammatory, antimicrobial and mucolytic 
drugs in CF. 
Systemic delivery 
The alveolar area is the target area for systemic absorption. Drug losses in conductive and transitional 
airways should be kept to a minimum, as medication landing here is less likely to reach the vascular 
endothelium where absorption in the systemic circulation can take place. 
How to achieve the highest drug concentration in the target area. 
To achieve optimal clinical effect, most of the drug dose should be deposited in the target area for that 
drug. Whether this is possible or not, depends on where the target area is located. When the upper and 
central airways are to be treated (as with bronchodilators), larger particles can be used theoretically 
and the velocity with which these particles are released into the respiratory tract can be higher than 
for peripheral lung deposition. The particle momentum (the product of mass and velocity) should not be 
too high however, to prevent substantial losses in the oropharynx, which reduces the dose available for 
the lung. Because of the small surface area of the upper and central airways, high drug concentrations 
can be achieved in these areas. However, the surface area of the airways increases exponentially 
towards the alveoli. Due to this increase and the drug losses in the upper airways (chapters 1 and 5) it is 
impossible to reach the same high concentrations in the peripheral lung. Neither can a homogeneous drug 
distribution within the whole lung be achieved: regardless of particle size, there will be a decrease in drug 
concentration from large to small airways because of this exponentially increasing surface area and the 
approximate 1 : 1  : 1  deposition ratio in the conducting, transitional and peripheral airways. 1 5- 1 7  In a study 
with monodisperse particles of salbutamol of 6, 3 and 1 .5 µm, particles were inhaled with a relatively 
slow inhalation of 30 L/min followed by a breathhold period. This resulted in an increase in peripheral 
lung deposition from 1 0  to 250/o with decreasing particle size from 6 to 1 .5 µm. 18 250/o of the total dose of 
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1.5 µm particles deposited on an estimated 950/o 
of the lung surface area whereas 31 0/o deposited 
on the other 50/o of the total lung surface area 
resulting in a almost 25 fold mean concentration 
difference. For larger particles, this concentration 
difference is even larger. Using an inhalation flow 
of 67 L/min resulted in a lower peripheral lung 
deposition for all three particle sizes compared to 
the slower inhalation flow. 
Therefore, when the small airways are the target 
area, drug concentration there will inevitably be 
lower than in higher airway generations. 
9.3 Particle size and inhalation 
manoeuvre : it takes two to tango 
The interaction between particle size and 
inspiratory flow rate determines deposition. 
Ideally, ICS particles should be 1.5 µm for optimal 
small airway targeting and should be inhaled 
with a low to moderate flow rate; currently, a 
range of 1-3 µm is the most feasible size fraction 
from all types of pMDls, DPls and nebulizers. 
For bronchodilators the particle size fraction 
can be broader (3-5 µm) as the target area is 
confined to airway generations 7-14. Indeed, it 
has been shown that for bronchodilators larger 
particles are more efficacious and achieve more 
bronchodilation than smaller particles with a 
change in FEV, of 551 ml for 6 µm particles, 457 
for 3 µm and 347 for 1.5 µm.18 
With a slower and longer inspiration, the same 
area can be reached with a slightly larger particle 
size as with a faster and therefore shorter 
inhalation of slightly smaller particles. This has 
been confirmed in quite a few studies. As an 
example, in a radionuclide study comparing 
nebulizer generated aerosols with an MMAD of 
5 µm with a 9.5 µm MMAD aerosol, an extremely 
slow inhalation of less than 0.5 L/min during 10 
seconds resulted in a higher conductive airway 
deposition of the large particles compared to 
cyclic tidal breathing of the smaller particles.1 9  
Chapter 9 General discussion 
1 Delivered fine , 
I particle dose 1 
, (1-3 µm) 1 
,... _  -� I 
- - -
o� Drug distributi�n 
I and conccntrat,on 
I 
• t 
> Deposition mechanisms 
lr:ert1al impaction ard 
seclirrorntation ----+-
> Deposition efficiencies 
40 - 60% ____ ..,. 
IMPROVING DRUG DELIVERY TO THE LUNGS 1 23 Towards better inhalation therapy 
Chapter 9 General discussion 
-- --- -----------------------------------
Targeted delivery to smaller airways with saline solution droplets ( 1  and 3.7 µm droplets) mixed with 
the radio isotope (99m)Tc was possible with smal ler droplets inhaled at a lower ( 18 L/min and 38 L/ 
min) inspiratory flow rate from functional residual capacity.20 Other studies also show that regional lung 
deposition is dependent on particle size, inhalation volume and flow rate.21 Nebulization of tobramycin 
inhalation solution with the eFlow® rapid reduced nebulization time, but also resulted in a 4O0/o reduced 
whole lung deposition compared to LC® plus nebulizers.22 This is in agreement with our study presented 
in this thesis, in which the particle size distribution of the eFlow® rapid is shifted to larger particles 
compared to Pari LC® plus (chapter 6).2 Of interest, in healthy subjects, lung deposition of both devices 
was comparable. The larger particles may impact easier in more severely  obstructed airways. A high fine 
particle fraction is necessary to reach beyond diseased airways with reduced airway cal iber.23 
For younger children using a pMDl-spacer combination with a face mask, quiet breathing is essential .  
Crying has proven to reduce lung delivery in nebulized budesonide due to the high flow rates generated 
and the resulting impaction in upper airways.24 
Although a large fine particle dose should be more effective than an equivalent dose of coarse particles, 
this has not been conformed in vivo so far. Reasons for that may be that many studies are of too short 
duration, compare different drugs and devices in the same study, and do not report on inhalation 
parameters and environmental conditions that are a l l  important as we have shown in this thesis. Further, 
the exponential ly increasing surface area of the lung towards the periphery can result in too smal l 
differences in deposition and therefore in clinical effectiveness. To investigate this, the power of studies 
should be increased by enrolling more patients and/or studying them for a longer duration. Final ly, the 
plateau of the dose-response curve may have been reached, so that a higher local drug deposition, e.g. in 
more peripheral airway targeting, does not result in a cl inical difference.25 
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9.4 Fine particle fraction : 
devices and cond itions 
The absolute fine particle fraction from a drug 
dose primarily depends on the choice of delivery 
device. In this thesis we demonstrated that this is 
true for pMDl's, pMDl-spacer combinations, DPl's 
and nebulizer systems {chapters 4-8). 
Although this finding is not new, the extent to 
which differences between delivered doses exist, 
surprisingly high: they are up to a double dose 
and can thus be considered clinically relevant. 
As expected, pMDl 's differ in their delivered fine 
particle fraction ( 1-3 µm volume median diameter 
(VMD), however the differences in delivered fine 
particle dose are unexpectedly high between 
380/o of label claim for fluticasone ( 125 µg/dose) 
and 610/o of label claim for ciclesonide ( 160 µg/ 
dose){chapter 4). These large differences result 
from the formulation. Valved holding chambers 
or spacers reduce the fine particle dose released 
from the spacer (and thus the dose available for 
inhalation), leading to a further reduction of the 
fine particle dose. 
For fluticasone with Volumatic® this further 
reduction is 440/o of the 380/o fine particle 
dose directly from the pMDI and 600/o of 
610/o for ciclesonide with the (non anti static) 
AeroChamber®. These reductions of fine 
particle dose due to losses in the spacer are 
considerably less at higher humidity {chapter 4). 
We hypothesise that losses in the spacer are less 
with increased humidity, primarily because of 
reduced electrostatic charge; electrostatic charge 
that continues to play a role despite washing (or 
priming) of the spacers. 
For pMDls and valved holding chambers we need 
to know the output of the various drug-device 
combinations as function of the environmental 
conditions (e.g. air humidity). For pMDl-spacer 
combinations, ICS fine particle output increases 
with higher humidity. Ciclesonide and HFA-BDP 
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both had highest fine particle output with the 
AeroChamber Plus® {chapter 4). 
For dry powder inhalers (DPls) the output depends 
on effective drug dispersion, which is often 
dependent on the pressure drop across the inhaler. 
A high pressure drop is preferred as it results in 
a lower inspiratory flow rate compared to a low 
pressure drop. Further, a flow dependent increase 
in fine particle dose release can compensate 
for impaction in upper airways associated with 
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increased flow rates.26 Release of the dose early during inhalation enables relatively peripheral deposition 
{chapter BJ. 
Nebulizer-compressor systems can be used with different drug solutions and suspensions, but the 
properties of the aerosol and output rate should be investigated for each drug formulation. Moreover, 
once the aerosol properties for a particular drug formulation from a nebulizer are known, no changes in 
type of compressor or jet flow can be made without changing the aerosol properties too. For nebulizer­
compressor systems, fine particle output is dependant on the choice of a nebulizer and it increases with 
increasing jet-flow {chapter 7). 
9.5 Patient related factors : 
inhalation instruction and 
adherence 
As lung deposition of inhaled drugs generally 
increases with age, children and adults can 
use the same nominal dose of inhaled drugs. 
A few studies provide some evidence for this 
statement, e.g. a pharmacokinetic study with 
budesonide27 and a study with Technetium 
labeled salbutamol. For young infants with 
the nose as an effective filter the dose needed 
might be higher.28 
Inhalation instruction is crucial in inhalation 
therapy and should be repeated frequently to 
ensure a correct inhaler technique.29 Probably 
the most important determinant of the success 
of inhalation therapy is adherence. In clinical 
trials in pediatric asthma, adherence to 
treatment as monitored by electronic devices 
may be as low as SQO/o-770/o.30 As participation 
in a trial usually increases adherence, these 
percentages are presumably (much) lower in a 
non-selected asthmatic population.31 
Also, adherence to cleaning instructions is 
essential. In a study with a mesh nebulizer, 
inadequate cleaning resulted in loss of drug 
output. The mesh needs to be replaced timely 
as the volume median diameter increases over 
the course of time {chapter 6).2 Increasing of 
adherence to treatment and cleansing may 
therefore be considered an effective and cheap 
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way ("low hanging fruit") to improve disease- and symptom control and high priority should  be given to 
research related to improving adherence in asthma and CF patients. 
9.6 How to measure pulmonary drug delivery 
This thesis provides exact data on the total output and the fine particle fraction from 4 ICS delivered by 
pMDls without and with 4 va lved holding chambers and on 4 antibiotics delivered by 5 different nebulizer 
systems under various conditions. Also 2 dry powder inhalers for insulin were compared with each other 
(chapters 4-8). We have shown that an optimal fine particle fraction may be obtained by selecting the 
best devices and optimizing environmental factors as air humidity. Now that an optimal fine particle 
fraction can be generated, this leads to the most important question how these findings relate to daily 
life, or in other words, how do aerosol doses delivered at a patient's mouth relate to pulmonary deposition 
and clinical effects? Ideally, the most relevant outcome of drug delivery to the lungs would be the clinical 
effect (no symptoms, no exacerbations). However a direct relation between drug dose and clinical effect 
may be difficult to measure, as the clinical response may be influenced by many other factors than the 
location of deposition only. 
Which factors affect the clinical response to medication in asthma? For children with asthma, asthma 
severity, duration of asthma (maybe related to airway remodeling), baseline pulmonary function and 
pharmacogenetic make-up can obscure the dose-response relation and influence c linical effect. Both 
response to bronchodilators, as response to ICS are subject to these factors.32-36 In preschool children 
outcomes are even more difficult to define, in particular as pulmonary function tests like flow-volume 
loops cannot be performed. 
For patients with cystic fibrosis, factors that obscure a direct dose response effect are the different 
mutation classes in CF, the presence of modifier genes and disease progression. 
Therefore other methods of determining lung deposition are used as a proxy for clinical effectiveness and 
will be explained for asthma and CF in the next paragraphs. 
Other methods of determining lung deposition as a proxy for clinical effectiveness in asthma 
Information on the area of deposition for ICS can be obtained directly from radio-labeled studies of 
aerosols with gamma scintigraphy or PET-scanning.37 In general, pulmonary deposition measured with 
gamma scintigraphy can be expected to be slightly elevated as it measures also a proportion of drug that 
may subsequently be removed from the lungs by mucociliary clearing mechanisms.38 
Information on deposition can also be obtained indirectly from plasma sampling after an inha led dose32•39, 
urinary excretion, pulmonary function tests like peripheral airway resistance, measurement of lung 
clearance index and changes in ventilation heterogeneity40•41 , air-trapping on expiratory CT scans42•43, 
gas distribution as measured with the use of hyperpolarized helium with magnetic resonance imaging 
(MRl)44•45, from side-effects like endogenous cortisol suppression46 and lung models.47.48 
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Deposition based on clinical effectiveness 
For bronchodilators, information on the deposition has been obtained by measuring effectiveness as 
change in FEV, and measuring side effects by measuring heart rate and tremor. A study measuring the 
speed of bronchodilator response to salbutamol showed that the relative potency of pMOI and Volumatic® 
was twice that of the Oiskus®. The results also indicate that it would require approximately twice the 
dose of salbutamol administered via the Oiskus to obtain the same recovery times as those recorded when 
salbutamol is administered via the pMOI + Volumatic®.49 In general, studies on clinical effects do not 
report on humidity conditions with spacer use, which, as we have shown, are important (chapter 4), nor 
on inspiratory manoeuvre and whether a breathold was applied with the OPI (chapter 8). 
Lung deposition may be assessed by measuring side effects of inhaled medication. To give an example, the 
lung bioavailability of fluticasone propionate as expressed by the level of adrenal suppression was about 
twofold greater with hydrochlorofluorocarbons than with hydrofluoroalkane as propellant, and therefore 
these 2 pMOls are not interchangeable.50 
Symptom free days and nights, time to first exacerbation, emergency visits and hospital admissions are 
common endpoints in randomized controlled trials on the clinical efficacy of ICS. To give an example, 
for ICS, the dose equivalence of CFC-BOP to H FA-BOP has been established as a 2.6 : 1  ratio based on an 
efficacy study in adults. In this RCT, 323 adults with asthma received either 100, 400 or 800 µg of CFC 
or HFA-BOP over 6 weeks and based on the shift of the FEV, dose-response curve to the left for CFC-BOP 
the 2.6:1  ratio was calculated.51 In a dose reduction study, budesonide by Turbuhaler® and fluticasone by 
Oiskhaler®, both drugs and devices were equally effective in a µg for µg comparison.52 
Increased ventilation heterogeneity in the small airways, as can be measured with the concentration of a 
tracer gas with the multiple breath wash-out technique, is a sensitive marker of small airways disease and 
associated with poor asthma control.41 From this multiple breath wash-out technique, parameters can 
be derived that reflect ventilation heterogeneity in convection-dependent airways [Scandl and ventilation 
heterogeneity in diffusion-dependent, acinar airways [Sacinl - A low Sacin reflects increased involvement of 
peripheral airways in patients with asthma, and it was only the patients with increased involvement of 
peripheral airways that had benefit from switching from equivalent doses by budesonide OPI to HFA­
BOP.40 Of note, all patients with asthma also presented conductive airway abnormality at baseline, but no 
changes were observed in this lung zone with the switch to the ultrafine aerosol HFA-BOP. 
Deposition based on pharmacokinetic studies 
With pharmacokinetics, blood levels of an inhaled drug are measured after the drug has been absorbed 
from the lung. Usually the plasma concentrations are plotted in an area under the curve graph and 
compared to the systemic availability of the same drug given intravenously. A caveat in pharmacokinetics 
from inhaled drugs is that these drugs may enter the systemic circulation not only by the pulmonary, but 
also via the gastro-intestinal route. This gastrointestinal route may be blocked by charcoal ingestion. 
The systemic bioavailability may also be influenced by first pass metabolism by the liver. For example, 
this first pass metabolism is responsible for the very low oral bioavailabilty of fluticasone being less than 
10/o.53 Salbutamol pharmacokinetics showed large variation depending on anti-electrostatic handling of 
the plastic spacer in pediatrics, with primed or used spacers delivering an up to two fold higher dose 
than spacers that had not been used before, or primed but just rinsed with water.54 Another study on 
salbutamol inhaled with Oiskus® (OPI). Oiskhaler® (OPI) or Easy-Breathe® (breath actuated device) found 
that in healthy volunteers, the Oiskus® resulted in significantly lower bioavailability as a surrogate for 
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l u ng del ivery.55 Lung deposition and systemic ava i la bi l ity of budeson ide with th ree different nebu l izer 
systems were al l  1 40/o- 1 60/o and 1 5- 1 70/o respectively of nomina l  dose in  adu l ts, When related to dose­
to-subject or  actua l  dose, despite the greater drug output from the nebu l izer because of the lowest 
residue in  the reservoi r, l ung de l ivery and systemic ava i lab i l ity for this nebu l izer producing 7 µm (MMAD) 
particles was re lative ly low with 360/o and 440/o respectively compared to those va lues for the nebu l izers 
with 5 (580/o and 630/o) en 3 µm particles ( (590/o and 640/o).56 Cicleson ide inha led d i rectly from pMDI  or  
from AeroChamber Plus® resu lted in  equa l  serum concentrations in  adu lts57 ; cu rrently cicleson ide is not 
registered with a spacer. 
Deposition based on CT and MRI imaging studies 
Another surrogate for lung deposition might be endpoints on CT or MR I  scans. HFA-BDP treatment for 
4 weeks in steroid na ive patients resu lted in a sign ificant improvement compared to CFC-BDP rega rd ing  
l ung attenuation on CT and less i ncrease i n  a i r  trapp ing after methacho l ine provocation, a lthough  c l in ica l  
effectiveness was s imi lar. 58 Another study compa ring 400 µg  of HFA-BDP by  breath activated i nha le r  
to  FP 500 µg Diskus resu lted in  s imi lar  decreases in  trapped a i r  after 3 months of  treatment.59 Although 
ca refu l i nha lation in  th is study was stressed, there is no information on inha lation flow rate and  breath 
hold, both importa nt determinants of periphera l  deposition. 
I n  a technetium (Tc)- labe l led HFA-BDP study with the AeroChamber Plus®, a slow maxima l i nha lation 
fo l lowed by a 5 - 1 0-s breath-ho ld resu lted in  an  increased lung deposition compared with 5 tida l  b reaths 
in ch i ldren from 5 to 1 7  years.3 However, it is not clea r from this study if patients exha led to residua l  
vo lume before sta rting i nha lation and at wh ich inspiratory flow, both importa nt determinants for 
peri phera l a i rways deposition. Chi ldren �5 yrs of age a re now encouraged to use the deep exha lation­
s ing le  breath i nha lation techn ique with breath hold if possib le.4 
Of ch i ldren with asthma who were treated for 4 weeks with 400 µg budeson ide, the majority had increased 
peri phera l  deposition in a scintig raphic study after a month of treatment compared to the start of the study, 
suggesting improvement of a i rway patency and thus increased periphera l  deposition.60 A lung deposition  
of  over 500/o with a h igh periphera l deposition was  demonstrated for the  sma l l  particle cicleson ide on  
both 2-d imensiona l  and 3-D rad ionucl ide imag ing studies.61 The use of  a breath-actuated device o r  pM DI  
with HFA-BDP, which has the advantage of both sma l l  particl e size and lower p lume velocity with p roper 
inha lation techn ique, resu lted in  a lung deposition of over 500/o.62 I n  many radionucl ide label ing studies, 
there is no comparison with another drug or device. 
Other methods of determining lung deposition as a proxy for clinical effectiveness in CF 
Deposition based on clinical studies 
Studies on inha led aminog lycosides63, aztreonam64, DNAse65 and hypertonic sa l ine66 have primari ly 
focused on c l in ica l  effectiveness instead of deposition and have shown beneficia l c l in ica l effects. The 
newly developed Tobramicin I nha lation Powder (TI P) , usi ng l a rge porous particles has shown to be non­
inferior to nebu l ized tobram icin.67•70 
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A trial on la rge a i rway versus small airway deposition of inhaled DNAse using the AKITA device by adjusting 
pa rticle size, breathing pattern and timing of aerosol bolus resulted in significant improvement of FEF 
750/o in both g roups within 4 weeks of switching from a conventional nebulizer system to a so called 
sma rt nebulizer.25 Both groups (targeting the small airways in the one g roup and the larger airways in the 
other g roup) improved, probably as a result of increased pulmonary delivery. Further, improvement may 
also be caused by increased adherence due to the effect of being included in a clinical trial. 
Deposition based on pharmacokinetic studies 
The advantage of aerolized tobramycin over intravenous administration is that higher sputum levels may 
be obtained with low systemic concentrations. The sputum concentration can reach levels that exceed 
the minimal inhibitory concentration (M IC) of the Pseudomonas aeruginosa isolates by 25 times in 950/o 
of patients with an estimated systemic bio-availability of 11.70/o for a 300 mg dose.71 Although the 
sputum concentration may be high in the upper airways, there will definitely be a concentration g radient 
of aminoglycosides towards the lung periphery with a factor 25, possibly resulting in a level just above 
M IC in the peripheral a i rways (chapter 5). 1 4  For aminoglycosides, high peak levels (fa r above the M IC) 
a re needed to make use of the reported post-antibiotic effect of this class of drugs. U rinary excretion of 
aminoglycosides has been shown to reflect lung deposition.72 
Deposition based on radionuclide labeling with gamma scintigraphy 
Gamma scintig raphy can be used to compa re lung deposition between different drug formulations or 
devices. For example, efficient deposition for the T IP powder was demonstrated using gamma scintigraphy 
in healthy volunteers and compared to pha rmacodynamic measurements. 1 6  Consistent with the 
pulmonary deposition data, twice as much tobramycin reached the systemic circulation using the TIP 
powder compared to nebulized tobramycin. In another study, gamma scintigraphy demonstrated 400/o less 
lung deposition of nebulized tobramycin when nebulized with the e Flow® rapid compared with LC Plus® 
nebulizers in patients with CF.22 
9. 7 Myths i n  inhalation technology: the big 7 
The translation of aerosol and deposition studies to everyday clinical practice has shown to be difficult for 
clinicians and several myths exist in inhalation technology. The 7 most important myths will be unravelled 
here. 
First, as much emphasis has been placed on fine pa rticle dosing, many physicians believe that 'the smaller 
the pa rticle, the better� However, this is not correct as particles < 1 µm are mostly exhaled again. Although 
fine particle aerosols from HFA pMDls may lead to an improvement of deep lung deposition, this is not 
only because thei r  pa rticles a re smaller, but also because of the lower plume velocity from many HFA 
driven pMDls compared to the older CFC driven pMDls. Both smaller pa rticles and lower release velocity 
lead to less upper airway impaction and therefore, the effect of small pa rticles can not be attributed to 
pa rticle size alone. 
Another myth is that doctors presume that a homogeneous lung deposition can be reached with inhalation. 
Considering the most optimal drug distribution over the entire lung that can be achieved (approx. one 
third in the upper [generation 0-11] ,  one third in the intermediate [generation 12- 16] and one third in the 
peripheral [generation 17-23] lung) 1 5- 1 7  and the exponentially increasing lung surface from the trachea to 
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the alveoli, the drug concentration will decrease by at least a factor 25 from generation O to generation 
23 (chapter 3}.14 
Third, in general it is believed that the mass median aerodynamic diameter (MMAD) of an aerosol, is the 
most important characteristic of an aerosol. However, the MMAD does not give any information about it 's 
size distribution, nor about the mass fraction of the dose for which the MMAD is given. Fine particle doses 
are only a fraction of the label claim and MMAD does not reveal which fraction. Besides, DPls do not have 
a single MMAD. Aerosols from DPls have a bimodal distribution, one for the drug bound to carrier and 
one for the drug released from the carrier. The aerosol from a DPI is therefore a mixture of (small) drug 
and (large) carrier particles with drug particles still attached to their surface and the distribution curves 
of both particles may show overlap. If an MMAD for a dry powder aerosol is given, it has to be defined for 
which size fraction of the particles in the aerosol and which mass fraction (compared to label claim). 
Fourth, a flow rate independent fine particle fraction is considered important.73 However, deposition shifts 
to larger airways with increasing flow rate. To obtain the same central and deep lung deposition, more 
fine particles need to be released with increasing inspiratory flow and preferably these particles have to 
be finer too.26 
A fifth myth is that a high resistance device would require a larger amount of work than a lower resistance 
device. High resistance inhalers generally have highly effective dispersion principles. They deliver the 
same fraction of the dose as fine particles at the same approximate pressure drop (within the range 2-4 
kPa) as low resistance devices. However this pressure drop across a high resistance DPI results in a much 
lower air flow rate compared to a low resistance DPI, which reduces mouth and throat deposition. When 
the air flow rate is low, pressure equilibrium between the lungs and the ambient air takes longer than 
when the air flow rate is high. This enables the patient to generate a higher pressure drop across the 
higher air flow resistance and to continue this high pressure drop over a longer period of time. When the 
resistance is low, the air flow rate is high and inhalation time thus short. This philosophy is illustrated in 
the paragraph "Message in a bottle" (chapter 1). 
Next, a common misunderstanding is that the use of spacers always increases lung deposition compared 
to deposition from pMDls without spacer. In fact, spacers only decrease upper airway deposition and thus, 
reduce local side effects. Additionally, they help to overcome coordination problems. Depending on the 
inhalation manoeuvre, lung deposition may be increased or decreased with a spacer in comparison with 
a pMDI without a spacer, according to the design of the spacer, the aerosol formulation, the patient's 
inhalation technique and the extent to which the electrostatic charge within the spacer is controlled. 
Last, although organizations as the Dutch Asthma Foundation and scientific societies as the European 
Respiratory Society4 promote uniform instruction for each type of device, we want to make clear that this 
may not always be correct.26 For example, low resistance DPls with a flow rate independent fine particle 
fraction should not be used while inhaling forcefully, as this will shift the deposition from the deep lung 
towards larger airways. For such inhalers it is better to confine to a pressure drop of 2-4 kPa across the 
device. For high resistance devices, which do not facilitate high flow rates, this is less critical, particularly 
when they also release more fine particles at higher flow rates. 
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9.8 What remains to be done: future perspectives 
Increased skills of the health care professional, improved patient adherence, newly developed devices and 
drug formulations may all change pulmonary drug deposition and clinical effect for the better (Figure 
9. 1). 
Although the benefits of inhalation treatments are clear from both a clinical and scientific point of view, 
in clinical practice this may not be the case from a patients perspective. Encountered difficulties with 
young children may be poor cooperation, even smaller airway diameters, poor inspiratory performance 
and poor understanding of the instructions given. Adolescents are a challenge particularly in increasing 
adherence. Further, administration of inhaled drugs may be time consuming and spacers are not easy 
to take with you while travelling or attending school. For all these reasons, inhalation treatment may 
be difficult to adhere to. The voice of the patient and caregiver should be heard in order to improve 
treatments by making them faster and easier to administer. As the patient is the one with the disease 
(Law number 4 in "The House of God" )74 devices as well as instructions should be easy and clear with as 
few doses a day as possible to increase adherence.75 
Additionally, improvement of the knowledge of the health care professional is desired. In practice, many 
doctors, nurses and clinical researchers believe that the MMAD is the most important parameter determining 
where drugs wil l  be deposited, but this view is very incomplete. The inspiratory flow manoeuvre is equal ly 
important in determining the site and extent of drug deposition. The severity of the disease in the various 
airway generations and airway calibre also influence deposition pattern. Furthermore, most clinicians do 
not know that large differences exist in (fine-particle) output between various pMDls and pMDl-spacer 
combinations, DPls and nebulizer compressor systems (chapters 3, 4, 6-8}. It is therefore important to 
have a balanced view on the many variables and their interactions (Figure 9.1), as they all determine the 
amount of drug and the location of drug deposition in the airways. 
It is possible that in the past, inadequate delivery systems for inhaled drugs have hampered clinical 
success. We provided suggestive evidence for this statement regarding inhaled insulin (chapter 8), but 
others have suggested that inadequate delivery systems might have played a role also for the failure of 
inhaled disodium cromoglycate76, which is still used successfully for allergic conjunctivitis. For nebulized 
drugs and high dosages delivered by DPI, faster administration may be important, especially when many 
drugs need to be used as in cystic fibrosis ("so many drugs, so little time" ).77 
An ideal DPI should preferably have a high internal resistance with a flow dependent increase in fine 
particle dose to compensate for the higher impaction in the upper airways with increased flow rates. The 
resistance should not be too high on the other hand, because of insufficient energy for proper dose release 
and dispersion. Besides, at very low flow rates with too high resistance, the inhalation time from residual 
volume to total lung capacity may be too long, leaving no time for a breath hold pause. Further, the dose 
range for which the same inhaler can be used should ideally be expanded, especially for systemic delivery 
and preferably as a single inhalation. For relatively low dose drugs, as ICS and bronchodilators that are 
given in 100-1000 microgram range, current DPls do their job well enough. For drugs given in high doses, 
as antibiotics (given in a 1 00-200 mg range) as wel l  as for drugs needing systemic del ivery (insul in, also 
given in 1 -1 0  mg range) more effective DPls are needed with effective dispersion, allowing for high doses 
to be inhaled with a single inhalation and release of the drugs early during inspiration. 
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Developing new formulations which need to be administered once daily may improve patient adherence.75 
Likewise developing DPI formulations instead of nebulization fluids may increase adherence to treatment. 
However, the Tobramycin Inhalation Powder (TIP), developed to save time in patients with CF, when 
compared to inhalation of tobramycin solution, requires the inhalation of four capsules twice a day, which 
only halves the administration time compared to current smart nebulizers. 
Improved inhalation therapy will further improve by inhaling the required dose with one inhalation. We 
have shown that this is feasible for insulin (chapter B). Lower fine particle dose variability is especially 
important in drugs with a narrow therapeutic index such as insulin. Monodisperse fine particle aerosols 
could be a way forward, but unfortunately they can only be generated in low concentrations in wet 
aerosols. For systemic delivery a relatively large dose would be needed to reach the desired effect. 
The benefits of liposomal drugs with controlled release78 could lead to a lower dosing frequency probably 
increasing adherence.75 
Drug formulations may contain additives, which preferably should not be inhaled. Indeed the development 
of a conservative free tobramycin solution has been related to reduced side effects and increased 
tolerability.79 The upcoming Afrezza® insulin also contains many additives to create optimal aerodynamic 
characteristics, but as we have shown with the Exubera® insulin formulation consisting of large porous 
particles, lung delivery can also be improved by using more effective inhalation technology (chapter 8). 
Then, although a high fine particle dose might increase clinical effects, in vivo studies could not prove 
this. The ideal study to compare effects of large and small fine particle ICS doses from pMDI- valved 
holding chambers combinations would include 1 )  determination of fine particle output under known in 
vitro conditions as inspiratory flow rate and application of a breathhold 2) randomized controlled trials 
of longer duration, with 3) preferably 2 doses per ICS and 4) recording of humidity, inhalation manoeuvre 
(preferably a single inhalation after exhalation to residual volume followed by a 5-1 0 s breath hold) and 
5) focus on important clinical endpoints as asthma control, symptom free days, exacerbations, doctors 
visits and hospital admissions. It may be expensive and difficult to take all these factors into account, but 
all have an impact on outcome. Preferably, studies should not have a non-inferiority design as new drugs 
and devices should be superior in either efficacy or convenience of use. 
In many studies comparing different ICS with DPl's, pMDI-VHC combinations or nebulizer systems, it is 
usually not only the effect of the 2 drugs that are compared, but also the effect of 2 delivery systems (e.g. 
a high and a low internal resistance DPI or a HFA- and CFC-pMDI). The study results are thus only valid 
for the drug-dose-device combinations investigated and using another device or dose comparison might 
yield other results. 
Study results in children should be reported separately from those in adults, as their airway diameters 
differ from adults. Smaller airway diameters are likely to change particle deposition, as has been decribed 
when patients with asthma were compared to healthy controls.80 This change in deposition may well be 
caused by enhanced flow velocity and turbulence in smaller airways, especially when airway diameters 
are further reduced by bronchospasm, inflammation and/or mucus hypersecretion.23 
Optimal pulmonary drug delivery depends on patient related factors (age, disease, adherence), device 
related factors (fine particle dose), drug related factors and environmental conditions (humidity for 
spacers, jet flow for nebulizers). Clear communication and instruction is therefore essential to further 
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improve treatment. The patient should be central in this approach and should be involved in the decision 
making process.81 -83 It is essential in a patient centered care approach with shared decision makingto 
explicitly take into account patient circumstances and preferences.84 
9.9 What have we learned 
A high fine particle fraction (1-3 µm) inhaled with a slow inhalation, followed by a breath hold pause is 
optimal to treat diseases that affect the entire airway, like asthma, COPD and CF. The alveoli need to be 
reached for systemic absorption, which requires the same inhalation manoeuvre. The studies in this thesis 
stress the importance that in vitro data from drug-device combinations should be used in interpreting 
clinical studies and also pave the way for studies taking environmental conditions such as air humidity 
into account. 
Taken together, in this thesis we have shown that higher relative air humidity leads to a relevant increase 
in fine particle output from pMDl-spacer combinations compared to lower air humidity (chapter 4}. 
Second, as a proof of principle, a larger fine particle fraction obtained with improved inhaler technology 
that facilitates an appropriate inspiratory manoeuvre for deep lung deposition, including a longer breath 
hold pause, results in increased systemic availability of insulin (chapter B). This may open avenues for the 
development of vaccines and treatment by inhalation for many other diseases including tuberculosis. 
Third, besides the driving flow of a nebulizer (chapter 7), the patient compliance with cleaning instructions 
has a huge influence on the drug output. Despite clear and repeated instructions it is difficult to adhere to 
time consuming regimens (chapter 6). To improve adherence, shared decision making and patient centred 
communication skills are essential and the expression "drugs don't work in patients who don't take them" 
will always be true. 
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SUMMARY 
The British a nd Dutch sha re a long nava l- ,  war- and med ica l  h istory, in good t imes aswe l l  as bad. 
The ir  l anguage has a common Germanic o ri g i n ,  but the Eng l ish people may use spec ia l  ways to 
express va l u es or op i n ions, from wh ich the sometimes pa radoxica l mean ing is not a lways clear  
to the othe r  pa rty. Pa rticu larly with the Dutch, renowned for the i r  d i rectness, th is may cause 
confusion. We provide a comprehensive set of expressions, each with pa ired i nterpretations, to 
foster Ang l o-Dutch cooperation. 
Editor's Note: 
From time to time (Canadian translation for rarely or never] I feel it is important to publish an article 
that will further international relationships and clarify scientific discourse. The following paper is an 
example of such a publication. It is quite clear that in certain parts of  the world hockey seems to have 
been supplan ted by the sinking of ships and football. 
-Victor Chernick 
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INTRODUCTION 
The British and Dutch share a long history, in good times as well as bad. In the Anglo-Dutch wars, 
Michie! Adriaenszoon de Ruyter played a major role as a ski l led Dutch admiral as did his famous British 
counterpart Admiral Robert Blake. Nowadays the Royal Navy and Royal Dutch Navy still cooperate 
together at high level in the Flag Officer Sea Training. Our health systems differ, but also share common 
ground: the Dutch equivalent of the National Health Service is a compulsory health insurance system 
for everyone. British and Dutch doctors meet in conference and on other occasions; scientific articles 
are written together and reviewed by both nationalities. Medical care is strongly influenced by centuries 
of development of cultural beliefs and ideas, as has been beautifully written up by (the deceased) Lynn 
Payer. 1 Differences between the two nations exist in many areas, although for the outside world the 
Dutch and the British seems to get along quite well. Despite the differences in the success or otherwise 
of their respective football teams.2 the Dutch and British have a lot in common besides the weather. 
The medical communities of both countries have a significant profile in preclinical and clinical research. 
Language- and cultural differences may play an important role at conferences and in the process of 
submitting and reviewing articles. The aim of this article is to improve mutual understanding during 
these professional and social encounters as well as in the writing and reviewing process of scientific 
articles. We hope to show that the provision of a comprehensive set of expressions, each with pai red 
interpretations, fosters Anglo-Dutch cooperation. 
MATERIALS AND METHODS 
In-depth interviews with Dutch expats and thei r British employers on common expressions and thei r 
meanings resulted in "misunderstandings" that were checked and cross checked for meaning and 
interpretation. In the following years these expressions have been tested on multiple occasions. Editorial 
comments and those of reviewers of medical scientific articles were picked out by the authors on the 
basis of suspected paradoxical meaning and discussed among the authors. 
RESULTS 
The results from the in-depth interviews and reviewers and editorial comments are posted in tables with 
the expression itself, it's meaning and how it might be understood by non-British citizens. Although we 
share a rich history and ideas, there are nevertheless often cases where the communication between 
the two nations is not as straight forward as might be expected. This is clear from reading Tables 1 and 
2 for social encounters and the reviewing process respectively. 
What the British say 
I hear what you say 
You must come by for dinner sometime 
Very interesting 
With the greatest respect 
I 'm sure it's my fault 
That is an original point of view 
I almost agree 
You'l l  get there (eventually) 
I ' ll bear it in mind 
Could we consider some other options 
I would suggest 
By the way 
Perhaps you could give this some more thought 
Quite good 
Not bad 
What the British mean 
I disagree completely 
Just being polite; Goodbye! 
I don't agree 
You must be a fool 
It's your fault! 
You must be crazy 
I don't agree 
No way you will make it 
I won't do anything about it 
I don't like your idea 
Do it as I want you to 
The primary purpose is 
Don't do it, it's a bad idea 
A bit disappointing 
(very) good 
a Where "he" is mentioned "she" can a lso be read. 
Tablel Translation Guide Social 
What the Dutch understand 
He" accepts my point of view 
He will invite me for dinner in the course of time 
He likes my idea 
He respects me/my view 
It is his fault 
They like the idea 
He almost agrees 
Encouragement to go on 
He will use it when appropriate 
He is still in the process of thinking 
An open suggestion 
Not very important 
Consider possible road blocks 
Quite good 
Average or poor 
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DISCUSSION 
From these study results is it is clear that the British use of language often causes confusion among 
the other nationalities. English people may use special ways to express values or opinions, from which 
the sometimes paradoxical meaning is not always clear to the other party. Particularly with the Dutch, 
renowned for their directness, this may cause confusion. We hypothesize that the differences may well 
have their origin in the gentlemanlike, polite nature of the British (according to the Dutch authors) 
or their utter dishonesty (the British version). It has been shown that British gentleman-like behavior 
is often even maintained in disastrous circumstances such as the sinking of the Titanic (April 15th 
1 912). where British nationality overall (corrected for class of travel) resulted in lower probability of 
survival (P<0.01 ) compared to other European nationalities and US citizens.3 Time is of importance 
however, and a more slowly sinking ship may lead to a different view: the Titanic sank in 2 hr 40 min, 
the Lusitania in just 1 8  min; the latter leading to more selfish behaviour.4 This guide may helpful not 
just to British and Dutch medical doctors, but also to native speakers from other European languages 
and even those using American- English or Australian-English. Both Dutch and English have developed 
from the Germanic languages [http://en.wikipedia.org/wiki/English_language] . This can be illustrated 
by the conjugation of verbs (present/past/past participle): "eten/at/gegeten" and "to eat/ate/eaten'.' 
Nevertheless, the possibilities for misunderstandings are numerous, as we show in Table 1 for social 
encounters, and in Table 2 for the scientific review environment. As a rule of thumb, most Dutch 
people are less used to playing with the language as the British. This contrasts with the much greater 
levels of Dutch footballing schools.2 Both may be just as true for German, Spanish, and other European 
nationalities. However, eloquence on the football field and in the use of language seem to be two 
different things. This guide should at least help people to get to grips with the latter. The former we will 
leave for another year when we can all talk about football again without the relative recent memory 
of a world cup. 
What the British write 
Please consider 
I have a further suggestion 
The method described is rather original 
I have a few preliminary suggestions 
Reads well 
I am somewhat disturbed by the methodology 
With all due respect 
A few issues that need to be addressed 
An issue that worries me slightly 
I am sorry we have to reject your paper 
on priority grounds 
I am sorry to disappoint you on this occasion 
What the British mean 
Do it or forget it 
Take it or leave it 
Bullshit 
I strongly suggest you to follow my 
suggestions 
Really good 
I am crossed 
You don't know what you are doing, I have a 
better suggestion (polite disagreement) 
A whole lot needs to be changed 
A great worry 
Your paper sucks 
I could not care less 
a Where "he" is mentioned "she" can a lso be read .  
Table 2 Translation Guide: Professional (Review Process) 
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What the Dutch read 
Hea leaves it up to me 
He leaves it up to me 
It's a good method 
Don't change anything until final 
suggestions have been made 
Average 
He is not feeling too comfortable about it 
With the greatest respect 
2-3 issues need rewriting 
A minor issue 
My paper nearly made it 
He is sorry 
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BACKGROUND AND CONTRIBUTIONS 
Prof. A.  Bush is the 2008 Jonxis medallist; his prize lecture "Asthma: Problematic, Difficult, and Therapy 
Resistant-the Brampton experience" in 2008 was completely eclipsed by BR's presentation of some of 
these ideas. NR developed Tab/e l of the translation guide on the basis of her work with Dutch expats.5 
BR has tested elements of this translation guide on different occasions with British medical doctors, 
which always resulted in a good laugh as these elements are generally believed to reflect the true 
meaning. The naval inspiration results from fulfilling the military service as a ships doctor for the Royal 
Dutch Navy, where Dutch and British doctors did get along well. AB added even more intercultural 
flavor to the translation guide and reviewed the English. The reference to football was initiated by the 
World Cup tournament in July 2010. 
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Summary 
The general aim of this thesis is to improve inhalation treatments for pulmonary and non-pulmonary 
diseases. In this thesis issues in inhalation therapy in asthma and chronic obstructive pulmonary disease 
(COPD), both being highly prevalent diseases which are treated with inhaled corticosteroids (ICS) 
and inhaled bronchodilators, are adressed. Patients with cystic fibrosis (CF) frequently use inhalation 
therapy with inhaled antibiotics and mucolytics. Newer areas or areas under research for inhalation 
treatments include tuberculosis, the administration of vaccines (influenza, measles) and the inhalation of 
chemotherapeutic drugs in lung cancer, immunosuppressants after lungtransplantation, vasodilators in 
pulmonary hypertension and insulin in diabetes. 
In this chapter the major research findings from this thesis are summarised. The chapter starts with a 
short introduction into particle and fluid dynamics in the airways and deposition mechanisms for inhaled 
aerosols, which are suspensions of solid particles or liquid droplets in a gas. Specific diseases and their 
targets for inhaled drug treatment will be shortly discussed and an overview of the techniques used in 
this thesis is presented. All these topics are covered in more detail in chapter 1. 
Most inhaled drugs work locally, but drugs like insulin and vaccines need to be absorbed in the large, 
highly perfused alveolar surface area to have a systemic effect. The advantages of inhaled therapy for 
local treatment in the lungs are delivery of a high dose in the target area with strongly reduced systemic 
adverse side effects when compared to oral or intravenous treatment. The advantage of vaccines, 
e.g. against childhood diseases, in a powder formulation for inhalation are that for administration no 
needles are required. Subsequently there is no need for disposal of needles, which reduces infection risks. 
Moreover, vaccines in powder formulation for inhalation can be stored at room temperature instead of 
in the refrigerator. 
Despite many advantages, inhaled therapy is not that simple. Drug deposition in the lung after inhalation 
depends on a variety of factors such as the type of disease, disease severity, the airway geometry depending 
on age, the particle size distribution of the drug and the inhalation manoeuvre. 
The bronchial tree is a branching system starting with the trachea (generation 0), which divides into a 
main stem bronchus for each lung (generation 1) and then continues to branch by dichotomy like a tree, 
progressively reducing the airway diameters with each new generation. From the trachea to the alveoli 
there are 23 generations and consequently 223 branches. The diameter decreases from 18 mm for an 
adult trachea to less than 0.5 mm in the preterminal bronchioli, just before the alveoli. The number of 
airways within each generation increases faster than the airway diameters decrease, which results in an 
exponentially increasing total cross sectional area towards the alveoli and a concurrent decrease of the 
air flow velocity and thus, velocity of the aerosol particles. This decrease in velocity is important for the 
drug deposition mechanisms in the airway. Similar to the exponential increase in the total cross sectional 
area, the surface area were drugs can be deposited also increases exponentially (Figure 1). The last 7 
airway generations make up for 950/o of total lung surface area. 
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Figure 1 The branching airway system consists of 23 
generations with an exponentially increasing surface 
area towards the peripheral airways. 
Upper airways 
Airway generations O - 11 :  conducting airways 
1 O/o surface area 
Summary 
Airway generations 12-1 6: transitional airways 
40/o surface area 
Airway generations 17-23 : respiratory airways 
or peripheral airways 
950/o surface area 
For efficient deposition in the central and peripheral airways, particles with an aerodynamic diameter of 
less than 5 µm are needed. The preferred size range is rather in the range between 1 and 3 µm. Particles 
that are larger than 5 µm deposit primarily in mouth, throat and upper airways, whereas 40-50°/o of 
particles smaller than 1 µm is exhaled for a large extent, even after a breath-hold of several seconds. 
Mostly particles in an aerosol have different sizes. Wet aerosols, as released from a pressurised metered 
dose inhaler (pMDI) or a nebulizer system are usually spheric (round). Most devices release aerosols in 
a size range form 0.1-10 µm. Moreover, dry aerosol particles may have different shapes and densities. 
Therefore aerosols can not be compared on size only as the aerodynamic behaviour of aerosol particles 
depends on size, shape and density. The sizes of irregularly shaped particles can be compared with each 
other using the equivalent volume diameter (DE) (Figure 2). Particles with the same DE can aerodynamically 
behave differently when they have different shapes and densities. Particle shape can be expressed using 
the dynamic shape factor (x) which equals 1 for a sphere, whereas x > 1 for i rregular particles. Usually 
particle density (p) is given in g/cm3• The density of water is 1 g/cm3, whereas the density of solid dry 
particles is mostly larger than 1, unless they are extremely porous. To standardise for these variations in 
shape and density, the aerodynamic diameter (DA) is frequently used (Figure 2). 
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p = 1 . 5 g/cm3 
X = 1 . 0 
Equ iva lent vol ume 
d iameter 
p = 1 . 5 g/cm3 
x = 1 . 1 7 
I rregu la r  parti c le 
p = 1 . 0 g/cm3 
X = 1 . 0 
Aerodynamic 
d iameter 
Figure 2 Methods to characterise irregularly shaped particles in the aerosol technology. DE is the equivalent volume diameter: 
the diameter of a sphere (round particle) having the same volume as the irregular particle in consideration. DA is the aerody­
namic diameter, defined as the diameter of a sphere (x = 1) with the density of water {p = 1 g/cm3) having the same settling 
velocity in still air. Particles with the same DA have the same aerodynamic behaviour. DA = OE,/ (p/x) 
Most aerosols contain particles within a certain size range and are called therefore called polydisperse 
aerosols. Polydisperse aerosols are usually characterized by measuring the particle size distribution. 
Particle size distributions are usually derived from a mass, volume or number distribution curve subdivided 
in diameter classes. Within each diameter class, the contribution of particles to total number, volume 
or mass can be computed and graphically depicted. From this cumulative distribution graph, a median 
diameter can be read. Despite the fact that most aerosol distributions are skewed (not log-normal), 
aerosols are usually compared using median diameters. The median diameter is the midpoint diameter; 
500/o of the volume, mass of number is in coarser particles and 500/o is in finer particles. For a distribution 
curve based on volume, as measured with laser diffraction analysis, the median diameter is the volume 
median diameter (VMD or X50). In the same way, from a cumulative mass distribution curve the mass 
median diameter (M MD) can be read. When the mass distribution is measured as a function of the 
aerodynamic diameter, this enables to characterise these aerosols with their mass median aerodynamic 
diameter (MMAD). For spherical droplets with unit density (as from diluted aqueous solutions), the VMD 
measured by laser diffraction analysis equals the Mass Median Aerodynamic Diameter (MMAD). Particles 
with the same aerodynamic diameter, whether large and porous (such as Exubera® dry powder insulin or 
Tobramycin Inhalation Powder) or spheric and irregularly shaped, will aerodynamically behave in the same 
way and reach the same target areas with the same inspiratory flow manoeuvre. Despite the emphasis 
many clinicians place on the importance of MMAD, chapter 1 explains why MMAD alone is not enough 
to characterize an aerosol. 
Aerosol generation devices can be divided into four different groups depending on their principle of 
operation: pressurized metered dose inhalers (pMDls), dry powder inhalers (DPls) nebulizers and soft mist 
inhalers. In childhood, pMDls are always combined with a valved holding chamber (VHC) or spacer to 
overcome coordination problems and to decrease local side effects. DPls usually contain micronised drug 
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blended with larger (lactose) carrier particles. The drug needs to be dispersed (released) from the carrier 
during inhalation. A more forceful inhalation usually results in higher fractions of particles released 
from the carrier which may also be smaller with the possibility of deeper lung penetration. Nebulizers 
convert drug solutions or suspensions into an aerosol by either a jet stream generated by a compressor (a 
nebulizer-compressor system) or by means of high frequency vibration applied to a perforated membrane 
in contact with the drug solution (mesh nebulizer). 
The combination of aerodynamic particle size and inspiratory flow determines the site of deposition. 
The aerosol speed in entering the airways depends on the forcefulness of the inhalation manoeuvre, the 
inhaler resistance to air flow and the speed with which the aerosol is released from the device. Usually 
the patient's inhalation manoeuvre and the inhaler resistance are the most important determinant of the 
three, except for pMDls. The appropriate inhalation manoeuvre depends on the device. Nebulizers release 
an aerosol in a 5-15 minute time frame, and the aerosol is inhaled with tidal breathing. An aerosol from 
a nebulizer system may reach all airways by diffusion (mixture) taking place during the exchange of 
inhaled and exhaled air. Some dry powder devices may have a short emission time enabling inhalation of 
the entire dose in a single inhalation. In general, the optimal manoeuvre to reach the peripheral airways 
is exhalation to residual volume prior to an inhalation to total lung capacity followed by a 5- 10 second 
breath-hold. A breath-hold increases deposition by sedimentation. 
Aerosol particles can be deposited on the airways by three mechanisms: impaction, sedimentation and 
diffusion. Impaction is the ·crashing · of aerosol particles on the walls of an airway conduit. This is either 
due to high velocity, high particle mass or both, resulting in a particle following its own straight track 
instead of following the carrying airstream in bends and bifurcations of the airways. To keep the drug 
losses due to impaction in mouth, throat and the first airways bends to a minimum, inhalation should 
not be too fast. 
Sedimentation is particle settling by the force of gravity. Sedimentation mainly occurs in the central and 
peripheral airways, where the air velocity is much lower and distances to the airway wall are shorter. 
The settling velocity increases with the second power of the particle diameter. Sedimentation is a time 
dependent mechanism of deposition and the efficacy of particle settling by sedimentation may thus be 
increased by a longer residence time of particles in the airways by a breath-hold. 
The site in the lungs where drugs are needed (target area) generally depends on the localisation of the 
disease process and the localisation of the receptors for a specific drug. 
The inflammatory process in asthma involves all airways and in particular the peripheral airways. ICS are 
considered the most powerful anti-inflammatory treatment modality in asthma {chapter 2) and COPD. ICS 
receptors are present in all airways, but their density increases towards the peripheral airways. Therefore, 
airway generations 7-23 are the main target for ICS. Bronchodilators in asthma and COPD aim at smooth 
muscle relaxation to counteract the bronchoconstriction caused by smooth muscle contraction. Smooth 
muscle is mainly present around the conducting and transitional airways, The airways with smooth muscle 
but without protecting cartilage are airway generations 7-1 4. Thus, the target area for bronchodilators 
(generations 7-14) is more proximal than that for ICS (generations 7-23). 
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In cystic fibrosis, both bugs and mucus are present in all airways and therefore, all airways are the target 
area for inhaled antibiotics and mucolytics. 
The optimal target area within the lungs for the delivery of drugs to the systemic circulation (e.g. inhaled 
insulin) is the alveolar region, where the barrier for absorption is thin and only minimal mucociliary 
clearance occurs. 
Chapter 2 reviews current anti-inflammatory treatment in asthma and makes clear that ICS are still the 
mainstay of maintenance treatment. With the inflammatory process being present in all airways with 
emphasis on the small airways, as well as the density of ICS receptors increasing towards the periphery 
with an exponentially increasing airway surface area, the peripheral airways are the main target area for 
ICS. 
In chapter 3 the particle size distributions of aerosols from the most commonly used ICS-pMDls in the 
Netherlands are compared with each other. HFA-propellant based pMDls only deliver the aerosol at a 
low plume velocity (compared with the -now phased out- CFC-pMDls) when having ethanol as a co­
solvent An aerosol with a smaller MMAD does not always contain a larger fraction of ICS in the relevant 
particle rage of 1-3 µm, as these aerosols may also contain more submicron particles (< 1 µm) that are 
exhaled to a large extent. Of note, there was a significant decrease in delivered dose during lifespan for 
fluticasone 125 and 250 µg/dose pMDls. The large variations in performance that were found over pMDI 
life span and delivered fine particle fraction underscore that the in vitro evaluation of ICS pMDls under 
well-controlled conditions is mandatory for adequate evaluation of drug delivery studies in patients. The 
output in small particles in this study was the highest from the ciclesonide and HFA-beclomethasone 
pMDls and therefore theoretically, these pMDls are most suitable for pediatric use. 
Chapter 4 deals with several variables that have an impact on the delivered (fine particle) dose from 
a PMD I with spacer. It is often stated that spacers increase the dose available for inhalation due to 
selective retention of larger particles (that would be lost in the spacer due to the force of gravity). 
However, the study in chapter 4 failed to show such a selective retention of the larger particles. Further, 
there was no influence of inspiratory flow rate on the particle size distribution from the spacer. However, 
we would advice against a fast inhalation as this will lead to more drug losses by inertial impaction in the 
upper airways. The effect of a longer lag time (waiting time between releasing a dose and inhaling it from 
the spacer) on output up to 20 seconds is considerably less than was found in previous studies. The most 
important finding of chapter 4 was that an increase in relative humidity from low (25-350/o) to high (75-
800/o) can result in an up to two-fold increase in drug output from the spacer. From bench to bedside, the 
efficacy of the therapy might thus be improved by administrating the medication in a humid environment 
(e.g. a used bathroom). The particle size distribution does not change with increasing humidity, thus a 
higher output translates directly to a higher fine particle fraction. 
In chapter 5 the drug target area in CF is described, in order to advice on the choice of device and 
inhalation manoeuvre to optimally treat Pseudomonas aeruginosa. As airway inflammation, infection 
and obstruction by mucus in CF is present in all airways, the entire airway should be targeted. With the 
exponentially increasing airway surface area from 50/o for airway generations 0-16 to 950/o for airway 
generations 17-23 {figure 1), it is clear that the peripheral airways should be targeted. It is hypothesised 
that the conductive airways (generations 0-11) will be treated by the drug 'losses· by (mainly) impaction 
during inhalation. Even with optimal peripheral targeting (which depends on particle size distribution 
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and breathing manoeuvre) a 25 fold drug decrease in concentration between conductive and peripheral 
airways will remain. 
Chapter 6 describes the effect of 6 months use of two types of nebulizers in daily practice by patients 
with CF and the effect of (lack of) adherence to cleaning instructions on their nebulizers · performance. A 
new nebulizer, the eFlow rapid® became very popular in the CF community before registration studies were 
performed. The advantages of the eFlow rapid® compared to many nebulizer-compressor combinations 
are its small size and silent operation. In chapter 6 it is demonstrated that the eFlow rapid® produces 
tobramycin aerosols with a VMD of 3.5 µm, which is considerably larger than the VMD of 2.8 µm produced 
by the Pari LC® plus nebulizer with Turboboy ® N compressor. As the chance of impaction is related to 
the second power of the particle diameter, it may be expected that the drug losses in mouth, throat and 
upper airways are higher for the aerosol from the eFlow Rapid® than for the aerosol from the Pari LC® 
Plus. The eFlow Rapid® makes use of a vibrating mesh in contact with the drug solution. The oscillation 
of the mesh forces the drug solution through funnel shaped pores in the membrane, thereby creating 
an aerosol, Despite instructed not to do so, patients used the eFlow Rapid® to nebulize other described 
drugs and they only partially adhered to cleaning instructions. This resulted in partial clogging of the 
mesh and consequently, in a decreased output rate and change in particle size distribution over time. As 
the used eFlow Rapids® automatically switched off after 1 0  minutes, this led to a decrease in delivered 
dose. After the mesh was replaced, the system functioned normally again. It was also found that the 
VMD of the aerosol from the Pari LC® Plus increases after 6 months use. This study demonstrates that 
communication between patient and health care provider is important, but does not automatically lead 
to full adherence. 
Chapter 7. Two commonly nebulized antibiotics in CF, tobramycin and colistin are both available in two 
different formulations. The particle size distributions of the aerosols from these four formulations were 
compared after nebulization with four nebulizer systems. Each of the nebulizers was tested with four jet 
pressures ranging from 1 -2.5 bar, as it is known that a higher pressure results in a smaller particle size. 
When tested under the same circumstances (same nebulizer and same jet pressure), all formulations 
resulted in the same particle size distribution and they are therefore interchangeable. With a jet pressure 
of 1 bar the VMD varied from 3.5 to 2.5 µm; at 2.5 bar this difference is smaller : 2.2 and 1 .6 µm. As 
explained earlier, based on the impaction parameter these differences can be expected to be relevant for 
the area of deposition in the airways. Use of the Ventstream® nebulizer resulted in the smallest particle 
size under all circumstances. 
In chapter 8. we describe the use of an insulin dry powder formulation (Exubera®) ,  which is now withdrawn 
from the market, to treat patients with diabetes. First, we recorded the primary particle size distribution 
of this insulin formulation by laser diffraction from RODOS dispersion. Then, we determined the mass 
fraction of fine particles (1 -3 µm) of this insulin formulation from two DPls : the Exubera® inhaler and 
the Twincer™ . Third, we looked at the effect of the dose weight on the particle size distribution of the 
aerosol from both inhalers. Based on in vitro characteristics, especially the released fine particle dose with 
optimal inhalation manoeuvre, we predicted the dose from both inhalers that would lead to equivalent 
systemic insulin availability from both devices. In the Twincer™ , half of the Exubera® insulin formulation 
leads to equivalent blood insulin levels compared to the Exubera® inhaler. This unique experiment 
demonstrates that the combination of an increased fine particle dose and the appropriate inhalation 
manoeuvre (exhalation to residual volume, followed by a slow, deep inhalation and a 5-10 second breath-
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hold) leads to h igher  system ic  ava i l ab i l ity due to i ncreased periphera l  deposition and absorption .  Fu rther, 
the Twincer™ is ca pable of re l easi ng the i nsu l i n  ea rly du ri ng i nspiration ,  so the d rug can i ndeed reach the 
periphera l  a i rways. This concept paves the way for the retu rn of i n ha led i nsu l i n ,  but more importa ntly, it 
a lso opens up avenues for the adm in istration of vaccines (e.g .  aga inst m eas les) , TBC treatment and  loca l 
chemotherapy against l u ngcancer. 
Chapter 9 gives a n  overview of a l l  contributing factors to i mproved d ru g  de l ivery to the l u ngs of which 
many were covered in this thesis (Figure 3}. Myths in i nha lation techno logy a re d iscussed in th is chapter 
and d i rections for futu re research a re g iven.  
Taken together the choice of a d rug-device com bination ca n have a l a rge impact on the de l ivered fi ne 
pa rticle dose. Envi ronmenta l  c i rcu msta nces may have a n  im pact too :  h i ghe r  air h um idity l eads to increased 
fi ne particl e dose from spacers. The fi ne particle dose as fou n d  in vitro was i ndeed pred ictive for systemic 
absorption of insu l in .  
Reci proca l commun ication between health care p roviders and  patient is of utmost importance to ensure 
correct i nha lation techn ique  and  adherence to clea n ing  instructions. M a ny im provements a re possible 
and needed. Com mun ication is not on ly a key factor between doctors and patients, but a lso between 
resea rchers of va rious cou ntries. In the a ppendix it is made clea r that, despite a common orig i n  of their 
l a nguages, the British and the Dutch may attribute a d ifferent mean i ng  to the same expression ,  possibly 
leading to misi nterpretations. 
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Het centrale thema van dit proefschrift is het verbeteren van de toediening van geneesmiddelen aan en 
via de luchtwegen. De bekendste ziektebeelden waarbij gebruik wordt gemaakt van inhalatiemedicatie 
zijn astma en COPD (chronic obstructive pulmonary disease, "longemfyseem '). De gebruikte medicijnen 
voor deze ziektebeelden zijn met name ontstekingsremmers (inhalatiecorticostero"i"den, ICS) en luchtweg­
verwijders. Bij Cystic Fibrosis (CF, 'taaislijmziekte') warden vooral antibiotica en middelen om het 
luchtwegslijm beter kwijt te kunnen raken ge"l"nhaleerd. Nieuwere toepassingsgebieden voor medicijnen in 
de luchtwegen zijn geneesmiddelen tegen tuberculose (TBC), vaccins, chemotherapeutica bij longkanker, 
vaatverwijdende middelen bij pulmonale hypertensie (hoge bloeddruk in de long) en insuline bij diabetes 
mellitus ('suikerziekte'). 
In deze samenvatting warden de belangrijkste onderzoeksbevindingen uit dit proefschrift besproken. Deze 
bespreking wordt voorafgegaan door een algemene inleiding over de luchtstroming in de luchtwegen en 
het gedrag van meegevoerde aerosoldeeltjes daarin, die van belang zijn voor transport en afzetting van 
deze deeltjes. Een aerosol is een mengsel van vaste deeltjes of vloeistofdruppeltjes in een gas. Verder 
warden de ziekten waarvoor inhalatietherapie veel gebruikt wordt of kan warden, de doelgebieden 
voor de geneesmiddelen tegen deze ziekten en de toedieningsvormen waarmee de geneesmiddelen in 
aerosolen kunnen warden omgezet en warden toegediend besproken. Oak wordt een overzicht gegeven 
van de technieken die voor het onderzoek in dit proefschrift zijn gebruikt. In uitgebreide vorm warden al 
deze onderwerpen in hoofdstuk 1 besproken. 
Veel van de inhalatiegeneesmiddelen moeten lokaal werken in de luchtwegen, maar  in geva l van vaccins 
en het toedienen van insuline gaat het om opname via de longen in de bloedbaan. Doordat de luchtwegen 
zich steeds verder vertakken en uiteindelijk uitmonden in een netwerk van longblaasjes met een groat 
oppervlak die in nauw contact met de bloedbaan staan, kunnen medicijnen daar effectief warden 
opgenomen. Voor de medicijnen die lokaa l  in de luchtwegen hun werking moeten doen is het voordeel 
van toediening per inhalatie dat met een veel lagere dosering kan warden volstaan in vergelijking met 
medicijnen die via de orale (met tabletten of drankjes) of parenterale (met injecties) route warden gegeven 
waardoor de bijwerkingen oak beduidend minder zijn. Bij vaccins (bijvoorbeeld tegen kinderziekten) is het 
een groat voordeel dat deze als poeder lang houdbaar zijn buiten de koelkast en zonder naalden kunnen 
warden toegediend. Dit kan voor veel ontwikkelingslanden een voordeel zijn. Verder zijn naalden een 
potentiele bran van besmetting en moeten deze na gebruik veilig warden afgevoerd. 
lnhalatietherapie heeft dus veel voordelen, maar een effectieve toediening aan of via de luchtwegen 
is afhankelijk van veel factoren. Die factoren zijn onder andere het ziektebeeld, de geometrie van de 
longen afhankelijk van de leeftijd van de patient (kind of volwassene), de deeltjesgrootteverdeling van het 
geneesmiddel en de manier van inhaleren. 
De luchtwegen vertakken zich van boven (trachea) naar beneden (alveoli). ledere vertakking wordt een 
bifurcatie genoemd omdat uit elke luchtweg steeds twee nieuwe ontstaan, resulterend in een nieuwe 
generatie. In totaa l  zijn er van de trachea (generatie 0) tot aan de alveoli globaal 23 generaties en daarbij 
neemt het aantal vertakkingen toe tot 223• Oak neemt de diameter van iedere volgende generatie af van 
globaal 1 8  mm (volwassen trachea) naar minder dan 0.5 mm in de voorlaatste bronchiole, vlakbij de 
alveoli. Het aantal luchtwegen per generatie neemt echter sneller toe dan de diameter afneemt, waardoor 
de totale doorsnede voor luchtstroming exponentieel toeneemt richting alveoli en de snelheid van de 
lucht en de daarin meegevoerde aerosoldeeltjes naar rato afneemt. Dit is van belang voor de mechanismen 
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waarmee de aerosoldee ltjes i n  contact warden gebracht met de wanden van de l uchtwegen. Naast de 
toename i n  doorsnede voor stroming richti ng de a lveo l i ,  neemt tege l ij k  oak het oppervlak  toe waarop de 
aerosoldee ltjes warden afgezet (Figuur 1) . De laatste 7 luchtweggeneraties vormen samen 950/o van het 
tota le  oppervlak  van de longen. 
-----;A·::.· __ 
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Figuurl De /uchtwegen opgebouwd uit 23 generaties 
met toenemend oppervlak voor stroming en afzetting van 
aerosoldeeltjes. 
Bovenste l uchtwegen 
Generaties O - 1 1 : hogere luchtwegen  
1 O/o oppervlakte 
Generaties 1 2  - 1 6 :  centra le l uchtwegen 
40/o oppervlakte 
Generaties 1 7-23 :  perifere l uchtwegen 
en  a lveol i  
950/o oppervlakte 
Om geneesmiddelen effectief tot i n  de centra l e  en perifere l uchtwegen te laten doord ringen,  moeten ze 
een deeltjesgrootte bezitten k le iner dan 5 micrometer (0.005 m i l l imeter) .  Bij voorkeu r moet h u n  d iameter 
zelfs in het bereik tussen 1 en 3 m icrometer l iggen. Deeltjes g rater dan 5 micrometer warden voor  een 
belangrijk deel i n  mond- en kee l holte en de hogere l uchtwegen afgezet. Van deeltjes kleiner dan 1 m icro­
meter wordt meesta l meer dan  40 tot 500/o weer u itgeademd. 
Omdat deeltjes i n  een aerosol meesta l versch i l lend van g rootte z ijn  en bij d roge aeroso len (vaste deeltjes) 
oak nag versch i l lende vormen en d ichtheden (soorte l ijke gewichten) ku nnen hebben, z ijn de meeste 
aerosolen n iet eenvoudig onderl i ng te verge l ijken. Het ged rag van een aerosoldee ltje wordt door a l  deze 
eigenschappen be"invloed. De vorm kan met een (dyna mische) vormfactor (x) warden beschreven en de 
d ichthe id (p) in g/cm3• De d iameter kan op versch i l lende man ieren warden u itgedrukt. Bijvoorbee ld  een 
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rand staafje kan zowel op lengte als op diameter warden gekarakteriseerd. Om toch een enkelvoudige 
uitdrukking te kunnen geven aan onregelmatig gevormde deeltjes, is in de aerosoltechnologie de equivalent 
volume diameter (DE) ingevoerd. DE is de diameter van een bol met hetzelfde volume als het onregelmatige 
deeltje (Figuur 11.2). Deeltjes met eenzelfde equivalent volume diameter kunnen zich aerodynamisch (in 
lucht of in een luchtstroom) echter nog verschillend gedragen door verschillen in vorm en dichtheid. 
Daarom wordt in de praktijk gebruik gemaakt van de aerodynamische diameter (DA) . Een uitdrukking voor 
het aerodynamische gedrag van een aerosoldeeltje is de valsnelheid van dat deeltje in stilstaande lucht. 
DA is daarom gedefinieerd als de diameter van een bol met de dichtheid van water die in stilstaande lucht 
dezelfde valsnelheid heeft als het onregelmatige deeltje. Voor een bol geldt dat de dynamische vormfactor 
(x) gelijk is aan 1. De dichtheid van water is 1 g/cm3• 
p = 1 . 5 g/cm3 
X = 1 . 0  
Equ iva lent vo lume 
diameter 
p = 1 . 5 g/cm3 
x = 1 . 1 7 
Onregelmatig 
deeltje 
p = 1 . 0 g/cm3 
x = 1 . 0 
Aerodynam ische 
d iameter 
Figuur 2 In de aerosoltechnologie gebruikte methoden om onrege/matig gevormde dee/tjes te karakteriseren. Uitdrukking 
aan onregelmatige deeltjes kan warden gegeven via de equivalent volume diameter OE' ofwel de diameter van een bot met 
hetzelfde volume, en de aerodynamische diameter DA' gedefinieerd als de diameter van een bot met de dichtheid van water 
(1 g/cm3) en dezelfde terminate valsnelheid als het beschouwde onrege/matige dee/tje. Bij voorkeur wordt gebruik gemaakt 
van de aerodynamische diameter omdat dee/tjes met ge/ijke DA hetzelfde aerodynamische gedrag vertonen ongeacht hun 
geometrische diameter, vorm en dichtheid. DA = OE,/ (p/x) 
Aerosolen bestaande uit deeltjes van verschillende grootte zijn evenmin met een enkelvoudige diameter 
te beschrijven. Deeltjes van verschillende grootte kunnen in klassen warden ingedeeld op basis van aantal, 
volume of massa. Per diameterklasse wordt het aantal deeltjes gemeten en een aantalverdeling als functie 
van de diameter opgesteld. Als het aantal deeltjes per klasse in procenten van het totaal wordt uitgedrukt, 
wordt een frequentieverdeling verkregen. Tenslotte kan hieruit een cumulatieve frequentieverdeling 
warden gemaakt door de opeenvolgende klassen steeds bij elkaar op te tellen. In de aerosoltechnologie is 
het echter niet gebruikelijk om met aantalverdelingen te werken maar met volume-of massaverdelingen. 
Uit de cumulatieve verdelingen kunnen mediane diameters warden afgeleid (de 500/o-waarden) . Mediane 
diameters geven de waarde aan waarbij 500/o van het totaal (in aantal, volume of massa uitgedrukt) zich 
in kleinere en 500/o in grotere deeltjes bevindt. Bij een volumeverdeling wordt de 500/o waarde als volume 
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mediane diameter (VMD) aangeduid, bij een massaverdeling als masa mediane diameter (MMD). Als de 
massaverdeling als functie van de aerodynamische diameter is gemeten, dan wordt de MMD een MMAD 
(massa mediane aerodynamische diameter) genoemd. In hoofdstuk 1 wordt besproken waarom de in de 
literatuur veel gebruikte MMAD niet altijd de idea le variabele is om een inhalatieaerosol te beschrijven. 
Voor de toediening van medicijnen in aerosolvorm aan de luchtwegen warden in de praktijk vier soorten 
inhalatiesystemen gebruikt. Het meest voorgeschreven zijn zogenaamde 'pressurized metered dose 
inhalers' (pMDl's) of dosisaerosolen. De aanduiding 'pressurised' is afgeleid van de aanwezigheid van 
drijfgas (gas onder druk) in de formulering. Het drijfgas zorgt door snelle verdamping voor de eigenlijke 
aerosolvorming uit een farmaconoplossing of -suspensie, maar is oak verantwoordelijk voor een hoge 
uittredesnelheid van de aerosol uit een pMDI, zoals in hoofdstuk 1 nader wordt uitgelegd. pMDl's warden 
meestal gecombineerd met een voorzetkamer (valved holding chamber) of 'spacer'. Voorzetkamers warden 
gebruikt om vooral bij kinderen en ouderen problemen met de coordinatie tussen het afvuren van een 
dosis en het gelijktijdig inhaleren van de aerosol te omzeilen. Oak warden voorzetkamers gebruikt om 
te voorkomen dat er te veel medicijndeeltjes in de mond- en keelholte van de patient warden afgezet 
vanwege de (te) hoge snelheid waarmee het geneesmiddel uit de dosisaerosol vrijkomt. Dit heeft een 
verlaging van de longdosis tot gevolg en geeft kans op lokale bijwerkingen in de keel, met name bij het 
gebruik van inhalatiecorticosteroiden. 
Een tweede type inhalatiesysteem om geneesmiddelen aan de luchtwegen toe te dienen is de droog­
poederinhalator (DPI). Een droog-poederinhalator bevat geneesmiddel in de vorm van een poeder, 
dat door de inademingkracht van de patient in de juiste deeltjesgrootteverdeling moet vrijkomen. De 
gemicroniseerde medicijndeeltjes zijn meestal via natuurlijke adhesiekrachten aan het oppervlak van veel 
grotere dragerdeeltjes (lactose) gebonden en de energie aanwezig in de ingeademde luchtstroom moet 
de medicijndeeltjes hiervan losmaken. Als het inademen krachtiger gebeurt, leidt dat in veel gevallen 
tot de afgifte van kleinere geneesmiddeldeeltjes waarmee een verschuiving in de depositie naar hogere 
luchtwegen bij krachtiger inhaleren kan warden gecompenseerd. 
Bij een derde type inhalatiesysteem wordt het geneesmiddel uit oplossing of suspensie toegediend 
door middel van verneveling. Een klassieke jet vernevelaar bestaat uit een spuitkop (nozzle) met twee 
gescheiden (co-axiale) kanalen en een persluchtsysteem. Uit het persluchtsysteem wordt lucht met hoge 
snelheid door een van beide kanalen geleid. Dit persluchtkanaal heeft een uitstroomopening op hetzelfde 
niveau als het tweede kanaal dat de farmaconoplossing aanvoert. In deze gemeenschappelijke opening 
wordt de farmaconoplossing door de hoge snelheid en impulsoverdracht van de luchtstroom opgebroken 
in een aerosol. Het precieze ontwerp van de vernevelaar en speciale voorzieningen zorgen er voor dat 
de juiste druppelgrootteverdeling wordt afgegeven. Modernere vernevelsystemen werken niet meer 
met perslucht, maar bijvoorbeeld met vibrerende membranen (vibrating mesh technology). Ze geven in 
combinatie met Adaptive Aerosol Delivery (AAD) alleen medicijnen af tijdens de inademing waardoor er 
geen aerosolverlies aan de omgeving optreedt tijdens perioden van uitademing. De daarvoor benodigde 
elektronica kan oak warden gebruikt om het tijdstip en de duur van toediening vast te leggen. 
Tenslotte zijn er diverse nieuwe typen vernevelsystemen in ontwikkeling of reeds op de markt gebracht, 
zoals de Respimat®, die oak wel als Soft Mist Inhalator (SMI) wordt aangeduid. 
Om in het gewenste doelgebied in de luchtwegen te komen is een combinatie van de juiste aerodynamische 
diameter van de geneesmiddeldeeltjes en de manier (snelheid) waarop deze deeltjes warden ingeademd van 
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belang. De snelheid waarmee deeltjes de luchtwegen binnen treden hangt af van de inhalatiemanoeuvre 
van de patient en de snelheid waarmee de aerosoldeeltjes door het inhalatieapparaat warden afgegeven. 
Meestal is de inhalatiemanoeuvre bepalend en deze hangt weer af van het gebruikte type inhalatie­
apparaat. Vernevelaars geven gedurende een periode van enkele (5-1 5) minuten een dosis in aerosolvorm 
af en de patient neemt deze in via rustige ademhaling. De aerosol uit een vernevelaar bereikt in principe 
alle luchtwegen door vermenging en diffusie tijdens de langdurige uitwisseling van in- en uitgeademde 
lucht. De meeste andere typen inhalatoren hebben een zeer korte emissietijd waardoor de volledige dosis 
in een enkelvoudige ademteug wordt ge"inhaleerd. Om daarmee effectief tot in de laagste luchtwegen te 
komen is het nodig dat de patient eerst diep uitademt tot restvolume en daarna diep inademt tot totale 
longcapaciteit. Aansluitend is het nodig om de adem gedurende tenminste 5 seconden vast te houden 
zodat de geneesmiddeldeeltjes voldoende tijd krijgen om uit te zakken. 
Deeltjes kunnen in principe in de luchtwegen warden afgezet (en daar hun effect uitoefenen) door drie 
depositie-(afzettings-)mechanismen: inertiele impactie, sedimentatie en diffusie. In de praktijk speelt 
diffusie echter een ondergeschikte rol van betekenis. lmpactie is het botsen van een deeltje met de 
luchtwegwand door een (te) hoge snelheid en/of massa, waardoor het bijvoorbeeld bij een vertakking van 
de luchtweg in de oorspronkelijke richting blijft voortbewegen en niet de afbuiging van de luchtstroom 
kan volgen waarin het deeltje wordt meegevoerd. Dit principe van het 'uit de bocht vliegen' kan warden 
beschreven met de stopafstand van het deeltje of de op het deeltje uitgeoefende centrifugaalkracht. 
Om verliezen van farmacondeeltjes in de eerste bochten (mond- en keelholte) en vertakkingen van de 
luchtwegen via impactie gering te houden, moet de inhalatiesnelheid niet te snel zijn. Sedimentatie is 
het uitzakken (vallen) van een deeltje onder invloed van de zwaartekracht. Dit mechanisme van depositie 
wint aan betekenis als de lucht (en de daarin meegevoerde deeltjes) bijna tot stilstand is gekomen. De 
valsnelheid neemt toe met de tweede macht van de diameter van een deeltje. Het aantal deeltjes dat in 
een luchtweg kan sedimenteren is verder grater als de verblijftijd in de luchtweg !anger is. Dit is dan oak 
de reden waarom het van belang is om de adem zo lang mogelijk vast te houden na de inhalatie van de 
aerosol. 
Om de deeltjes in de luchtweg op de juiste plaats te krijgen is het belangrijk te weten waar het ziekteproces 
in de luchtwegen zich afspeelt en/of waar zich de receptoren bevinden waarop de geneesmiddelen moeten 
aangrijpen om hun werking te kunnen uitoefenen. De plaats van het ziekteproces en die van de receptoren 
bepalen het doelgebied van de medicijnen. 
Bij astma is er sprake van een ontstekingsproces in de hele long, met name oak in de kleine luchtwegen. 
De receptoren voor inhalatiecorticostero·iden zijn oak in de hele long aanwezig, maar de dichtheid daarvan 
neemt toe in de richting van de kleinere luchtwegen. Daarom zijn de luchtweggeneraties 7 tot 23 het 
belangrijkste doelgebied voor inhalatiecorticostero·iden, die nag steeds de beste onderhoudsbehandeling 
geven tegen ontstekingen bij astma (Hoofdstuk 2) en COPD. Luchtwegverwijders bij astma en COPD 
ontspannen de spieren om de luchtwegen waardoor deze niet meer warden vernauwd. Deze spieren zijn 
vooral om de grotere en middelgrote luchtwegen aanwezig. De luchtwegen met spieren zonder kraakbeen 
vormen de generaties 7-14. Het doelgebied voor luchtwegverwijders ligt dus wat hoger dan dat voor 
inhalatiecorticostero·iden (generatie 7-23). 
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Bij Cystic Fibrosis zijn de bacterien die met antibiotica moeten warden behandeld ook in de hele luchtweg 
aanwezig, evenals het slijm waarvoor slijmverdunners kunnen warden ge"inhaleerd. 
Geneesmiddelen die in de bloedbaan terecht moeten komen, moeten voornamelijk via de longblaasjes 
warden geabsorbeerd en dus heel diep warden afgezet. Een voorbeeld hiervan is insuline (Hoofdstuk BJ. 
In hoofdstuk 2 wordt de huidige onderhoudsbehandeling van astma besproken. lnhalatiecorticostero"i'den 
(ICS) vormen daarbij nog steeds de hoeksteen. Uit het feit dat het ontstekingsproces van astma in de hele 
luchtweg aanwezig is tot in de hele kleine luchtwegen en dat in die kleinere luchtwegen bovendien 
het grootste aantal van de ICS-receptoren aanwezig is, evenals de grootste fractie van het totale 
luchtwegoppervlak, kan warden geconcludeerd dat in de perifere luchtwegen ook de grootste fractie van 
de totale dosis gewenst is om de ontsteking zo goed mogelijk te kunnen behandelen. 
In hoofdstuk 3 word en de deeltjesgrootteverdelingen van de aerosol en uit de in Nederland meest gebruikte 
ICS-pMDl's met elkaar vergeleken. De resultaten laten zien dat de op het drijfgas HFA gebaseerde pMDls 
alleen een fijnere aerosol afleveren (t.o.v. de oudere CFK-pMDl's) als zich als oplosmiddel ethanol in de 
samenstelling bevindt. 0verigens garandeert een fijnere aerosol (kleinere MMAD) niet altijd een grotere 
fractie (hoeveelheid) in het voor ICS relevante deeltjesgroottebereik van 1 tot 3 micron, doordat deze 
fijnere aerosolen oak meer submicron deeltjes (< 1 µm) bevatten. Een opvallende bevinding is verder 
dat van het veel gebruikte fluticason in de sterktes 250 en 1 25 µg, de grootte van de afgeleverde dosis 
afneemt met het aantal afgegeven doses. Deze studie toont aan dat er een groat verschil is in de fijne 
deeltjes fractie van verschillende merken pMDls, waarbij de fijne aerosolen vanwege hun grate fijne 
deeltjes fractie in het gewenste bereik het meest geschikt lijken voor kinderen. 
Hoofdstuk 4 behandelt de variabelen die een invloed uitoefenen op de afgeleverde (fijne deeltjes) dosis 
uit een voorzetkamer. Het doel van het onderzoek in dit hoofdstuk was om te onderzoeken wat de dosis uit 
een voorzetkamer is ten opzichte van de dosis uit de pMDI waarmee de voorzetkamer wordt gecombineerd 
en welke combinatie van voorzetkamer en pMDI uit de beschikbare mogelijkheden de grootste fijne 
deeltjesfractie levert. De invloed van verschillende variabelen, zoals de snelheid van inademen vanuit de 
voorzetkamer, de tijdsduur van wachten tussen afvuren van een dosis in de voorzetkamer en het inhaleren 
daarvan en de relatieve luchtvochtigheid is hierbij onderzocht. In de literatuur wordt vaak aangegeven 
dat voorzetkamers de beschikbare longdosis kunnen verhogen door het selectief achterhouden van 
grotere deeltjes (die door de zwaartekracht in de voorzetkamer zouden neerslaan). Voor de in hoofdstuk 4 
onderzochte combinaties is het selectief uitzakken van de grotere aerosoldeeltjes echter niet aangetoond. 
Er is verder geen effect gevonden van de inhalatiekracht waarmee de aerosol uit de voorzetkamer wordt 
ge'inhaleerd op de deeltjesgrootteverdeling van de aerosol. Te snel inademen is echter niet goed voor de 
longdepositie omdat het leidt tot meer keeldepositie. Het effect van tot 20 seconden wachten tussen het 
afvuren en inhaleren van een dosis is veel geringer dan in eerdere, beperktere, studies werd vastgesteld. De 
meest interessante bevinding uit deze studie is dat een verhoging van de luchtvochtigheid kan resulteren 
in een verhoging van de voorzetkameroutput met maximaal een factor 2. Naar aanleiding van deze 
studie zou een praktisch advies kunnen zijn om een ICS-pMDI met voorzetkamer in een pas gebruikte 
badkamer te gebruiken. De toename in output bij verhogen van luchtvochtigheid heeft geen effect op de 
deeltjesgrootteverdeling in de aerosol. Een verhoging van de luchtvochtigheid resulteert dus direct in een 
grotere kleine deeltjesfractie. 
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In hoofdstuk 5 wordt uitgelegd wat het doelgebied is voor inhalatie-antibiotica bij CF en met 
welke inhalatiemanoeuvre en welk type toedieningsvorm dit doelgebied het beste te bereiken is. De 
luchtwegschade, de infecties en ontstekingen bij CF bevinden zich in alle luchtwegen, van groat tot 
klein. De gehele long is daarom het doelgebied. Vanwege het hiervoor aangegeven enorme verschil in 
oppervlakte tussen de hogere plus centrale luchtwegen, die samen slechts 50/o van het luchtwegoppervlak 
bedragen, en de perifere luchtwegen die 950/o aan het totale oppervlak bijdragen (Figuur 1), is het het beste 
om de depositie te richten op die perifere luchtwegen. De grate luchtwegen warden daarbij voldoende 
behandeld met de verliezen die met name door impactie onderweg in de hogere en centrale luchtwegen 
optreden. Ondanks perifere 'targeting' zal het concentratieverschil voor het medicijn tussen de hogere en 
centrale ten opzichte van de perifere luchtwegen groat zijn en tenminste een factor 25 bedragen ! 
Hoofdstuk 6 beschrijft het effect van het dagelijkse gebruik van twee typen vernevelsystemen voor de 
inhalatie van antibiotica (voor een periode van 6 maanden) door volwassenen met CF op het functioneren 
van deze systemen. In de praktijk is dit effect afhankelijk van het opvolgen van de reinigingsadviezen. 
Vernevelsystemen die bestaan uit een vernevelaar en een compressor zijn vaak volumineus en lawaaiig. 
Toen een stil, klein vernevelapparaat beschikbaar kwam dat op batterijen werkte, werd dat al snel enorm 
populair. Deze studie laat zien dat het nieuwe, stillere en snellere systeem, de eFlow rapid® druppeltjes 
produceert die met een VMD van 3,5 µm aanzienlijk grater zijn dan de 2,8 µm van de geregistreerde 
Pari LC PLUS® vernevelaar met TurboBoy N® compressor. Doordat de kans op impactie van een deeltje 
toeneemt met het kwadraat van de diameter, is de kans op mond- en keelverliezen voor de aerosol uit 
de eFlow rapid® bij een gelijke inhalatiemanoeuvre dus aanzienlijk grater dan die voor de aerosol uit de 
Pari LC PLUS®. Gebleken is dat van de aerosolen uit beide systemen de gemiddelde deeltjesgrootte na 6 
maanden gebruik nag verder toeneemt waardoor beide aerosolen oak gedurende de tijd minder geschikt 
warden voor depositie in de kleine luchtwegen. De eFlow rapid® maakt gebruik van een zogenaamde 
'vibrating mesh', een geperforeerd membraan dat aerosoldruppeltjes in de gewenste grootte afgeeft. Uit 
de studie werd duidelijk dat patienten ondanks het advies om dit niet te doen, hetzelfde systeem oak voor 
andere geneesmiddelen gebruikten en bovendien de mesh niet volgens de instructies schoonmaakten. Dit 
leidde tot een vermindering van de output per minuut door verstopping van een deel van de gaatjes in de 
mesh, en omdat de eFlow rapid® oorspronkelijk na 10 minuten automatisch afsloeg, tot een vermindering 
van de toegediende dosis. Na verwisseling van de mesh functioneert het apparaat weer naar behoren. Uit 
deze studie blijkt oak dat communicatie tussen zorgverlener en patient heel belangrijk is en toch vaak niet 
leidt tot het juist opvolgen van adviezen. 
Hoofdstuk 7. Twee antibiotica, tobramycine en colistine, die bij CF veel gebruikt warden zijn elk in 
twee verschillende vernevelvormen (formuleringen) beschikbaar. Deze vier variaties werden op 
deeltjesgrootteverdeling onderzocht uit vier verschillende vernevelaars. De vernevelaars werden elk 
getest met 4 verschillende verneveldrukken, omdat bekend is dat een hogere druk leidt tot een kleinere 
deeltjesgrootte. Onder dezelfde omstandigheden getest (dezelfde vernevelaar met dezelfde verneveldruk) 
leveren alle vier formuleringen dezelfde deeltjesgrootteverdeling op en daarom zijn ze vanuit dat oogpunt 
onderling uitwisselbaar. De vernevelaars zijn dat zeker niet. Bij 1 bar varieert de VMD van 3.5 tot 2.5 µm; 
bij 2,5 bar is dit verschil kleiner: de VMD varieert dan tussen 2,2 en 1,6 µm. De Ventstream® vernevelaar 
blijkt de kleinste VMD te leveren onder alle omstandigheden en is daarmee het meest geschikt voor een 
hoge depositie in de perifere luchtwegen en evenredige verdeling over de hele luchtweg met de juiste 
ademhalingsmanoeuvre. 
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In hoofdstuk 8 is een studie beschreven waarin met een destijds beschikbare (inhaleerbare) droag paeder 
formulering van insuline (Exubera®) een patient werd behandeld met diabetes. Eerst werd bepaald wat 
de primaire deeltjesgroatteverdeling is van deze insulinevarm (door middel van laser diffractietechniek 
uit RODOS dispersie). Daarna is gekeken wat de massafractie aan kleine deeltjes ( 1-3 micron) is van 
deze insulinevorm vanuit twee verschillende inhalatoren, de Exubera® inhalator en de Twincer™ . Oak is 
gekeken naar het effect van de daseringen uit deze inhalatoren op de deeltjesgroatteverdelingen van 
de afgeleverde aerosalen. Op basis van de verschillen in in vitro depositie werd de haeveelheid insuline 
bepaald die via beide inhalatoren moet warden toegediend voor eenzelfde klinische effect (dezelfde 
insuline spiegel). Daarbij is gebleken dat de Twincer™ met de helft van de Exubera® insulineformulering 
equivalent is aan de Exubera® inhalator. Het unieke van deze studie is dat hiermee is aangetoond dat de 
combinatie van een hoge fijne deeltjesfractie met de juiste inhalatie-instructie en inhalatiemanoeuvre 
inderdaad leidt tot meer opname van insuline in het lichaam. De Twincer™ geeft daarnaast de volledige 
dosis af in de eerste fase van de inademing, waardoor het medicijn oak tot in de diepste luchtwegen kan 
doordringen. Al deze verbeteringen ten opzichte van de Exubera® inhalator bieden gaede perspectieven 
voor de terugkeer van inhaleerbare insuline, maar belangrijker nag, het biedt oak gaede mogelijkheden om 
middelen tegen bijvoorbeeld tuberculose, longkanker en vaccins (zoals tegen mazelen) via de luchtwegen 
toe te dienen. 
In hoofdstuk 9 warden de variabelen die de effectiviteit van inhalatietherapie bepalen in hun onderlinge 
samenhang aan de hand van een figuur (Figuur 3, pagina 166) besproken. 
Samenvattend is het duidelijk dat de keuze van de toedieningsvorm (de inhalator), inclusief de keuze vaor 
een specifieke voorzetkamer bij een bepaald type pMDI, de afgeleverde fijne-deeltjesfractie be pa alt. Externe 
factoren, zoals de luchtvochtigheid, kunnen hierbij van belang zijn: een hogere luchtvochtigheid is gunstig 
voor de fij ne-deeltjesfractie u it een voorzetka mer, maar ongunstig voor somm ige droog-poederi n ha latoren, 
omdat achtergebleven poederresten aan de inhalatorwanden kunnen plakken. De communicatie en 
interactie tussen zorgverlener en zorggebruiker is van groat belang voor juiste voorbereidingshandelingen 
en inhalatietechniek, maar oak het opvolgen van bijvoorbeeld schoonmaakinstructies. Er zijn dus nag veel 
verbeteringen mogelijk. Daarvoar warden in dit haofdstuk 9 verdere aanbevelingen gedaan. 
Tot slot is communicatie oak bij samenwerken en het schrijven en beoordelen van medisch onderzoek van 
belang. In de appendix staat beschreven hoe cultuurverschillen tussen Engelsen en Nederlanders ondanks 
een gemeenschappelijke taalaorsprong en veel andere parallellen, toch tot een andere interpretatie van 
Engelse uitspraken kunnen leiden. 
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DANKWOORD 
Heel veel mensen hebben een bijdrage geleverd aan mijn ontwikkeling, en daarmee oak aan de tot­
standkoming van dit proefschrift. Het dankwoord biedt een uitgelezen gelegenheid hen daarvoor te 
bedanken! De opdracht is niet voor niets "To all who teach". 
Mijn promotor, prof. dr. Eric Duiverman, bij de kennismaking in je huis in Moordrecht klikte het meteen en 
ik werd kinderlongarts in opleiding in Groningen. lk ben je enorm dankbaar voor het altijd in mij gestelde 
vertrouwen en de ruimte die je altijd biedt. lk bewonder hoe goed je beslissingen kunt nemen en de 
belangrijke vertrouwensrol die je voor veel mensen in het kinderziekenhuis hebt. Je hebt onze afdeling 
gemaakt tot een hele krachtige, met eenheid in verscheidenheid. 
Mijn co-promotor, dr. Anne de Boer, de Willy Wortel van de afdeling Farmaceutische Technologie en 
Biofarmacie, door je snelle denken en je tomeloze enthousiasme duizelde het soms als ik bij je vandaan kwam, 
maar je zekerde hiermee de kwaliteit van dit proefschrift. Bedankt voor al je praktische en morele steun. 
De !eden van de beoordelingscommissie, prof. dr. Dirkje Postma, prof. dr. Paolo Colombo en prof. dr. Rolf 
Berger, wil ik alle drie bedanken voor het beoordelen van het manuscript. Prof. Colombo, although we 
have not yet met in person, it immediately became clear to me that you are a fast working, very friendly 
and charming authority in the field. I am very pleased that you will be attending the defence of my thesis. 
Prof. dr Berger, kindercardioloog, wij delen niet alleen de belangstelling voor de organen in de borstkas 
(oak al zijn we het soms oneens of het ·cardiaal'of ' pulmonaal' is), we hebben oak veel raakvlakken op 
het gebied van de patientenzorg en transplantatie, van met name kinderen met pulmonale hypertensie. 
Vanwege deze raakvlakken, je leuke collega ·s en je positieve uitstraling ben ik heel blij dat je lid bent van 
de beoordelingscommissie. 
Prof. dr. Dirkje Postma voor jou begin ik een nieuwe alinea. lk wil je bedanken voor je enorme morele steun 
en praktische hulp bij een aantal manuscripten. Manuscripten die daardoor beknopter en veel beter leesbaar 
werden. lk vind het enorm jam mer dat je er voor hebt gekozen toch naar Australie te gaan, maar ben blij dat 
dr. Nick ten Hacken wel beschikbaar is voor de ·grate commissie', ook als gewaardeerd vertegenwoordiger 
van het GR IAC: het gerenommeerde Groningen Research Institute for Asthma and COPD. 
Prof. dr. Henk Jan Verkade, jij wilde mij ·even· spreken eind 2011 en daarmee volgde een periode van 
·overview first, then details', met zowel richting als perspectief. Dank je wel voor de wending die je daarmee 
bereikt hebt, het enthousiasme en de (tijds)inzet waarmee je hebt gespiegeld. lk hoop dat je snelle den ken 
gepaard aan de vraag 'of ga ik soms te langzaam' niet tot problemen voor mij leidt bij de verdediging. 
Prof. dr. Pieter Sauer, de eerste maanden in Groningen ben je zelfs nag mijn opleider tot kinderarts geweest. 
In de loop der jaren is er een vriendschap ontstaan, met als kroon ons enthousiasme voor de stedenband 
Groningen-Murmansk, waarbij we interactief kindergeneeskundig onderwijs in St. Petersburg hebben 
kunnen lanceren. lk ben heel blij dat je op 28 november de voorzitter van de promotiecommissie kunt zijn. 
Prof. dr. Erik Frijlink, bedankt voor je enorme enthousiasme en de mogelijkheid onderzoek te doen op het 
lab Farmaceutische Technologie en Biofarmacie. Je hebt een fantastische groep mensen om je heen die 
uitstekend onderzoek verricht. Paul Hagedoorn, naast Anne de 2e pilaar onder mijn onderzoek, hartelijk 
bedankt voor al je praktische inzet en uitleg en je enorme positieve uitstraling. Verder wil ik Doetie Gjaltema, 
Maarten van den Noort en Francesca Scotti, hartelijk bedanken voor al jullie meetwerk. Dr. Tjalling de 
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Vries, kinderarts in Leeuwarden, jou ken ik door onderwijs, patienten2org en d it onder2oek, vol ideeen 
voor onder2oek en met oog op praktische toepasbaarheid, more le ondersteuner. G iann i  Bacca, nag meer 
lta l iaanse i nvloed in  het onderzoek, dank je wel voor jouw steun en vriendschap en dat je m ij n  g rappen 
over lta l ianen 20 weet te waa rderen en te pareren. Jet van der Hu lst delen we nag, maar ge lu kkig hoort 
Ma rianne Zwolsman bij het CF-team en niet bij het diabetes team. Anne Lexmond, j ij hebt a l  een start 
gemaakt met inspirerend vervolgonderzoek. 
M ij n  d i recte col lega 's prof. d r. Gera rd Koppelman ,  d r. El ianne Vrij landt en d r. Brig itte W i l lemse ( 'de fe l low ·, 
maar n iet 2omaar een) d ie samen met on2e kindera l lergoloog prof. d r. Ewoud Dubois en geleid door p rof. d r. 
Eric Du iverman on2e sectie vormen, ha rtel ij k  dank voor ju l l ie  col legia l iteit en steun .  Wat fijn dat ju l l ie mij 
veel ru imte gaven voor het schrijven van de l aatste stukken voor d it proefsch rift. Dr. Jorrit Gerritsen, j ij hebt 
m ij en mijn ge2in a ltijd heel harte l ij k  ontvangen en oak a ls k inder longarts van het eerste uu r  b ijgedragen 
aan mijn ople id ing, aangevuld met ERS (Eu ropean Respi ratory Society) perspectief. 
Het werk in een academisch k inder2iekenhu is is 20 boeiend door het samenwerken, opleiden en de 
mu ltidisc ip l ina i re problematiek. De k inder-thoraxchirurgen prof. dr. Tjark Ebels en Tja l l i ng Waterbo lk, 
bedankt voor open overleg rand congen ita le longafwijkingen en prachtige transpla ntaties. Nu maken oak 
Sara h  Arrigon i ,  Yvonne den Drijver en d r. Gu ido Michielon deel u it van het kinderteam. De tra nsplantatie 
a rtsen dr. Wim van der Bij, dr. George Nossent en dr. Erik Verschuu ren, bedankt dat ik j u l l ie voor  een 
donor aanbod en transpla ntatie overleg a ltijd lastig kan va l len .  Dr. M ichie l Erasmus, transplantatiech i rurg 
en Wi l l i e  Steenhu is a ls boegbeeld van het secreta riaat longtransplantatie, oak ha rtel ijk dank. Verder 
m ijn kamergenoot dr.Terry Derks, de kinderi ntensivisten en a l l e  andere (deelspecia l istische) co l lega ·s, 
verpleegkund igen en secreta resses van het kinder2iekenhu is die 2ich 20 in2etten. Anneloes, jij fig u reert oak 
a ls kindera rts in  ople id ing in  d it boekje, dank je wel. Een be langrij k  deel van het werk heeft betrekking op 
CF: bedankt col lega ·s van het CF team,  oak het volwassen CF team voor de goede samenwerking .  Marjanne 
van Smaa len ,  longfunctie, bedankt oak voor p lannen van kinderen voor de virtuele astmakl in iek samen met 
Christine van Baak en het secreta riaat van Jackel ine van Gelder en Aaf Teuben. 
De basis voor de belangste l l ing voor kinder long2iekten is gelegd in  het WKZ, door d r. Hein Brackel en 
d r. Han van der Laag. Prof. dr. Kors van der Ent, dank je we l  voor de weloverwogen gesprekken over 
k indergeneeskunde en kinderlong2iekten in het laatste deel van mijn ople id ing. Dan k  je wel dat je wi l  
deelnemen aan de oppositie. Natuur l ij k  hebben met name de kinderen met CF, d ie i n  de jaren 90 nag vaa k  
bij e lkaar  l agen (op afdel ing Eskimo) en a ltijd genoeg cater ing hadden en verhalen om de d iensturen goed 
door te komen, mij n  enthousiasme in de richting van kinderlong2iekten laten gaan. 
D r. Christian Benden, thank you for introducing me in the I nternational Pediatric Lung Transplantation 
Consorti um ( IPLTC), with d r. Sam Goldfa rb as a chair and d r. Jackson Wong as treasu rer, a l l  making me feel 
very welcome. Prof. dr. Ernst Eber cha i r  of the Pediatric Assembly (ERS) , thank  you for a l lowing me to serve 
as a secretary for the Paed iatric Asthma and Al le rgy g roup. Prof. d r. Andy Bush, thank  you for speaking you r  
famous words (meant for another col legue) "May h is problems b e  huge, a n d  h is fel low unwel l" a s  wel l as 
our mutual efforts to improve British-Dutch understanding as described in  this thesis. 
Twee 2omers in Camp Poynte l le (dank  a.a .aan Jack Cohn and Pau l  H i l lman) en het werk a ls tol k-aan-boord 
bij Northwest Airl i nes waren een enorme internationa le ervar ing. Thank  you for h i r ing me, Jerry M ichler� 
Manager l nfl ight ft Food service Atlantic reg ion and Birthe N ielsen,  lead interpreter en mijn col l ega 's. Dat 
de Boston-based crews van Northwest Airl ines oak na opgaan in  Delta Air l i nes een rei.inie met de tolken 
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hebben gehad in Amsterdam is heel b ijzonder. Lex Verstraaten, jou wi l  ik g raag bedanken voor a l l e  ru imte 
d ie  je me bi nnen NW gegeven hebt! Het werk a ls scheepsa rts bij de Kon inkl ij ke Ma rine, volgend op de 
m i l ita i re vorming in Bak 93-2, heeft me ook een n ieuwe wereld laten kennen. Wat een bemanning, speciale 
dank aan mijn commandant Rob Teeuwisse� eerste officier Hu ibert van Eijsden en het hoofd log istieke d ienst 
Frank  Marcus. 
Al meer dan 10 jaar WinterKLAS organ isatie met Ka ro ly I l ly en prof. d r. Pau l  B rand. De Werkg roep 
l n ha l atietechnologie, met nu onder a ndere prof. dr. Richard Dekhu ijzen (of zoa ls de gestrande terugreis 
va nu it ler land duidel ij k  maakte m r. iPhone), prof.ctr. Wim van Alderen en mijn bunkmaatje dr. Hans i n  't Veen. 
Het red igeren van het werkboek k inderlongziekten ,  ge"fnspi reerd door Lucky Luke en de Daltons, geleid door 
MA, was heel leuk en heeft me veel over formu leren en sch rijven geleerd. Enorm bedankt daarvoor, d r. 
Ma rie l le  Pijnenburg, d r. Peter Merkus en d r. Rene van Gent. Het is heel bijzonder dat november 201 2 ook d it 
boek oplevert. De basis daarvoor werd gelegd op een vergadering met een tapa per persoon. Peter, ik hoop 
dat je je a ls Da lton gepast kleedt a ls l id van de  oppositie. 
Prof. d r. Edmond Rings, paran imf, we fietsen a l  10 jaar samen naar het werk en dat is heel goed om het 
hoofd leeg te maken en te lachen over a l les wat er om ons heen gebeu rt. Een professor a ls paran imf, dat 
is extra leuk. Dank  je voor al le steun ,  en dat geldt ook voor d r. Rienk Tamminga en d r. Wim Tissing d ie met 
ons het Peizer Pediatrisch Peleton vormen. 
Zander Marg reet van Roest, Erik E lfer ink en Gera rd Brom had dit boekje er  niet zo mooi u itgezien. Enorm 
bedankt voor ju l l ie enthousiasme en snelheid , daardoor heb i k  heel vee l  p lezier gekregen in het maken 
van dit boekje. Het eerste proefsch rift va n de DavosSchool. lk ka n ju I lie a ls vormgevers zeker aanraden, en 
in een keer a l les laten aan leveren is vast een heel goed idee. Janette Tienkamp, voor de laatste fase van 
ad ressen opzoeken onmisbaar, ha rte l ij k  bedankt. 
Lieve mam en pap, ju l l ie zorgden dat wij opg roeiden in een wa rm gezin met een brede b l i k  op a l l e  mensen 
in de samenleving en aandacht voor iedereen in de d irecte omgeving .  Pap, dat zag ik ook als i k  wel eens 
meel iep met je werk a ls KNO a rts, h umor en compassie. Je g roette werkel ij k  iedereen en nog steeds wordtje 
door iedereen in het ziekenhu is herkend en gegroet. Die erva ringen zijn het belang rijkste dat i k  heb ge leerd 
en wat ik graag wi l  doorgeven aan onze kinderen. De buurt en 'buren · in Alkmaa r waar ik opgroeide zijn 
u n iek en gel u kkig hebben we i n  Peize een vergel ij kba re bu ren en vriendenkri ng. Joost jij bent een topbroer 
en Ma rleen, j ij bent mijn l iefste zus. lk ben b l ij dat je m ijn pa ran imf wil zijn  en dat wij met zijn d rieen zo'n 
goede band hebben. Jouw man Frank  en Joost ' s dochter Lau ra horen er natu ur l ij k  ook bij. 
Ten aanzien van onderzoek doen en pub l iceren hebben de d rie zonen van Andrea en mij ook een goede, 
re l ativerende invloed die n iet wordt geh inderd door impactfactoren en pol itiek. Maarten zei eens met de 
nodige spot "jee, leuk zo'n artikel wat door 0,000001 0/o  van de wereldbevolking wordt gelezen''. Pepijn vroeg : 
"Maar kun je dat tijdschrift dan ook in de win kel kopen?" en Sebastiaan " krijg je d · r ook money voor?" Wat 
ben ik bl ij met ju l l ie en trots op ju l l ie !  Daarom vind ik het extra jammer dat ik ju l l ie op Twitter niet mag volgen. 
Twee weken a ls coassistent bij d r. And rew Ratchford : zijn vrouw Jackie en hun  d rie dochters wa ren genoeg 
voor Jackie om bij het afscheid te zeggen : '' I 'm  su re Andrea deserves a meda l for putting up with you ''. l k  
kan n iets anders dan d a t  toegeven :  Lieve And rea , bij ons trouwen heb j e  d ie gouden meda i l le van h en  ook 
gekregen en je verdient hem nag steeds dubbel en dwars !  
Bart Rottier, oktober 201 2 
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Abbreviations 
ABBREVIATIONS 
ABPA Al lerg ic bronchopulmonary asperg i l l osis 
AC AeroChamber® 
BDP Beclomethasone d i  proprionate 
BPD Bronchopulmonary dysplasia 
BUD Budesonide 
CAI Cascade impaction ana lysis 
CF Cystic fibrosis 
CFC Ch lorofluorocarbon 
CIC Ciclesonide 
CLD Ch ronic lung disease 
Cmax Maximal concentration 
COPD Chronic obstructive pu lmonary disease 
Capt Optical concentration in the aerosol. 
CT Computed tomography 
DA Aerodynamic diameter 
DE Equ iva lent volume diameter 
DPI Dry powder inha ler 
FEV1 Forced expiratory vo lume in 1 second 
FPD Fi n e  particle dose 
FP Flut icasone diproprionate 
FPF Fine particle fraction 
FRC Functiona l  residua l  capacity 
GSD Geometric standard deviation 
(for log-normal distributions) 
H FA Hyd rofluora l kane 
ICS I n h a l ed corticosteroids 
LDA Laser d iffraction ana lysis 
M IC M i n ima l  i nh ibitory concentration 
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MMD  Mass med ian d iameter 
M MAD Mass med ian aerodynamic d iameter 
M RI Magnetic resonance imag ing 
N EB Nebuhaler® 
PA Pseudomonas aeruginosa 
PCD Primary c i l i ary dyskinesia 
pMD I  Pressurized metered dose inha ler 
PSD Particle size distribution 
RCT Randomized contro l l ed tria l  
RH Relative a ir hum idity 
RS Relative span of the size d istribution ;  
ratio of  (X90-X10) to  Xso 
Tl DM Type 1 d iabetes mel l itus 
TBC Tubercu l osis 
TI P Tobramic in Inha lation Powder 
TLC Total l ung  capacity 
VHC Valved ho ld ing chamber 
VMD Volume median d iameter 
VOL Volumatic® 
X10 Diameter derived from the cumulative volume 
distribution curve: 1 00/o of the volume  is in 
particles sma l ler than X10 (micron) 
Xso Diameter derived from the cumulative volume 
distribution cu rve: 500/o of the vol ume is in 
particles smal ler than Xso (m icron) 
X9o Diameter derived from the cumulative volume 
d istribution curve: 900/o of the volume  is in 
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